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Cancer is a leading health concern worldwide with approximately 17 
million new cases in 2018. Treatment for cancer includes the use of 
chemotherapeutic drugs, radiation and surgery. Research into possible 
new therapeutics, and improvement of existing treatment for the different 
pathologies of cancer, is predominantly undertaken under laboratory 
conditions with the use of secondary immortalised cell lines cultured as 
monolayers before testing in animal models and then clinical trials in 
patients. There is often a disconnect between the reported efficacy of 
therapeutic agents in these monolayer cultures and the response in situ, 
often with the latter showing a reduced response compared to the former. 
Immortalised cell lines can be cultured as 3D aggregates of cells referred 
to as ‘spheroids’. These spheroid cultures often exhibit responses to 
therapeutic agents more similar to that of tumours and can serve to 
bridge the efficacy gap between 2D and tumours in situ. 
This research examines the relationships between data streams from 2D 
monolayer and 3D spheroid cultures through the use of statistical 
modelling, specifically PLS-SEM path modelling, an established 
technique that to the author’s knowledge, has not been applied to 
biological data of this kind. Data from variables concerning cell viability 
and proteomics in monolayer cultures and viability and morphometrics 
data in spheroid cultures were collected experimentally and used in a 
PLS-SEM path model designed for these variables. The research 
hypotheses explored are that: (1) variables collected from monolayer 
cultures correlate with variables from spheroid cultures after exposure to 
therapeutic insult over time: and (2) relationships between the monolayer 
viability and proteomic variables and spheroid morphometric indicators in 
responses to therapeutic insult over time could be exploited through the 
use of statistical modelling to predict the spheroid response from 2D data 
inputs.  
Results show that the novel application of PLS-SEM path modelling was 
successful in linking the data streams from both monolayer and 
 
v 
spheroids. Findings of note from the evaluation of the model showed that 
the results of higher concentrations of 5-FU at longer time points provided 
stronger values of predictive accuracy and reliability in the endogenous 
spheroid latent variables and the pronounced mediating effect via the 
monolayer viability construct between the proteomics and spheroid 
constructs. From these findings there is scope for future work within the 
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1 Chapter One, General Introduction 
Cancer is one of the leading causes of death worldwide and every year vast 
amounts of money and time are dedicated to the research of the biology of 
cancer and the discovery and development of cancer treatments. For example 
in 2017-18, Cancer Research UK spent £423 million on cancer research 
(Cancer Research UK, 2018). In spite of the efforts and funding put into 
research, the prevalence of cancer is widespread, with approximately 17 million 
new cases a year, and 9.6 million cancer related deaths in 2018 (Cancer 
Research UK n.d.). 
 
The research and development of anticancer drugs follows a well-established 
pipeline of drug development (Figure 1.2). Within drug development, less than 
20% of all drug candidates that begin clinical testing are subsequently approved 
for use (Fisher, Cottingham and Kalbaugh, 2015), from 5-10,000 potential 
compounds initially identified, only one drug will be approved for use (Matthews 
et al., 2016). This high failure rate occurs mainly due to poor efficacy of the 
candidate drug upon reaching trials.  
 
In the initial stages of anti-cancer drug research, the ‘gold standard’ is the use 
of immortalised cancer cell lines cultured in vitro. In the majority of cases, these 
cells are grown as monolayers and drug efficacy testing is performed under lab 
conditions using these monolayers. Whilst monolayer systems have been used 
for decades and have very well-established protocols for setup and 
measurement, a large fraction of investigational drugs that are shown to be 
effective in these monolayer cultures are later shown to be ineffective when 
tested within animal models or later in clinical trials.  
 
Immortalised cells lines can also be cultured as three dimensional (3D) cancer 
spheroids, aggregates of cancer cells either supported within a scaffold or 
matrix or free-floating in a culture medium. These 3D cultures differ from their 
monolayer counterparts in morphology, cell-cell interactions and the 
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establishment of nutrient and oxygen gradients within the cultures despite being 
cultured from the same cells as monolayer systems. The literature has reported 
that in many instances drug efficacy in spheroid cultures is reduced compared 
to monolayer cultures and often more closely resembles the response of 
tumours in vivo (Weiswald, Bellet and Dangles-marie, 2015).  The use of 3D 
cultures such as spheroids with cancer research and drug development is on 
the rise but is not yet routine due to more complex and expensive culture 
mechanisms and testing protocols.  
 
In addition to the development of new experimental systems, there is an 
increase in the use of computational biology and modelling approaches within 
cancer research.  In particular, and in recognition of the interconnections among 
different scales in biological systems, systems biology approaches to the study 
of disease seek to explore and discover multi-scale biological responses to 
stimuli, including drugs, in silico. These approaches allow for the incorporation 
of vast sets of data from a myriad of variables to find a ‘signal in the noise’ of 
large cohorts of data. They have been applied in diagnostics to devise sub-
classifications of cancers types based on genomic profiling (Torchia et al., 
2015), informed by protein-protein interaction networks (Guda, Chittur and 
Guda, 2009).   
 
Cancer researchers recognise there is a disconnect between the current routine 
practice of conducting cancer research for drug discovery with the use of 2D 
monolayer cultures and the clinical response of those discovered anticancer 
drugs in patients. There is an increasing use of 3D spheroid models since these 
systems seek to bridge that gap between monolayer and in vivo tumours. 
Importantly, however, despite the reported differences in response to treatment, 
monolayers are still a valuable research tool and there is a wealth of available 
protocols and experimental procedures developed for quantifying variables in 
this monolayer system that are routinely used for the scale of high-throughput 
testing required in drug discovery and development (Langhans, 2018). By 
looking at the relationships and correlations between drug responses in 
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monolayer and spheroid cultures, and mapping these relationships with the use 
of modelling, the relationships could be exploited to predict the drug response in 
spheroid cultures from data derived from more robust, simpler monolayer 
systems.   
 
This thesis explores the relationship between data streams from 2D monolayer 
systems and data streams from 3D spheroid cultures through computational 
modelling. Specifically, a partial least squares structural equation modelling 
(PLS-SEM) path model was developed to explore the relationships between the 
results of different levels of therapeutic insult over time in 2D and 3D and to 
investigate the predictive relevance of the set of variables collected from 
monolayer for the set of variables collected from spheroids. 
1.1 Structure of the thesis 
This thesis begins with a literature review that provides a general introduction to 
cancer and cancer research, introduces colorectal cancer as the system of 
study in this thesis, and provides an overview of three-dimensional cancer 
cultures spheroids and their application in cancer research. Following this, the 
thesis presents an introduction to the methods of statistical modelling with a 
focus in partial least squares structural equation modelling, the chosen method 
for this research. 
The Thesis Methodology is set out over two chapters. Chapter 2 focuses on the 
methods used in the biological experimentation to generate the monolayer 
system data, including cell viability and proteomics, and the spheroid system 
including viability and morphology. Chapter 3 considers both PLS-SEM for the 
statistical analysis of the multi-scale data and model application to link 2D and 
3D data streams. 
The Results are presented over three chapters. Chapter 4 focuses on the 
results of the biological experimentation, presenting the range of measures in 
2D and 3D at different drug dosages over time. Chapter 5 considers the results 
of the statistical analysis of the biological results and the validity testing of the 
PLS-SEM path modelling results and this is an important foundational chapter 
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before the PLS-SEM model itself can be explored. Chapter 6 presents the 
findings of the path modelling, using 3D visualisation to support interpretation of 
the major relationships identified by the model. 
Chapter 7 discusses both the results of the biological experimentation and the 
findings of the path model, considering the model results in a biological context. 
This research was approached from two sides, i.e., a biological comparison of 
monolayer spheroid cultures and a statistical modelling approach to combine 
the biological data from the two culture methods, and this approach is reflected 
in the dual methodology and results sections. The thesis completes by drawing 
together those two sides into a final conclusion.  
1.2 Cancer  
Cancer is one of the leading causes of death worldwide, around 8.2 million 
deaths occurred worldwide from cancer in 2012 (Torre et al., 2015). Cancer is 
an umbrella term for a group of over 200 diseases, characterised by abnormal 
growth and invasion that can occur in almost any cell type. Cancer can occur 
from a genetic mutation occurring from environmental stresses, inherited 
genetic traits or a combination of both (Anand et al., 2008).  
 
Cancer is characterised by the functional dysregulation of cell signalling 
pathways. This disruption to cell signalling can sometimes lead to some mix of 
the six hallmark features of cancer with the possibility of at least two more 
hallmarks as described by Hanahan and Weinberg that can be used to describe 
cancerous cells. These hallmarks are: (1) the ability to sustain proliferative 
signalling; (2) evading growth suppressors; (3) activation of invasion and 
metastasis; (4) the ability to replicative immortality; (5) induction of 
angiogenesis; and (6) the ability to evade programmed cell death, (Hanahan 
and Weinberg, 2000). In 2011 an updated review added an additional two 
emerging hallmarks (7) deregulating cellular energetics and (8) evading immune 
system destruction, and two enabling characteristics (1) tumour promoting 





In 2014 (Wang et al., 2014) discussed the cancer hallmark network framework 
which establishes that the cancer hall mark traits can be represented by 9 
molecular networks. These networks are as follows; 1) survival network, 2) 
mutating network, 3) de-differention network, 4) angiogenesis, 5) immune 
escaping network, 6) EMT (epithelial-mesenchymal transition) network, 7) 
genome duplication network, 8) metabolic network and 9) stroma network.  
 
Wang et al. (2014) posed that these hallmark traits are all interlinked within the 
networks and that they can be quantified based on the cell biology of the 
hallmarks on both an operational and molecular level. Thus cancer is a highly 
complex disease which is notoriously difficult to study and understand due to it 
being governed by multivariate, multi-scale spatial and temporal parametric 
biological and environmental indices (Bown et al., 2012). While progress has 
been made so far within the field of cancer research, there is still a great need 
to identify new treatment targets and develop novel therapeutic techniques 
(Giamas et al., 2010). 
1.2.1 Colorectal Cancer  
This thesis selected colorectal cancer (CRC) as its model system as CRC is the 
second most commonly diagnosed cancer in females, and the third most 
commonly diagnosed in males with incidence rates tending to be higher in 
males in the majority of the world (Torre et al., 2015). Although incidence rates 
are increasing, mortality rates are decreasing. This is most likely due to an 
increase in colorectal screening and/or improved methods of treatment 
(Edwards et al., 2010). An increase in incidence rates of CRC are mainly due to 
environmental factors such smoking (Zisman et al., 2006), diet (Willett et al., 
1990) and low physical exercise (Golshiri et al., 2016). 
There have been a number of gene mutations observed in CRC, such as the 
inactivation of TP53, a tumour suppressor gene that has been shown to be 
mutated in around half of all CRC cases (Pritchard and Grady, 2011). Other 
clinically relevant oncogenes in colorectal cancer is KRAS, a mediator of EGF 
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signalling, which has been shown to be mutated in 40% of colorectal cancer 
cases and is linked to ineffectiveness of anti-EGFR mAb cancer therapies such 
as cetuximab and panitumumab, which are commonly used in colorectal cancer 
cases (Lièvre et al., 2006).  
 
Figure 1.1 An overview of the EGFR pathway  
Above shows an overview of the two main pathways activated by epidermal growth-factor receptor 
(EGFR). Both pathways play a role in the control of several cellular responses such as cell proliferation, 
cell survival, and apoptosis inhibition. Dysregulation of EGFR is often seen in many types of cancer, in 
CRC this has been reported to be caused by protein overexpression, as opposed to oncogenic mutations, 
in 35-50% of patients (Saletti et al., 2015). 
The proteins of interest used within this research each tie into the EGFR 
signalling pathways. The selection of these proteins of interest is discussed in 
further detail in Section 2.6. Vascular endothelial growth factor (VEGF) is 
upregulated by EGFR expression (Tabernero, 2007), positive correlations have 
also been observed between hypoxia-inducible factor (HIF1⍺) and EGFR (Xu et 
al., 2010). Carbonic anhydrase 9 (CA9) and BCL2/adenovirus E1B 19 kDa 
protein-interacting protein 3 (BNIP3) are both downstream targets of HIF1⍺ 
(Slemc and Kunej, 2016). In addition, PI3K/AKT signalling has been 
demonstrated to regulate Nuclear factor erythroid 2-related factor 2 (NRF2) 
activation (Reddy et al., 2015). 
The immortalised secondary cancer cell line used in this thesis was 
HCT116+p53. This is a cell line of colorectal carcinoma origin that has wild type 
p53. There are also p53 null variants of this cell line available (HCT 116-p53). 
HCT 116+p53 is a widely used cancer cell line within cancer research and has 
been well characterised (Rajput et al., 2008)  
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1.2.2 5-Fluorouracil for colorectal cancer treatment.  
The current treatment for cancer varies on a case-by-case basis and revolves 
around the excision of the tumor, chemotherapy, radiotherapy, and a host of 
FDA approved targeted therapy anti-cancer drugs. These anti-cancer drugs are 
designed specifically to affect molecular targets within the cell signaling 
pathways, with the goal of either returning the cells to normal functioning or 
promoting cell death. 
 
5-Fluorouracil (5-FU) is a widely used drug for a range of cancers such as 
colorectal, breast, gastrointestinal cancers, and the mode of action is largely 
understood (Wigmore et al., 2010). 5-Fu, an analogue of uracil, is taken up by 
the cancer cells where is converted into fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP). These active metabolites are involved in the disruption of 
RNA synthesis and the inhibition of thymidylate synthase (TS). 
Dihydropyrimidine dehydrogenase (DPD), found in abundance in the liver, 
breaks 5-FU down to 5-FU to dihydrofluorouracil (DHFU) (Longley, Harkin and 
Johnston, 2003).  
 
TS is the catalyst in the conversion of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP), the source of thymidylate and an 
essential precursor for DNA synthesis (Pullarkat et al., 2001). The inhibition of 
TS prevents the production of thymidylate and leads to lethal DNA damage and 
subsequently leads to thymine-less death (Liao et al., 2005). DNA and RNA 
damage caused by 5-FU has been shown to activate the tumour suppressor 
p53 (Osaki et al., 1997) (Eidi Nita et al., 1998), which in turn triggers apoptosis 
through the upregulation of pro-apoptotic genes, and the down regulation of 
anti-apoptotic genes (Miyashita et al., 1994). 5-FU has been routinely used to 
treat colorectal cancer (CRC) both along and in combination with other 
chemotherapeutic agents since its discovery in the 1950s and is still used 




5-FU was selected at the therapeutic agent for this research due to its longevity 
of use as a chemotherapeutic agent of cancer and its well documented mode of 
action and interactions, both with the chosen cell line and others. The effect of 
5-FU with both monolayer and spheroid cultures has also been well 
documented (Chen et al., 1999) showing that cells grown as spheroids cultures 
were generally more resistant to treatment than cell grown as monolayers. 
1.2.3 Anti-Cancer drug research 
The development of anti-cancer drugs has long followed a well-established 
pathway from discovery to production. A potential biomarker is identified 
through a rigorous screening process and the numerous drug candidates for 
this target will be designed and often are optimised using computational 
modelling (Sliwoski et al., 2014). Each drug candidate then undergoes a series 
of preclinical testing, typically starting with the use of established immortalised 
cell lines grown in monolayer, followed by use of relevant animal models. This 
initial process allows the researchers to establish the toxicity, specificity and 
potency of the compound (Parasuraman, 2011). In addition, preclinical testing is 
vital for determining the pharmacological properties of the new compounds 
including absorption rate, metabolites, safety and biological efficacy. Promising 
drug candidates that make it through the preclinical testing phase then enter the 
clinical phase of drug testing using human volunteers and, if effective, the drug 
will receive approval by the relevant governing body and be available for use. 
This process often takes in excess of 10 years and it has been reported that 
identified compounds achieving approval have a success rate of around 1 in 
10,000 (Tonkens, 2005). This has been illustrated in Figure 1.2, reproduced 




Figure 1.2 - Drug discovery and development pipeline.  
From target identification to regulatory approval the process can take up to 15 years. There is a low 
success rate with one potential drug candidate reaching approval status out of 5,000-10,000 identified 
compounds. 
This image was reproduced from (Matthews et al. 2016) under the creative commons license (CC BY 
4.0), figure adapted from http://cmidd.northwestern.edu/files/2015/10/Drug_RD_Brochure-12e7vs6.pdf 
, http://www.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf    
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There are several fundamental reasons why the success rate of new anti-
cancer drugs reaching FDA, and other licensing authorities, approval is so low. 
The cost of developing the drugs from bench to bedside along with 
manufacturing cost is one factor (Siddiqui and Rajkumar, 2012). It is estimated 
to cost around $2.6 billion (US) to get a single new drug through all clinical and 
preclinical testing (Boston: Tufts Center for the Study of Drug Development, 
2014), and in some cases, the cost per dose may not be affordable when 
weighed against clinical efficacy. 
 
Drug efficacy during preclinical and clinical trials is another major reason for the 
high attrition rate of potential drug compounds. This is especially prevalent 
during human trial phases, where many of the identified compounds that show 
promising results during the preclinical trials using established cell lines show 
limited efficacy when faced with a more complex 3D in vivo system (Ledford, 
2011). Animal models provide a partial bridge between the two systems, but in 
many ways are not relevant to human systems; see (Mak, Evaniew and Ghert, 
2014) for review. Any step away from the use of animal models, which are not 
only expensive but also ethically challenging, is clearly a positive one.  
Improving the translation between preclinical and clinical trials would allow 
ineffective drug compounds to be identified earlier within the process and would 
save resources, effort and time that could be redirected to be invested into other 
promising candidates.  
An avenue of research being explored to address these shortcomings is to re-
evaluate the value of 2D models in the overall process of drug testing. 
Monolayer cultures grown in sterile laboratory conditions using established 
immortalised cells lines are widely used in the development and efficacy testing 
of new drug compounds as part of preclinical trials. These cultures are easy to 
maintain, have a wealth of established protocols and assay kits, and are readily 
scalable for high-throughput testing (HTT). This makes monolayer cultures an 
ideal choice for the rigorous testing required for new drug compounds. 
However, 2D models lack some of the key features that are important to drug 
action in in vivo tumours.  
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When cells are grown on a flat surface the drug penetration rate, surface area, 
cell-cell interactions, gaseous gradients, and structural integrity are all markedly 
different from that of a 3D tumour (Weigelt, Ghajar and Bissell, 2014). Drug 
compounds are often shown to be significantly more effective in these 
monolayer cultures than when introduced to a 3D animal or human system 
(Torisawa et al., 2005). 2D models also lack the intricacy and diversity that 3D 
systems contain, which alters the cellular mechanisms that may be invoked in 
order to respond to and interact with therapeutic compounds. A potential model 
system that captures some of the features of 3D in vivo systems that could be 
used routinely in preclinical trials is the three dimensional cell culture 
(Astashkina and Grainger, 2014). 
1.3 Three-dimensional Cancer models 
There have been a number of 3D models developed, each with varying degrees 
of success for use in drug development and efficacy testing. The 3D model 
systems that have been developed and used within experimental cancer 
research include; whole perfused organs, tissue explants, scaffold/micro carrier 
based cultures, hollow-fibre bioreactors, organotypic cultures (including 
multicellular spheroids and cellular multilayers), and gel/matrix-based cultures 
(Vinci et al., 2012) as well as using animals to incubate tumour models. 
Researchers also believe that there is a potential future for some of these 
platforms to be expanded to utilised primary cell cultures for use in personalised 
cancer medicine (Cox et al., 2015). 
Where monolayer cultures are relatively simplistic to culture and have a wealth 
of available quantification methods, the response to therapeutic insult is often 
not comparable to the response in situ. Three dimensional models, such as 
spheroids, often require more complex culture methods and more sophisticated 
experimental techniques when compared to monolayer. In many cases, the 
responses to therapeutic insult in spheroids more closely resembles the 
response in situ due to the influence the three dimensional morphology has on 
drug uptake and metabolism. This is discussed further in the following sections.  
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1.3.1 Spheroid Culture models  
The most simplistic model to culture as well as to maintain is the multicellular 
spheroid model. This model was first developed in the 1970 by Sutherland and 
co-workers and has been found to be an advantageous tumour model 
(Sutherland, McCredie and Inch, 1971). Spheroids are useful due to their 3D 
tumour like structure which are described by Sutherland to resemble nodular 
carcinomas: they have a high cell count and are densely packed which leads to 
diffusion limitations. These limitations create heterogeneous cell sub-
populations of actively proliferating, dormant, hypoxic and necrotic cells similar 
to the microenvironment found within solid tumours (Khaitan et al., 2006). 
Although Sutherland was the first to coin the term spheroids, the classical 
hanging drop method had been utilised to form cellular aggregates from as 
early as 1907 (Harrison et al., 1907). Since then many other protocols have 
been developed for the production of spheroids depending on the size and 
quantity required for testing. 
When compared, the biological and physiological differences between 2D 
cultures and in vivo tumours are pronounced. When immortalised cancer cells 
are cultured using traditional 2D methods, the cells are adhered to a solid non-
porous surface on one side, and the other is exposed to a nutrient rich culture 
media at a depth that allows for gas exchange. The monolayer does not allow 
the nutrient and gaseous gradients typical of spatially structured cell aggregates 
to be established throughout as all cells are given equal exposure.  
Simply due to morphology, the cells within 3D structures are able to experience 
these gradients, causing there to be well-defined zones with varying degrees of 
exposure throughout a spherical culture when viewing a cross section. The 
interior of the spherical culture consists of a necrotic core, surrounded by a ring 






Figure 1.3 - Simplified top down cross-sectional view of a spheroid.  
A hypoxic necrotic core is the results of decreasing oxygen and nutrient gradients towards the 
spheroids centre. This is surrounded by a layer of viable quiescent cells. The outer most layer of a 
spheroid consists of proliferating cells. Designed on the information from (Byrne, 2010) (Sant and 
Johnston, 2017) . 
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Spheroids can be seen as simplistic 3D models in comparison to others such as 
scaffold based cultures (Tan, Krishnaraj and Desai, 2001), (Shin et al., 2016). 
However they still offer a suitably realistic model when trying to replicate the 
complexities of a tumour. Spheroid models consist of clusters of established 
immortalised cancer cells that form free-floating spherical aggregates. This 
clustering increases cell-to-cell interactions (Sutherland, 1988) and extra-
cellular matrix (ECM)-to-cell signalling (Khaitan et al., 2006), enhances 
proliferation gradients (Laurent et al., 2013), creates non-uniform exposure of 
cells to oxygen and nutrients (Mikhail et al., 2014), as well as to drugs (Achilli et 
al., 2015), and increased paracrine signalling (Huu Nguyen et al., 2015). 
 
Spheroids models have been used to explore chemosensitivity. When human 
lung cancer cell lines, are cultured as multicellular spheroids, they 
spontaneously develop resistance to a range of chemotherapeutic drugs, a 
phenomenon not seen in monolayer cultures from the same cell lines (Barrera-
Figure 1.4 - Representative image of a cancer spheroid.  
The colorectal cancer cell line HCT116+p53 was seeded into a 96 well ultra-low attachment (ULA) plate 
(Corning) at an approximate density of 3,000 cells in 200µL of DMEM cell culture media supplemented 
with 10% Fetal Bovine Serum (FBS) and 1% penicillin, streptomycin, glutamate. The plate was 
incubated at 37oC and 5% C02 in a sterile, humid tissue culture incubator. Image was taken at 10X 
magnification, scale bar is representative of 0.2mm.  
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Rodríguez and Fuentes, 2015) Leukemic cell lines when co-cultured with 
human bone marrow mesenchymal stem cells in 3D are more resistant to drug-
induced apoptosis in comparison to the same cells cultures in 2D or in 
suspension, as well as variation in resistance between cells lines in 3D (Aljitawi 
et al., 2014). Other studies have indicated similar findings with 3D cultures 
demonstrating increased levels of resistance to clinically relevant drugs 
(Loessner et al., 2010), (Karlsson et al., 2012a). Often this reported disconnect 
between drug response in monolayer and how drugs will respond in vivo can 
lead to the identification of promising drug targets in 2D being pursued only to 
fail when trialled in a 3D system (as noted, typically at the stage of in-vivo 
testing). 
 
In contrast, many studies have demonstrated an increase in sensitivity to 
therapeutic insult. (Howes et al., 2007) demonstrated that two PI3K inhibitors 
were unable to inhibit growth in monolayer cultures but caused a major 
suppression in spheroid growth, even at low concentrations. Similarly, (Hongisto 
et al., 2013) reported that JIMT1 breast cancer cells grown in three-dimensional 
cell culture with Matrigel were significantly more responsive than 2D models to 
63 drugs out of a pool of 102 drug candidates. Similarities between drug 
responses in xenograph tumours and spheroid cultures have been 
demonstrated in several different studies (Falkenberg et al., 2016),  (Mikhail, 
Eetezadi and Allen, 2013) and (Beloueche-Babari et al., 2015).  
 
Regardless of whether there is an increase or decrease in sensitivity in 3D 
compared to 2D, this research supports the view that using 3D cultures in drug 
development and efficacy testing is vital to decreasing the high rate of attrition 
in drug development and improve translation between seen in results reported 
in vitro, and those obtained from human trials. 
1.3.2 Role of Hypoxia in spheroid cultures 
A key feature of spheroid morphology is the presence of a hypoxic inner core as 
a result of the need for oxygen to penetrate into the spheroid, creating a 
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reducing oxygen gradient towards the centre (Figure 1.3). These features are 
established as the spheroid grows in size, with spheroids of 200-500µm in 
diameter developing oxygen and nutrient gradient and central necrosis 
developing when spheroid typically have grown to >500 µm in diameter. 
Therefore the size of the spheroid prior to therapeutic insult has an effect on the 
response to treatment (Hirschhaeuser et al., 2010). The presence of hypoxia in 
spheroids has been attributed to multicellular resistance to a number of 
routinely used anti-cancer drugs such as doxorubicin, fluorouracil and 
actinomycin D (Desoize and J.-C. Jardillier, 2000).  
Spheroids have been shown to exhibit alternative protein expression to that of 
monolayer counterparts (Gaedtke et al., 2007), (Kumar et al., 2008). In 
particular, the presence of a hypoxic core alters protein expression in spheroid 
cultures compared to monolayer in regards to HIF1α (Tian et al., 2010) and CA9 
(Logsdon et al., 2016).  
This research included protein expression levels in monolayer cultures as 
indicators in the final model. The proteins chosen for this research were 
selected based on their involvement in response to hypoxia and relevance to 
cell survival and drug response. The proteins selected were Hypoxia-inducible 
factor 1-alpha (HIF1α), BCL2/adenovirus E1B 19 kDa protein-interacting protein 
3 (BNIP3), Carbonic Anhydrase IX (CA9), Nuclear factor (erythroid-derived 2)-
like 2 (NRF2) and the Phosphorylated form of NRF2 (pNRF2), and Vascular 
endothelial growth factor (VEGF). The reasoning behind the inclusion of each of 
these proteins has been discussed within Section 2.6. 
1.3.3  Culture methods 
The classical method for developing spheroids, one that is still widely used 
today is the hanging drop method. This method was first developed in 1907 and 
involved the suspension of cells within an inverted drop of cell culture media 
and incubated under standard physiological conditions. The act of being 
suspended causes the cells to adhere to each other and form spheroids (Foty, 
2011). This is a popular method as it does not require any specialised 
equipment and can be used to produce uniform, individual spheroids and the 
method can be up-scaled for HTT. This technique does have its complications, 
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for example when changing media it is easy to disturb the drops or to overload 
the drops so that they are unable to maintain surface tension. Specialist gravity-
driven drop systems have been developed to simplify media changes and the 
administration of drugs to the drops (Tung et al., 2011).  
Other methods for the production of spheroids include agitation-based methods 
such as the use of a spinner flask or a rotary culture system. The spinner flask 
was the method developed by Sutherland and co-workers (Sutherland, 
McCredie and Inch, 1971). This method involves the use of a container 
containing a stirring element to keep the solution in a state of constant motion 
so that the cells are unable to adhere to the surface of the container but instead 
to themselves forming aggregates. This constant movement is thought to aid 
the transport of media and removal of waste (Kim, 2005). The medium can be 
frequently and easily changed providing a certain amount of control during 
culturing with this method as this allows long-term culturing of spheroids is 
possible and large number of spheroids can be generated (Breslin and 
O’Driscoll, 2013). The disadvantages of this system are its inability to control 
the size of spheroids produced, so if uniformly sized spheroids are required they 
must be manually selected. The medium requirements for this system are also 
larger than other static systems and the need for specialised equipment adds 
further to the cost. Spinner flasks work on the principle of agitation which can 
result in high shear forces that may damage cells or cause alterations to their 
physiology (Sutherland, McCredie and Inch, 1971) but because with the large 
number produced, undamaged spheroids of a similar size can be hand 
selected.  
Rotary culture systems work under much the same principle as the spinner 
flasks with the generation of spheroids through movement of the liquid media. 
The main difference is that instead of the flask containing a moving element, the 
whole vessel rotates which reduces the shear force so that spheroids grow 
larger than in spinner flasks and with less damage (Park et al., 2013). The 
National Aeronautics and Space Administration (NASA) developed a rotary cell 
culture system that has been shown to grow spheroids effectively from several 
cell lines (Ingram et al., 1997). This technique requires a specialist bioreactor 
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but after the initial high cost, provides a long-term high throughput production of 
spheroids. 
The use of non-adherent surfaces has long been a method for the culturing 
spheroids. Coating the wells of a cell culture plate in a non-adherent substance 
prevents cells binding to the surface so instead, cells bind to each other within 
the media. The wells can be coated in Poly-HEMA (poly-2-hydroxythyl 
methacrylate) before the cells are added (Xiang et al., 2011). A thin layer of 
agar or a film of agarose can also be used (Carlsson and Yuhas, 1984) or they 
may be coated with Matrigel (Li and Lu, 2011). A variation on this method is the 
use of low-binding 96 well plates which creates one spheroid per well which is 
highly reproducible and easily harvested for further assessment (Vinci et al., 
2012). This method uses Ultra low attachment plates and after establishing 
seeding densities, this method generates spheroids of between 300 and 500µm 
in diameter after 4 days. These plates can be bought already treated and ready 
to use, and save time by forgoing a pre-coating stage as well as removing 
inconsistencies that may occur when coating the wells manually in-house.  
A recent but more complex method for culturing spheroids is microfluidics. This 
culture method uses microfluidic chip technology to grow spheroids as both 
monocultures and co-cultures. A microfluidic chip consists of a series of micro-
channels created on a surface that is available in a range of materials such as 
glass, polymers and silicon. The microchannels facilitate the addition and 
removal of cell culture medium, therapeutic agents etc. to allow continual 
perfusion (Moshksayan et al., 2018). 
The reported advantages of using a microfluidic system are that the models 
include organ-level functions and interactions, the required sample sizes are 
smaller, the imaging, quantification and throughput are enhanced, as well as the 
systems being inexpensive and having increased controllability (Sung and 
Beebe, 2014). Several formats of microfluidics have been developed for the 
production of spheroids. These include a model that is compatible with 
conventional 96-well formats and can run 3D multicellular culturing and testing 
in parallel (Kim et al., 2015). An alternative format is a digital platform which 
enables the automation of liquid-handling protocols for the formation, 
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maintenance and analysis of spheroids in hanging drop culture (Aijian and 
Garrell, 2015). The versatility of the microfluidics system has allowed 
researchers to develop complex structures for using in drug development and 
testing. 
Recent advanced have seen the development of ‘organs-on-chips’ microfluidic 
cultures which have been proposed as a potentially replacement of animal 
models (Ingber, 2018). This methods has been used to generate 3D human 
lung-on-a-chip, (Zhang et al., 2018) and human intestines (Bein et al., 2018) 
among others.  
1.3.4 3D assays 
Despite the advances and increasing popularity of 3D models within drug 
development and testing, the use of spheroid cultures is not yet routine in all 
cell culture laboratories with 2D monolayer cultures remaining the gold 
standard. There has been a push in recent years to expand the market of 
assays developed for use in 3D cultures (Promega, 2015), (Amsbio, no date), 
(ProQinase, no date) or to modify existing protocols to make them more 
effective with 3D cultures (Ho et al., 2012). 
1.3.4.1 Cell Viability  
Arguably, the most common type of experimentation to carry out during drug 
efficacy testing is a cell viability assay. This assay allows researchers to 
quantify the effectiveness of the drug by how effectively it is causes cell death. 
With monolayer cultures, the results of cell viability often show much clearer 
results than when the same dosages and techniques are applied to 3D models, 
animal models, or on human participants. The reasons for this are varied. An 
anti-cancer drug added in solution to a monolayer has access to a wide surface 
area of cells with little to no penetration required to reach all of the cells. Drug 
penetration and uptake are often overlooked with monolayer cultures and can 
become a real challenge when working with 3D culture models and tumours 
(Mehta et al., 2012).  
Cell viability assays used on monolayer cultures often have the same issue with 
penetration and uptake; the reagents are able to access the viable cells easily 
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and so the cell viability within the monolayer is quantified accurately and 
consistently. Spheroids, due to their nature, often show a varied cell viability 
depending on the assay used (Ho et al., 2012). As spheroids are being reported 
increasingly to be a more suitable testing model, new assays are being 
developed that have drawn attention to this anomaly and corrected it (Buesch et 
al., 2016), (Zang et al., 2016).  
Common cell viability assays for monolayer cultures that have been adapted for 
use with spheroids include the acid phosphatase assay. This assay works on 
the principle of quantifying the cytosolic acid phosphatase activity. Acid 
phosphatases present in viable cells hydrolyse p-nitrophenyl phosphate to p-
nitrophenol and the extent of this change is directly proportional to viable cell 
numbers. (Friedrich, Eder, Castaneda, Doss, Huber, Ebner and L. a Kunz-
Schughart, 2007).  
ATP assays are also commonly used. The theory behind these assays is that 
the amount of ATP present is quantifiable and is proportional to the percentage 
of the culture that is still viable and actively producing ATP. These assays 
quantify cytoplasmic ATP by measuring the luminescence produced by the 
enzymatic breakdown of luciferin by luciferase, a process which requires 
cytoplasmic ATP (Kijanska, 2016). 
Other assays include the MTT assay (Toica, Linici and Ş, 2015), (Cultrex. 2013) 
measuring lactose dehydrogenase activity (De Witt Hamer et al., 2005), and the 
use of acridine orange to allow the analysis of spheroid cell viability using 
fluorescence microscopy (Eckerdt et al., 2016). Each of these techniques has 
had varying degrees of success when used with spheroid cultures. 
A method for rapid screening of spheroids cultured using green fluorescent 
protein (GFP) labelled cells has been developed as an alternative to the often 
laborious task of performing cell cytotoxicity assays. Viable cells tagged with 
GFP will emit a fluorescent signal that can be measured with the use of imaging 
techniques. The signal produced is proportional to the cytotoxicity of the culture 
and can be repeatedly measured over time; however this method is not suitable 
with fluorescent drugs (Karlsson et al., 2012a).   
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1.3.4.2 Morphological studies 
The assessment of morphological changes in response to therapeutic insult is 
possible with automated imaging techniques being developed for high 
throughput screening of spheroid cultures. The measurement of spheroid width 
and area have been explored as marker of compound treatment effectiveness 
as they will typically decrease when exposed to therapeutic agents (Sirenko et 
al., 2015), (Zhang et al., 2005), (Madous et al., 2017).  Automated imaging tools 
such as Celigo, a rapid plate-based image cytometry system (Celigo) have 
been used to develop high-throughput methods of recording changes in 
spheroid diameter, and monolayer confluence to determine IC50 concentrations 
from dose-response measurements (Kessel et al., 2016).  
Alterations to spheroid morphology such as volume and shape have been 
proposed as a source of variability in spheroid responses to treatment (Zanoni 
et al., 2015). Calculation of shape factors through image analysis has been 
used as a measure of spheroid infiltration, indicated by an irregular structure 
(De Wever et al., 2010).  A measure of roundness (Shape P2A) and area have 
been used to illustrate the effect of therapeutic insult on spheroid growth and 
morphology (Mittler et al., 2017).  
The measurement of spheroid diameter and spheroid circularity were included 
as morphological variables within this research. Diameter was chosen as a 
morphological variable as it provided information pertaining to changes in 
spheroid sizes when treated with therapeutic agents over time. Circularity was 
included as a variable for the information it provided in regards to spheroid 
integrity. Additionally monolayer confluence was measured in the monolayer 
cultures. The confluence of a monolayer is a descriptor of how much of the 
surface area is covered by cells, a confluent area refers to a monolayer where 
most if not all of the surface is occupied by living cells. As cells succumb to 
therapeutic insult, they die and no longer have the ability to adhere to the 
surface, leading to a reduction in cell confluence.   
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1.3.4.3 Proteomic profiling 
A standard western blot protocol is difficult to perform when using spheroids 
since it is hard to isolate a large enough protein lysate from the amount of cells 
present (Mehta et al., 2012). However there are modifications of this technique 
(i.e. microscale versions) available for use with spheroids as detailed by 
(Paguirigan et al., 2010) and (Pan, Chen and Jiang, 2010). These techniques 
can also be used in order to measure the expression of a range of different 
proteins with the use of the relevant antibody. 
Immunohistochemistry can be applied to spheroid cultures using paraffin 
(Weiswald et al., 2010) embedding, or cryosection (Walenta et al., 2000). The 
process of immunohistochemistry provides insight into localised expression 
through the cross section of the spheroid and how the distribution is affected but 
the presence of a hypoxic core towards the centre of the spheroid.  
This thesis carried out the protein expression quantification from 2D monolayer 
cultures using Immunocytochemistry (ICC) and Western blotting. Future work 
would look to include the quantification of protein expression levels in spheroid 
cultures using the above-mentioned methods.  
1.4 Statistical and modelling 
The over-arching aim of this research was to apply statistical modelling 
techniques to a variety of biologically collected variables in order to explore the 
relationships between variables collected from 2D and 3D cell cultures. The 
requirements of the model were the ability to incorporate a range of variables 
and relationships between them in a way that was informative and easily 
interpreted from a non-statistical background. As the data to be used with the 
model was collected from laboratory experimentation, the ability to provide a 
level of statistical accuracy with a limited data stream was also a concern.  
The application of mathematical and statistical models to biological data can 
provide insight into the complex network of mechanisms with cancer. Applying 
models of these sorts of data can allow researcher to apply a systems biology 
approach to research, and to study cancer as a complex system developed 
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from the integration of the wealth of data available (Blair, Trichler and Gaille, 
2012). 
  
Probabilistic graphical models (PGMs) such as Bayesian networks and 
undirected Markov networks have been used to describe the relationships 
between variables (Koller and Friedman, 2009). Cluster analysis has been 
implemented has been applied to high throughput data to identify clusters, and 
has been used to identify cancer subtypes through the clustering of gene 
expression data (Cp De Souto et al., 2008) 
Artificial neural networks (ANNs) have been widely applied to biological systems 
(Almeida, 2002). ANNs are an artificial learning tool that allows for the modelling 
of experimental data to identify relationships within datasets. They have been 
used within extensively cancer research for example the automatic analysis of 
prostate MRSI to detect cancer (Matulewicz et al., 2014), and intelligent breast 
cancer diagnosis  (Utomo, Kardiana and Yuliwulandari, 2014).  
These methods require very large sets of data that is beyond the scope of this 
thesis so a modelling approach of this sort would not be applicable to use with 
the scale of this research.  
For this research, multiple regression analysis (MRA) was researched as a 
possible method of modelling the collected data in this research. This method 
allows the prediction of a target variable from independent variables, and is 
considered a first generation multivariate analysis technique primarily used in 
the confirmation of an existing theory (Hair, 2013).  
Partial Least Squares regression (PLS regression) is a multivariate technique 
that explores linear relationships between multiple independent variables and a 
single (or multiple) dependent variables (Mateos-Aparicio, 2011). It is an 
extension of principle component analysis that is used to generate predictive 
relationships between independent and dependent principal components 
(Schaffer and Peltier, 2010). PLS regression has been applied, for example, to 
relate molecular signals to cellular responses in a data driven model studying a 
range of drug combinations and their effect on a number of cell lines (Lee et al., 
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2012). The application of PLS regression to signal-transduction networks has 
been reviewed alongside Principal Component Analysis (PCA) and clustering 
by Janes and Yaffe (Janes and Yaffe, 2006). Similar to the methods mentioned 
above, these methods were not suitable due the large data requirements.  
Partial least squares structural equation modelling (PLS-SEM) and covariance 
based structural equation modelling (CB-SEM) are considered second 
generation multivariate techniques (Benjamin and Gaskin, 2014) and allow the 
incorporation of unobserved variables through measures indicator variables 
(Chin, 1998). CB-SEM is primarily used for confirmatory studies of theories 
whereas PLS-SEM is used in exploratory research to develop theories (Joe F 
Hair et al., 2014a).  
PLS-SEM was chosen for this project for a number of reasons. Primarily on the 
ability to communicate the findings of the model visually, making it accessible to 
those without experience with the more abstract modelling techniques 
discussed previously. PLS-SEM has a focus on linear relationships, which are 
defined based on theory. Given there were limited data streams and the desire 
to explore relations between 2D and 3D data streams, PLS-SEM was chosen 
as the modelling method best suited to this research. 
1.4.1 Brief Introduction to PLS-SEM 
PLS-SEM was first developed as an alternative to CB-SEM (Wold, 1982). It 
focuses on maximising the explained variance of dependent latent variables in 
contrast to CB-SEM’s method of reproducing the theoretical covariance matrix 
(Hair, Ringle and Sarstedt, 2011). PLS-SEM applies ordinary least squares 
(OLS) as the estimating procedure for the path relationships within the model. A 
PLS-SEM model consists of two defined sub-models, the structural or inner 
model between the latent variables and the measurement or outer model 
between the indicators, or measurement variables, and the latent variables 
(Monecke and Leisch, 2012). The structure of these path models, and the PLS 
algorithm is described in more detail in Chapter 3. 
The PLS-SEM model has been widely adapted into several areas of business 
research, such as accounting (Lee et al., 2011) and marketing (Henseler, 
Ringle and Sinkovics, 2009), but has also been adapted for use in pollution 
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research (Gorai, Tuluri and Tchounwou, 2015), and healthcare (Avkiran, 2015). 
PLS-SEM was chosen for this research, as it is able to achieve a high level of 
statistical power with small sample sizes, it has a focus on predicting key target 
constructs, and is suitable with formatively measured constructs. As far as the 
author is aware, the use of PLS-SEM path modelling to biological data of this 
kind is novel by incorporating measured variables from monolayer and spheroid 
cultures to explore the relationships and predictive capabilities from 2D to 3D, is 
a new application area of PLS-SEM.  
1.5 Aims and objectives 
This research aims to integrate 2D and 3D systems in a novel way to explore 
the potential for prediction of 3D spheroid morphology based on the results of 
therapeutic insult in 2D monolayer experimental systems. The central 
hypothesis is that multivariate data streams from 2D monolayer cultures 
exposed to therapeutic insult can be used to inform the morphological changes 
of 3D spheroid cultures when responding to therapeutic insult.  
A range of drug effects were measured in monolayer and spheroid cancer cell 
cultures and the results of this experimentation were integrated into a PLS-SEM 
path model. The use of PLS-SEM allowed the exploration of relationships 
between the measured variables and assessment of the predictive capabilities 
of the variables from monolayer cell cultures on the results of spheroid cell 
culture variables. The research hypotheses explored are that: (1) variables 
collected from monolayer cultures correlate with variables from spheroid 
cultures after exposure to therapeutic insult over time: and (2) relationships 
between the monolayer viability and proteomic variables and spheroid 
morphometric indicators in responses to therapeutic insult over time could be 
exploited to predict the spheroid response from the 2D data inputs.  
 
The first major part of this research focuses on the effect of 5-FU exposure on 
monolayer and spheroid cultures, focusing on the effect on cell viability between 
the two cultures methods, and measuring morphological changes relevant to 
the two culture methods. The morphometric measures recorded were 
monolayer cell confluence, spheroid diameter, and spheroid circularity. Western 
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blotting was used to quantify 6 proteins of interest, BNIP3, CA9, pNRF2, NRF2, 
HIF1α, and VEGF with the first three being included within the PLS-SEM path 
model. Cell Viability was chosen as a variable as it provides a direct indicator of 
cell death caused by therapeutic insult. Proteomic indicators were included to 
show the effect of therapeutic insult on the internal pathways, focussing on 
proteins of interest (POI) pertaining to cell death pathways, and hypoxia. Three 
POI were included within the final model. Two morphometric variables were 
included from spheroid cultures, these were selected as they were indicators of 
the effect of therapeutic insult on the size, and integrity of the spheroids. 
Monolayer confluence was included as it provided a visual quantification of cell 
growth and death within the monolayer cultures. 
This research tested the use of two cell viability assays, the MTT assay and the 
CellTiter-Glo®, an ATP quantification based assay from Promega, in both 
spheroid and monolayer cultures and ultimately decided to use CellTitre-Glo to 
record the effect of 5-FU administration on cellular viability within the two culture 
systems. Quantification of the proteins of interest in monolayer was carried out 
initially using immunocytochemistry and through Western blotting for values 
included within the dataset. The morphological indicators were recorded 
through a variety of image analysis techniques.  
 
The second major part was the development of a PLS-SEM path model to 
explore the relationships between the measured variables, and explore the 
strength and predictive power of these variables. The results of the model can 
be viewed for each dose concentration of 5-FU and time point used. The 
biological variables were separated into four latent variables, these were group 
based on the variable type (morphometric, proteomic, spheroid viability, and 
monolayer viability). The monolayer variables were identified as the exogenous 
variables, and the spheroid variables as the endogenous variables. 
  
The results of the biological experimentation are set out in Chapter 4. The 
statistical assessment of the biological results, and the results of the PLS-SEM 




2 Chapter Two, Experimental methodology 
2.1 Introduction to the experimental methodology 
This Chapter will outline the experimental methods used during this project to 
collect the data to be used in the statistical model. Starting with an outline of the 
cell culture methods used to maintain and treat both monolayer and spheroid 
cultures for experimentation, followed by the method of quantifying cell viability 
in both cultures, imaging and image analysis, and lastly the methods used to 
carry out both immunocytochemistry and western blotting for proteomic 
experimentation in monolayer. An overview of the processes used and the 
variables obtained from them can be found in Figure 2.1. Indicative results have 
been used throughout this Chapter to support the explanations of the methods 
chosen, as well as to demonstrate where methods were refined or not carried 















Figure 2.1 - Flow chart outlining the experimental measures undertaken 
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2.2 Cell Culture 
The experimental work was carried out using monolayer and spheroid cultures 
generated from immortalised secondary cell lines. The cell lines used and the 
culture media used for each can be found in Table 2-1. The methods used to 
maintain these cell lines, as well as details of seeding and treatment for 
experimentation will be covered in sections 2.2.1-2.3.3. 
2.2.1 Mammalian cell culture 
The DMEM Glutamax™ media used for all cells was supplemented with 10% 
filter sterilized foetal bovine serum (FBS), and 1% penicillin, streptomycin and 
glutamate. Cell were maintained at 37oC and 5% CO2 with a sterile, humid 
tissue culture incubator. 
Table 2-1 - Cell lines used and relevant information 









HCT 116 -/-p53 Colon 
epithelial 





2.2.2 Sub-cultivation of Cell Lines 
The HCT116 cell lines were grown in T75 tissue culture flask and sub-cultivated 
when the cells reached approximately 80-90% confluence in order to ensure 
survival. This procedure was performed under sterile conditions in a tissue 
culture hood. Prior to the cells being removed from the incubator and placed 
within the tissue culture hood all media, buffers and trypsin were heated to 37°C 
by being placed in a water bath for around 30 min. Once the materials had 
reached an approximate temperature of 37°C, they were moved to the tissue 
culture hood after being sterilized clean with 70% ethanol solution. The growing 
cells were then viewed under a standard microscope at 10X magnification to 
check for any signs of contamination and to note confluence and health of the 
cells. Inside the tissue culture hood the old media would be poured off and the 
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cellular monolayer gently washed with sterile phosphate buffered saline (PBS). 
Then 5mL of trypsin EDTA was added to cells and the flask returned to the 
37°C incubator for 5 min or until the cells have detached from the flask’s 
surface. Equal parts of cell culture media (5mLs) were then added to neutralize 
the trypsin and the contents of the flask was transferred to a sterile 15mL 
centrifuge falcon tube and spun at 1000 RPM for 15 min in a centrifuge that was 
maintained at 37°C and to a pellet the cells. 
The cells were returned to the tissue culture hood following sterilization of the 
falcon tube with 70% ethanol and the pellet re-suspended in fresh media. If 
seeding for experimentation, then the protocol from 2.2.3 was followed. 
Depending on the quantity of cells, they would be split at a ratio of between 1:3 
and 1:10. An appropriate amount of media containing cells suspension was 
added to a new tissue culture flask containing 12-15mLs of media and placed 
into the tissue culture incubator. The protocol from 2.2.4 was then followed with 
the remainder of the cell solution. 
2.2.3 Cell Counting  
When preparing to seed for experimentation, cells were subjected to counting. 
A haemocytometer and cover slips were cleaned with the use of 70% Ethanol 
solution and lens paper and placed within the tissue culture hood. After the 
centrifuging step discussed in 2.2.2 cells were re-suspended in an appropriate 
volume of fresh media and aspirated with the use of a serological pipette. Using 
a micro-pipette, 20uL of cell suspension was transferred into each cell chamber 
underneath the coverslip by capillary action and viewed under a microscope 
using 10X magnification. The cells in 10 of the 0.04mm2 boxes (Figure 2.2) 
were counted and this number was noted. This was repeated twice with 10 
different boxes each time and the mean of these counts was calculated. The 
following formula was then used to calculate how many cells were in 1uL and 
from here the volume or cells suspension required to obtain the desired amount 
of cells per well can be calculated.  
The area of 10 of the 0.04mm2 boxes = 0.4 mm2 
Volume of 10 boxes = 0.4mm2 x 0.1 (height of camber) = 0.04mm3 
1mm3 = 1µL therefore 0.04 mm3 = 0.04µL 
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Cells in 10 boxes = 100 (as example) 
100 x 1 µL / 0.04 µL = 2500 
2500 cells in 1 µL. 
The number of cells seeded per well, the plate type, and the volume of media 
required per well differed for each experimentation type (Table 2-2).  
Table 2-2 - Cell seeding numbers, media volumes per wells, and experimentation type 
Plate type Number of cells 
seeded per well 
Volume of Media 
added up per 
well 
Experiment type 
96 well 3 x103 200 µL Cell viability 
96 well ULA 3 x103 200 µL Cell viability 
Spheroid Formation for 
image analysis and 
protein expression.  
6 well 5x104 2.5 mL Immunocytochemistry 
60mm round 
plate 
6x105  4 mL Protein extraction for 
western blotting                                                                                                                                                                                                                         
Figure 2.2 - Representative image of cell counting chamber.  




2.2.4 Cryopreservation of surplus cells and cell revival  
After passaging the remainder of the cells suspension was then centrifuged at 
1000 rpm for a further 7 min. The falcon tube containing the cell pellet was 
sterilised clean and returned to the tissue culture hood and the supernatant 
poured off. The cells were the re-suspended in 500µL of freeze-mixture per 
cryopreservation-tube (cryotube) with the aid of a micro-pipette. The cryotubes 
were labelled with the cell line name, passage number, the date of freezing, 
initialed, and stored at -80°C. The freeze mixture was prepared in the lab by 
making up a solution of 80% FBS, 12% media and 8% dimethyl sulfoxide 
(DMSO). This mixture was syringe filtered with a 0.2µm filter into a sterile 
centrifuge tube and then stored at -20°C. Before use it was thawed in a 37°C 
water bath until defrosted, then sterilised clean and transferred to the tissue 
culture hood.  
2.2.5 Spheroid Generation  
As explored in the literature review there are several methods available to 
culture spheroids with the use of secondary immortalised cancer cells line. 
Here, ultra-low attachment round-bottomed plates (ULA, Corning®) were used. 
These plates were cells seeded as standard 96-well flat bottomed plates using 
a multi-channel micropipette. Closely 3000 cells in 200µL media suspension 
was added to each well and the spheroids were kept in a sterile tissue culture 
incubator (37oC and 5% CO2) for 3-4 days to allow the spheroids to form before 
any treatment. The spheroid formation was monitored daily under a standard 
microscope during this time. When growing spheroids for extended periods of 
time the media would be refreshed every 2 days by removing 100µL of media 
from the well gently without disturbing the spheroids and replacing it with an 
equal volume of fresh media. This process would be repeated twice to allow for 
~75% of the media to be replaced. 
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2.3 Drug treatment regimes 
2.3.1 Drug and stock concentrations 
Depending on the experiment, different drug stock concentrations were used to 
best suit the concentrations required. The therapeutic agent used during this 
project was 5-Fluorouracil (5-FU), an anti-cancer drug that is routinely used in 
clinical settings. Drug (5-FU) stock was made up weighing the desired amount 
using a covered 4 decimal point scale. The drug was fully dissolved and diluted 
in sterile DMSO as stock. The stock solution was then syringe filtered into a 
sterile 1.5mL Eppendorf tube and stored in 4°C for 4 months. There were two 
stock concentrations used throughout this project (Table 2-3). 
Table 2-3 - Drug stock concentrations used throughout the duration of the project. 
Drug Stock 
Concentration 
Amount of drug Final Volume 
5 Fluorouracil  50mM 6.5mg 1mL 




2.3.2 Culturing and Treating Monolayer Cells (2D) 
Monolayer 2D cultures of cells were incubated (37oC and 5% CO2) for a period 
of 4 days after seeding to match the growth time of the spheroids with the 
exception of seeding to extract cellular proteins for western blotting, where the 
cells were seeded in 60mm tissue culture plates (Thermo Scientific) for 24 h 
before treatment.  
After incubation the complete media was then removed from the plate / well 
using a vacuum pump taking care to not disturb the monolayer in any way. 
Desired drug concentrations had been created from a stock by serial dilution 
and decreasing by 
1
3
 of each concentration. When carrying out serial dilutions, 
DMSO was added to the media used for the dilutions in the same concentration 
as the highest 5-FU concentration. This ensured consistent DMSO levels 
across all of the drug concentrations (Figure 2.3). The appropriate volume of 
media containing drugs was then added to each of the plates / wells and 
incubated in the tissue culture incubator for the duration of the experiment.  
2.3.3 Culturing and Treating Spheroids (3D) 
The treatment of the spheroid cultures was much the same as the treatment of 
the monolayer with the exception that only 50% of the media from seeding was 
aspirated off with use of a micropipette. This volume was then replaced with the 
Media containing equal concentration of 
DMSO to match highest concentration 





















media with drug 
stock added 
… 
Figure 2.3 - Illustration of serial dilution preparation.  
The highest concentration was made to a volume a third higher than required, then a third was removed and 
mixed thoroughly into the second highest concentration, and then removed to be mixed with the third 
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desired drug concentration at 2X. This was done so to minimise the risk of 
disturbing the spheroid during the treatment process: if the spheroids are 
disturbed by pipetting it would affect the imaging process to monitor the effect of 
the drug on spheroid morphology (Vinci, Box and Eccles, 2015). When using 
the 96 well ULA plates, the spheroids are seeded in 200µL, when treating the 
spheroids 100µL is removed and replaced with 100µL of media containing 2X 
the desired drug concentration.  
A full list of the concentrations prepared for each of the experiments can be 
found in Table 2-4. The number of concentrations used for the monolayer and 
viability assays, and subsequently the image analysis carried out to measure 
monolayer confluence, spheroid diameter, and spheroid circularity was far 
larger than the proteomics. This decrease in the number of 5-FU concentrations 
for the proteomics was informed by the results from the cell viability analysis 
and reduced to cut down on consumables and labour while still informing on the 
effect of the therapeutic agent, 5-FU. All experiments were carried out with 




Table 2-4 - Full list of the concentrations of 5-FU prepared for all the experiments.  
In the case of the spheroid viability, the prepared concentration is 2X the final concentration, the final 





Immunocytochemistry Western Blot 
300 µM 600 µM (300 µM) 96 µM 180 µM 
200 µM 400 µM (200 µM) 59 µM 96 µM 
180 µM 360 (180 µM)  59 µM 
133 µM 266 µM (133 µM)  26 µM 
96 µM 192 µM (96 µM)   
89 µM 178 µM (89 µM)   
59 µM 118 µM (59 µM)   
40 µM 80 µM (40) µM   
26 µM 52 µM (26) µM   
18 µM 36 µM (18 µM)   
 
2.4 Cell Viability Assays  
The purpose of carrying out cell viability assays was to assess the effect of 
treatment with 5-FU on the cultures. When researching suitable methods for 
use in both monolayer and spheroid cultures, several were identified and two 
were selected to be tested. These methods were the Methylthiazolyldiphenyl-
tetrazolium bromide (MTT) colourmetric assay, and the CellTiter-Glo® cell 
viability assay (Promega). The MTT assay is a well-established method of 
determining cytotoxicity (Mosmann, 1983), that has been used routinely. An 
explanation of the MTT assays mode of action can be found in 2.4.1. The 
CellTiter-Glo® cell viability assay is a newer method developed by Promega 
and is suitable for use in 3-D cultures. It mode of action is described in 2.4.4. 
Both methods were carried out for comparison and ultimately the CellTiter-Glo® 
cell viability assay was chosen.  
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2.4.1 MTT assay 
To quantify cell viability within both spheroid and monolayer cultures with the 
use of the methyl-thiazolyl-tetrazolium (MTT) colourmetric assay. The mode by 
which the assay works is through the reducing of MTT to formanzan by 
dehydrogenase enzymes involved in cellular metabolism, which is purple in 
colour. Dead cells are unable to metabolize, altering the amount of reduced 
formanzan produced. The absorption of the well at 560nm quantifies the 
amount of reduced formanzan present, which can be translated to cell viability. 
10X MTT stock solution was made by adding 5mg/mL of MTT powder into PBS 
and then sterile filtered. This was stored at 4°C in a fridge and covered to stop 
exposure to light.  
2.4.2 MTT protocol in monolayer 
To carry out the MTT assay, first 20µL of 5 mg/mL MTT stock reagent was 
added to each well and returned to the incubator for 4 h. After this incubation 
period the plates were returned to the tissue culture hood where all fluid was 
removed from the wells with the use of a vacuum pump and sterile filter tip and 
50µL of DMSO was then added to each well. The plate was placed into the 
tissue culture incubator for 15 min. This 50µL was then removed and placed 
into corresponding wells of a new plate and the absorbance of the wells was 
then measured at 560nm with a multiplate reader (MODULUS™, Promega). 
This method was used to observe the growth rate of the cell lines over time in 
monolayer cultures, as shown Chapter 4. From this preliminary experimentation 
this method was shown to be suitably reproducible for monolayer cultures. 
2.4.3 MTT protocol for spheroids 
The protocol for monolayer was modified and adjusted for the spheroids, in 
order to account for the time the reagent would take to penetrate the spheroids. 
The protocol that was followed was described in (Cultrex., 2013).After the 
period of treatment 20µL of 5 mg/mL MTT reagent was added to each well 
containing 200µL of media and one spheroid. The plate was then returned to 
the tissue culture incubator for a full 24 h to allow time for penetration. After this 
incubation period, 150µL of media was removed from the well using a 
micropipette and 100µL of DMSO was added. This was again returned to the 
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tissue culture incubator for 24 h to allow for penetration and the release of the 
formazan from the cells that make up the spheroid. Following this the fluid 
(disrupted and solubilized spheroid) was transferred to a clean well and the 
absorbance was read at 560nm.  
This method was not as reproducible during spheroid culture optimization 
(Figure 4.2). As indicated by the sizable error bars on the graph, the variance 
among the replicates was significantly larger than that of the replicates in the 
monolayer cultures. The MTT assay was also used preliminarily to assess the 
effect of the therapeutic agent, 5-FU, in both monolayer and spheroid cultures 
(Figure 2.4)  
 
  
Figure 2.4 – MTT based cell viability assay carried out to measure the effect of 5-FU exposure in 
monolayer and spheroid cultures  
Both spheroid and monolayer cultures were cultured with an initial seeding density of 3,000 cells and 
incubated following treatment for a period of 96 hours. Each point represents the mean of four replicates 
and the error bars are representative of 1 standard deviation. There was high variability between the 
spheroid replicates when using this experimental technique, shown by the large error bars. This was due 
to poor uptake of the MTT reagent during incubation, or insufficient lysis of the spheroids prior to reading 
the absorption. This high variability with the spheroid cultures made the assay unsuitable for this project. 
Due to the inaccuracy of this method to measure cell viability and the length of 
time required for the incubation of the spheroids, this method was ruled out for 
use in this project. The unsuitability of the MTT assays, and other related 





























(Walzl et al., 2014), (Kijanska and Kelm, 2016a), therefore alternatives assays 
were tested.    
2.4.4 CellTiter-Glo® cell viability assay 
The recent ready to use CellTiter-Glo® assay (Promega) was identified as a 
potential assay of interest as it had been adapted for use with 3D cell cultures 
and had shown reproducible results within the literature (Kijanska and Kelm, 
2016b). Promega was contacted to request a free sample of the premade 
reagent and received it shortly after.  
The manufacturer’s protocol supplied with the reagent was followed with only 
minor changes as set out below, (Promega, 2015) 
The assay uses the quantification of Adenosine 5′-triphosphate (ATP), a marker 
for of metabolizing cells, present to determine the amount of viable cells 
present. A single ready to use reagent is added to the wells, causing cell lysis 
and a luminescent signal is produced, the strength of this signal is proportional 
to the quantity of ATP.   
The reagent was stored at -20°C in a light safe container. The day before use it 
was removed from the freezer and thawed gradually overnight at 4°C. Before 
use, the reagent was removed from the fridge, and allowed to equilibrate to 
room temperature by placing the bottle into the 37°C water bath for around 10-
15 min before gently inverting the bottle to ensure a homogenous solution and 
placing into the tissue culture hood for 15 min.  
This assay was performed using opaque walled 96 well plates, but as the 
spheroids are initially seeded into clear 96 well ULA plates for imaging 
purposes, they must first be transferred to the opaque plate. An opaque plate is 
required as when using clear wells the luminescent signal from neighbouring 
wells can cause ‘cross-talk’. A slight diminishing in signal intensity may also 
occur (Riss et al., 2002).  
The plate containing the spheroids was first removed from the tissue culture 
incubator and placed inside the sterile tissue culture hood. The very tip of a 
200uL pipette tip was cut off using a sterile blade, in order to widen the opening 
for the spheroids to pass through. The spheroids were then pipetted up out of 
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the well alongside 50µL of media and transferred into corresponding wells on 
the opaque plates and allowed to equilibrate to room temperature for 30 min. An 
equal volume of CellTiter-Glo® reagent is then added to each of the wells 
(50µL) as well as to background wells containing only 50µL of media and no 
spheroids, and the plate is transferred to an orbital shaker for 5 min of vigorous 
shaking to induce cell lysis while being shielded from light. The plate is then 
placed on the laboratory bench to incubate for a further 25 min. During this time 
the plate reader is switched on and set up to read luminescence at an 
integration time of 1 sec (Promega recommends between 0.25 and 1 second) 
and the photomultiplier (PMT) is activated. The plate is the placed in the plate 
reader and the luminescence signal is recorded for each well. The results of 
optimization with differing cell seeding densities after being normalized to the 
background wells (0 cells) established that the optimum seeding density was 
3000 cells (Figure 2.5), as this produced results between the upper limit of the 
assay (around 10µM ATP) (Promega, 2015) and the lower limit to allow 
recordable growth and decrease of the spheroids.  
 
Figure 2.5 – CellTiter-Glo® cell viability assay based on measure of ATP carried out with spheroids 
generated with differing cell seeding for experiment optimization. 
 Seeding densities of 500-10,000 cells per 200µL added to wells of a ULA plate and incubated for 72 h to 
allow the formation of compact spheroids. The CellTiter-Glo was carried out and the results of the 
luminescence at an integration time of 1 sec was recorded. Each point was repeated in triplicate and the 





























2.4.5 CellTiter-Glo® assay for monolayer 
This protocol used for monolayer culture was very similar to that of the 
spheroids. The cells were seeded at a density of 3000 cells per well to match 
that of the spheroids. As far as possible conditions were matched in order to be 
comparable, so the cells were incubated for 3-4 days before treatment to match 
the growth of the spheroid cells for the 3-4 days they are left to form compact 
spheroids. The cells were seeded into opaque well plates directly. At the end of 
the desired incubation time, all media was removed from the well and 50µL of 
fresh media was added. The plate was left to equilibrate for 30 min to room 
temperature. An equal volume of CellTiter-Glo® reagent was then added to the 
wells (50µL), after having been prepared in the same manner as the spheroid 
cultures (2.4.4). The plate was then mixed vigorously on the orbital shaker for 2 
min, as opposed to 5 min of shaking used for spheroids, and incubated for 10 
min instead of 25 before the luminesce was recorded using the same 
parameters as the spheroids. This method was used to create a drug dose 
response curve for both the monolayer and spheroid cultures as well to 
calculate their IC50s, (Figure 4.3 and Figure 4.4).  
 
 
Figure 2.6 – CellTiter-Glo® cell viability assay based on measure of ATP used with spheroid and 
monolayer cultures of HCT116+/+ cells treated with 5-FU for 96 h.  
The results of both monolayer and spheroid drug dose response curves (Figure 4.3, Figure 4.4). Here the 
results have been plotted together to for comparison. Although the raw figures shown here differ, after 
normalization to show percentage decrease compared to the control the monolayer and spheroid results 




















Figure 2.6 shows the results from both the spheroid and monolayer cell viability 
assay plotted together. Although both cultures follow broadly the same trend in 
response to the drug treatment, the drug differs in effectiveness between the 
monolayer and spheroids, as shown by the IC50s calculated to be 93µM with a 
SE of 1.5µM  and 118µM with an SE of 6.2µM  from this experiment. The IC50 
value represents the half maximal inhibitory concentration and the EC75 is the 
concentration that causes the response to be reduced 25% from the maximal. 
The IC50 values were calculated using the analysis software Graph Pad Prism 
(www.graphpad.com). This was carried out through first normalising the data 
set using the normalise function, and then generating a nonlinear regression 
curve through the ‘[Inhibitor] vs. normalised response – Variable slope’ function. 
This provided the IC50 values. In order to generate the EC75 values, the 
[agonist] vs. response – find ECanything’ function was used, applying the 
following constraints; F=75 and the HillSlope value generated from the 
calculation of the IC50.    
2.4.6 The effect of therapeutic agents on cell viability 
The cell viability assays using CellTiter-Glo® was carried out at 24 h intervals 
during the treatment period, at 24, 48, 72 and 96 h respectively, on both 
monolayer and spheroid cultures using the protocol described above (2.4.4 - 
2.4.5).  
The effect of 5-FU on the monolayer cultures over time differs between the 
concentrations used. The three lowest drug concentrations (18µM, 26µM, and 
40µM) deviated very little from that of the controls. A higher concentration of 
300µM was included to cause near total cell death (Figure 2.7).  
This experiment was used to guide and inform the choice of time point and the 
drug concentrations used in the more labour and consumable extensive 
experiments such as the protein expression analysis. From the monolayer 
results it showed that the number of concentrations could be reduced as at the 





Figure 2.8 - CellTiter-Glo® cell viability assay based on measure of ATP used with spheroid cultures of 
HCT116+/+ cells treated with 5-FU for 24-96 h.  
Cells were incubated for 3 days after prior to treatment with 5-FU to allow spheroids to form. The CellTiter-Glo® 
assay was carried out at 24, 48, 72 and 96 hours. The graph above shows the results of the 5-FU treatment over time. There 
was high variation between replicates due to a practical complication. Error bars represent 1 standard deviation. N=3 
Figure 2.7 - CellTiter-Glo® cell viability assay based on measure of ATP used with monolayer cultures of 
HCT116+/+ cells treated with 5-FU for 24-96 h.  
Cells were incubated for 3 days after prior to treatment with 5-FU. The CellTiter-Glo® assay was carried out at 24, 
48, 72 and 96 hours. The graph above shows the results of the 5-FU treatment over time. There was little difference in effect 
at lower concentrations, and the highest concentration (300µM) causing near total cell death by 96 h. Error bars represent 
1 standard deviation. N=3 
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When this experiment was first carried out using the spheroid cultures, during 
the movement from the ULA plate and the white plate there was some pipetting 
errors where the spheroid would not be expelled from the tip, leaving the new 
well empty. When using the same tip for replicates of the same drug 
concentration, this also led to multiple spheroids being expelled into certain 
wells. This manual error accounts from the high error bars and the lack of 
significant change between drug concentrations (Figure 2.8).  
This was rectified during the latter half of the experiment by increasing the 
amount removed from the tip of the pipette tip slightly and ensuring that the 
media is pipetted up and down 2-3 time after transferring the spheroid to ensure 
the spheroid has not become ‘stuck’ on the inside of the pipette tip. The 
experiment was repeated with these modifications to and the issue was rectified 
(Figure 2.9).  
The concentrations chosen for the PLS-SEM model dataset were four (26, 59, 
96, 180µM) 5-FU concentrations alongside a control (UT). These were chosen 
as the represented high and low values from the viability dose response curve, 
Figure 2.9– Repeat of CellTiter-Glo® cell viability assay based on measure of ATP used with spheroid 
cultures of HCT116+/+ cells treated with 5-FU for 24-96 h.  
The experiment from Figure 9 was repeated with the practical modifications to the protocol. The results of this 
experiment showed far less variation between replicates. Also concentrations show a slight increase between 24 
and 48. 300µM 5-FU does not cause near total cell death as it does in the monolayer cultures. 
 
44 
alongside the IC50 and EC75 concentrations calculated form the 96 h 
monolayer viability drug dose response curve. The max concentration of 180 
µM was chosen as reduced the cell viability to close to 20% of the UT at 96 h, 
which allowed for sufficient extraction of proteins from the remaining viable cells 
to carry out western blot analysis.     
2.5 Imaging 
The morphometric measures of diameter, circularity and confluence were used 
as variables in this project. These measures would provide information 
pertaining to the observable effect of therapeutic insults in both spheroid and 
monolayer cultures. It is expected that as the dosage of the drug is increased, 
and over time the diameter and circularity of spheroid will decrease as the cells 
undergo death as a result of therapeutic insult and the spheroid shrink and lose 
integrity. To the same effect the monolayer confluence is expected to decrease.  
To collect morphometric measurements from the spheroids a variety of imaging 
techniques were explored in order to find one that best suited the requirements 
of the project. A range of different imaging equipment was used, and depending 
on the requirements of the experiment carried out different equipment was 
utilized as set out below. 
2.5.1 Imaging of spheroids 
When imaging the spheroids, a 2D top down image was taken of the 3D culture. 
When deciding what measures could be taken from this image that would best 
represent the 3D nature of the culture, it was decided to take the diameter at the 
widest point of the spheroid (ferret diameter), as well as taking into account the 
circularity (Sirenko et al., 2015), (Gong et al., 2015). When presented with a 
therapeutic agent, the spheroid not only changes in size, but the morphology 
alters (Mittler et al., 2017). The spheroid will change from having a smooth 
unblemished surface and be relatively spherical to having an uneven ‘rough 
surface’ surrounded by a halo of dead cells. This loss of spheroid integrity 
causes circularity to decrease (Friedrich, Eder, Castaneda, Doss, Huber, Ebner 
and L. a Kunz-Schughart, 2007) (Figure 2.10). 
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These images were taken using a Leica DMiR E2 microscope equipped with 
iXonEM +897 EXCCD camera (ANDOR technologies Ltd) captured at 10X 
magnification as this was found to produce the sharpest and most defined 
images of the spheroids for analysis.  
2.5.2 Image analysis 
The majority of image analysis was carried out using the free imaging analysis 
program ImageJ (Schneider, Rasband and Eliceiri, 2012). With this program it is 
possible to measure the circularity and feret diameter of particles, in this case 
spheroids. The circularity of an object, refers to how close the object is to a 
perfect circle and is calculated by ImageJ using the following formula: circularity 
= 4π (area/perimeter2). The (maximum) feret diameter of an object refers to the 
longest distance between two points on opposite sides of a particle (Merkus, 
2009).The following steps were carried out in order to gather quantifiable data 
from the images 
The images were first opened on ImageJ and duplicated. The duplicated 
images were converted to 8-bit images. The ‘find edges’ function was used and 
the image was then converted to a threshold image (standard across all 
images) and the space occupied by the spheroid defined using the standard de-
Figure 2.10 – Representative images of HCT116++ spheroids treated with 5-FU to illustrate 
changes in morphology.  
The spheroids seeded and then incubated for 4 days before treatment. The image on the left is of a 
spheroid treated with 200µM 5-FU, taken immediately following treatment. The image on the right is 




speckle and fill hole functions. The altered image was then saved so that it 
could be re-visited for reference. The scale of the image was set by taking an 
image of micrometer and using this to record a known distance in pixels. The 
scale was then set to global for all subsequent images analysed in that imaging 
session. The same scale was used universally on all images taken using that 
microscope and magnification. The measurements were set to measure the 
circularity and the ferret diameter and then the particles analyzed. The results 
were then recorded on an excel spreadsheet for analysis.  
Other imaging equipment was utilized depending on the requirement, a Nikon 
D5000 camera with microscope lens attachment was used with a standard 
microscope to take images a 4X magnification. 
2.6 Protein expression in monolayer 
The protein expression of monolayer culture was of interest in the model as the 
reported findings, discussed in detail in Chapter 1, show that the proteomic 
landscape of spheroids differ from that of monolayer cultures. By carrying out 
protein expression analysis in monolayer cultures as an indicator in the later 
statistical model it will provide insight into the effect of the proteins in regard to 
viability and drug response and any relationships they may have with spheroid 
indicators. 
The proteins of interest chosen in this project were chosen for their relevance in 
cell survival, and roles in response to hypoxia. The larger cohort of proteins 
included  
 BNIP3 - BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
 CA9 – Carbonic Anhydrase IX 
 HIF1α – Hypoxia-inducible factor 1-alpha  
 NRF2 - Nuclear factor (erythroid-derived 2)-like 2 
 pNRF2 – Phosphorylated form of NRF2 
 VEGF - Vascular endothelial growth factor 
This was later reduced to 3 proteins of interest to be included in the final 
statistical model.  
 
47 
BNIP3 is associated with cell death, and is induced by HIF1α under hypoxic 
conditions (Burton and Gibson, 2009).  The literature reports that p53 
suppresses BNIP3 promoter activity under both normoxic and hypoxic 
conditions when exogenous p53 expression is stimulated by 5-FU (Feng et al., 
2011a). The cells line being used in the project is +p53 wild type.  BNIP3 is a 
good prognosis indicator in colorectal cancer (CRC), and its silencing is 
associated with chemo resistance to 5-FU (He et al., 2017). 
CA9 is a transmembrane protein, and one of two tumour-associated membrane 
proteins in the carbonic anhydrase family. It plays a role in pH regulation of 
cancer cells (Benej, Pastorekova and Pastorek, 2014). CA9 is a predictive 
indicator of survival in colorectal cancer (Logsdon et al., 2016) and a 
representative marker of hypoxia as it is regulated under HIF1α and involved 
within hypoxia response pathways (Logsdon et al., 2016). 
HIF1 is a transcriptional factor that consists of two protein subunit, HIF1α which 
is degraded under normoxic conditions, and HIF1β which is constitutively 
expressed. It is activated under hypoxic stress, and it turn activates a number of 
genes involved in angiogenesis, cell survival, glucose metabolism and invasion 
(Semenza, 2003). HIF1⍺  is involved in the upregulation of VEGF expression, 
and the upregulation of CA9 expression.       
NRF2 is a master regulator of the antioxidant response (AR) pathway (Khalil et 
al., 2016).  Under basal conditions NRF2 is sequestered in the cytoplasm 
through Kelch-like ECH-associated protein1 (Keap1). Exposure to reactive 
oxygen species (ROS) causes NRF2 to stabalise, translocate to the nucleus 
and bind to antioxidant response elements (AREs) that regulate many 
antioxidant genes (Kim et al., 2011) (Kang et al., 2014). Phosphorylated NRF2 
(pNRF2) is known as the active form of NRF2. The phosphorylation of NRF2, 
triggered by oxidative stress, triggers the release of NRF2 from Keap1 (Niture, 
Khatri and Jaiswal, 2014). The NRF2-ARE pathway has been shown to be 
activated by 5-FU in colorectal cancer cells (Akhdar et al., 2009a). 
The VEGF family of proteins that are involved in angiogenesis (Duffy, Bouchier-
Hayes and Harmey, 2014). VEGF is a classic marker for hypoxic stress, as it is 
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upregulation by HIF1⍺ under hypoxic conditions. Within colorectal cancer it is  
associated with tumour growth and metastasis (Guba et al., 2004).  
 
Figure 2.11 –Simplified schematic representation of the interdependence of the proteins of interest  
The above schematic demonstrates some of the interdependent relationships between the proteins of 
interest chosen within this research. An increase in the presence of reactive oxygen species (ROS) leads 
to the uncoupling of Nuclear factor (erythroid-derived 2)-like 2 (NRF2) from Kelch-like ECH-associated 
protein1 (KEAP1), from here it undergoes phosphorylation and in translocated to the nucleus where it 
binds to the antioxidant response elements (AREs) to initiate transcription of antioxidant regulatory genes. 
Increased ROS also triggers the activation and translocation of Hypoxia-inducible factor 1-alpha (HIF1α) to 
the nuclease where it joins with subunit HIF1β and activates hypoxia response elements (HREs) leading to 
the production and upregulation of Vascular endothelial growth factor (VEGF), Carbonic Anhydrase 9 
(CA9_and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3). When exposed to 
therapeutic insult by 5-FU, tumour protein 53 (p53) has been shown to downregulate BNIP3.An increase in 
p53 expression induced by stress reduces HIF1α activity. The proteins of interest have been highlighted in 
red.    
As mentioned previously, each of the proteins of interest were selected based 
on their involvement within drug response, cell survival, or hypoxia response 
pathways. There is a degree of interdependence between the proteins of 
interest, demonstrated in Figure 2.11 that allows for a reduction in the number 





In order to assess which proteins should be used in the final statistical model 
(model is outlined in Chapter 5), protein expression analysis was first carried 
out using immunocytochemistry (ICC). This method was determined to be less 
time consuming and labour intensive to carry out than western blotting and 
allows establishment of an initial qualitative screening of potential proteins of 
interest before narrowing this pool down to carry out more in-depth quantitative 
analysis with western blots.  
The protocol used for ICC was adapted slightly from a protocol used by a post-
doctoral researcher within the research laboratory (Khalil et al., 2016). This 
method is detailed below in sections 2.6.1.1 - 2.6.1.449.  
2.6.1.1 Seeding and treatment of cells for ICC 
Before seeding cells for ICC, 6 well plates were prepared with a glass cover slip 
placed in each well after being sterilized using pure ethanol. Cells were then 
trypsinised and a cell count was performed as detailed before in 2.2.3. Close to 
50,000 cells were then seeded into each well in 2mL of media. The plate was 
then stored in the tissue culture incubator for 24 h to allow cells to attach to the 
coverslip and plate before treatment.  
After 24 h the plate was removed from the incubator and placed within the 
tissue culture hood, the media was then aspirated off using a vacuum pump and 
a sterile pipette tip. This media was replaced with 2.5mL of media containing 1X 
the relevant drug concentration. The concentrations used were the estimated 
IC50 (96µM SE 2.2µM) and EC75 (59µM SE 3.4µM) concentrations from the 
96-h time point as calculated from the cell viability experimentation alongside a 
control. The plate was the returned to the tissue culture incubator until the 
relevant time point. The cells were fixed at 24, 48, 72, and 96 h prior to carrying 
out ICC.  
Previous iterations of the experiment had treated cells with 18, 26, 40, 59, 89, 
133, and 200µM but this was reduced in order to cut down on labour time and 
consumables while still capturing the effect of the therapeutic drug on the 
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proteins of interest. This selection process was informed by the results of 
section 2.4.6.  
2.6.1.2 Fixing of cells for ICC 
The fixing solution, consisting of 3.5% Paraformaldehyde, was removed from 
the freezer in advance and left to defrost on the bench. The solution was mixed 
thoroughly to ensure it was clear with no particulates. The media was removed 
from each of the wells and they were washed with 1mL of ice-cold PBS three 
times. 100uL of 3.5% paraformaldehyde (PFA) was then pipetted directly on top 
of the coverslip, flooding it. This was left to sit at room temperature for 30 
minutes. 1mL of PBS was then added to the wells to gently wash the cells, then 
removed and another 1mL of PBS added and the plates wrapped in cling film; 
plates can then be stored in 4°C for up to 3 months. After all wells from all time 
points have been fixed, the ICC was performed all together. 
2.6.1.3  Monolayer cells (2D) and ICC 
The plates were removed from the fridge and then allowed to come up to room 
temperature on the bench for around 1 h. During this time the blocking and 
permeabilization solutions were prepared, the components of which are listed in 
Table 2-5. The details for the proteins of interest and working concentrations 
can be found in Table 2-6. 
Typically, two proteins were stained for on each set of slides, one being rabbit 
and the other mouse, each tagged either red or green depending on the 
secondary fluorescent antibody used. 
Table 2-5  - Components of solutions for use in ICC 
Blocking Solution for ICC 3% Bovine Serum Albumin (BSA), 
0.05% Triton-X-100 in PBS 















































































HIF1α Ab1 abcam 1/200 1/100 
– 
1/200 




Ab15086 abcam 1/1000 - rabbit Polyclonal 55kDa 
VEGF Ab46154 abcam 1/1000 1/200 rabbit Polyclonal 43kDa 
BNIP3 Ab10433 abcam 1/1000-
1/200 
1/200 mouse Monoclonal 30kDa 




rabbit Polyclonal 110kDa 
pNRF2 Ab76026 abcam 1/5000  rabbit Monoclonal 110kDa 
β-Actin Ab8226 abcam 1/2000 -  mouse Monoclonal 43kDa 
Anti-
mouse 




















The first step was permeabilization where the PBS was removed from the wells 
and 1mL of the permeabilization solution was added to each well and incubated 
for 10 minutes at room temperature. This was then removed using the vacuum 
pump and the wells were washed with 1mL of PBS. The coverslips were then 
removed from the wells and placed on a piece of tissue on a flat surface to dry. 
Once dry the cover slips were placed cell-side-up on a piece of Parafilm, labelled 
as to remember which condition is in which location.  
The coverslips were then blocked in order to avoid any non-specific binding later 
on. 100µL of blocking solution was added gently and directly on top of the cover 
slip and left to incubate for 30 min at room temperature before being submerged 
in 2 beakers of PBS one after the other as the washing step. The coverslips were 
the dried. A tray was made up with damp tissue paper underneath a section of 
clean Parafilm that had been divided into sections for each coverslip and labelled 
with a water proof marker.      
The first primary antibody solution was made up while the cover-slips were 
blocking and stored on ice until used. The antibodies were prepared in blocking 
solution at the concentrations recommended by the manufacturers, or for BNIP3 
at the concentration found to be most effective in preliminary analysis (Table 2-6). 
The first primary antibody (30µL) was added to the labelled Parafilm. The 
coverslips were placed cells down on top of the drops, the tray was covered and 
left to incubate at room temperature for 1 hour. 
 During this time the second primary antibody was prepared in the same manner 
and stored on ice until used. A new section of Parafilm was also prepared. The 
coverslips were the washed and placed cells down on the second primary 
antibody used following the same protocol as the first.  
This secondary antibody was of a complementary species to the first primary 
antibody (anti-rabbit with rabbit, anti-mouse with mouse) and was either 
AlexaFluor 488 which fluoresced green, or AlexaFluor 594, which fluoresced red. 
When two primary antibodies are stained, then the secondary antibodies are 
either green or red so that the two proteins will fluoresce under different 
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wavelengths. The secondary antibody was prepared under low light conditions 
and a light-safe tube was used to avoid exposure to light.   
Once the second primary antibody has been removed and the coverslips washed, 
30µL of the first secondary antibody was dropped on to a newly marked section 
of Parafilm, the coverslips placed on top cells down and incubated for 45 min at 
room temperature. This step was done in low light conditions and incubated in 
the dark. The process of washing and incubation was repeated with the second 
secondary antibody.  
The final stage was to mount the coverslips onto labelled slides. After the final 
secondary antibody staining the cover slips were removed and washed then 
dried and placed cell-side-up onto a clean piece of tissue paper and left to dry 
fully for 10-15 min in the dark. During this time slides were labelled and 
Fluorosheild™ mountant with DAPI (4′,6-diamidino-2-phenylindole) was 
removed from storage at 4°C and placed on the bench to come up to room 
temperature. A small drop of mountant was then deposited onto the slide and 
the corresponding coverslip placed cell-side-down on top of the droplet, and air 
bubbles carefully pushed out using the tip of tweezers. All slides were prepared 
in this manner and left to settle for around 15-20 min. The edges of the cover 
slip were then sealed with clear nail polish. The slides can be stored in low light 
conditions at 4°C for a couple of months. 
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2.6.1.4 Imaging for ICC 
Similar to the other experiments requiring imaging, two different microscopes 
were used and the one that yielded the best results for this experiment was 
selected. Images were first taken using a Leica DMR epifluorescence microscope 
and a Nikon D7100 camera. With the Nikon camera the staining showed up very 
weakly on these images and many post-imaging adjustments had to be made to 
the brightness and contrast in order for the staining to show up (Figure 2.12). 
The Leica DMiR E2 microscope equipped with iXonEM +897 EXCCD camera 
was used to image the same slides, with better results (Figure 2.13). This 
camera is a black and white camera creating greyscale images. To view 
Figure 2.13 – The presence of BNIP3 in HCT116+p53 cells treated with 133µM of 5Fu for 96 h  
HCT116 +p53 cells were seeded at 50,000 cells per well into 6 well plates and treated with 133µM of 5-FU for a 
period of 96 h. Cells were processed for ICC study of BNIP3 and imaged using a Leica DMiR E2 microscope 
equipped with iXonEM +897 EXCCD camera.. Images taken at 100X magnification 
Figure 2.12 – The presence of BNIP3 in HCT116+p53 cells treated with 133µM 5Fu for 96 h.  
HCT116 +p53 cells were seeded at 50,000 cells per well into 6 well plates and treated with 133µM of 5-FU for 
a period of 96 h. Cells were processed for ICC study of BNIP3 and imaged using a Nikon D7100 camera. 
The image on the left is representative of an untouched image. On the right is the same image after 
brightness and contrast had been edited in ImageJ.  
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coloured images false colour had to be applied to the images. This was carried 
out in ImageJ post-quantification, this software was also used to create 
composite images.  
2.6.2 ICC image analysis using ImageJ 
Analysis on the images was carried out on ImageJ to measure the Corrected 
Total Cell Fluorescence (CTCF), and the integrated density following the 
protocol from (Mccloy et al., 2014) 
The image was first opened in the program ImageJ, and the image was 
duplicated. This was to ensure any changes that may occur to the images will 
not affect the original image. The measurements to measure were set as area, 
integrated density, and mean grey value. The cell of interest was then outlined 
using the freehand selection tool and the values measured. The pop-up box 
contained the relevant information from the selected cell; this information is then 
copied into Excel (Figure 2.14). From each image 10 cells, or if the number of 
cells in the image was under 10 then all cells visible were selected, in some 
cases multiple sections of the slide were imaged to increase this number to 10, 
as well as at least three sections from the non-stained sections around the cells 
or each image were sampled to represent the background reading. Once all the 




CTCF = Integrated Density – (area of selected cell * Mean Fluorescence of 
Background readings) 
 
The CTCF from the 10 cells on each image were then averaged to give a 
representative sample of cells from each treatment and time point. The images 
were used to create composite images to show visually where in the cells the 
proteins were localized (Figure 2.15). 
Figure 2.14 – Representative image of ImageJ output.  
A representative image of the output provided by ImageJ. The measurements (area, mean grey value, 




The results from the ICC were considered when selecting which 5-FU 
concentrations and proteins of interest were included in the final selection. The 
number of 5-FU concentrations was narrowed down to for western blotting, as 
those experiment are more time consuming and labour intensive.  
2.6.3 ICC image analysis using CellProfiler 
Using ImageJ to quantify the strength of the fluorescent signal for each image 
was labour intensive and subject to human error, since there is a step by which 
cells are manually identified and outlined. Other methods that could be used to 
automate and to allow the process to be performed quicker and with less 
human error were explored. The free open-source software CellProfiler was 
used to carry this out. CellProfiler was designed for biologist as a way of 
quantitatively measuring phenotypes from large cohorts of images (Carpenter et 
al., 2006). There are a range of modules within the program that allow for 
pipelines to be built from scratch to best suit the projects need or a pre-built 
pipeline can be imported and modified.  
Figure 2.15 - Composite image showing the presence of VEGF and BNIP3 HCT116 +p53 cells treated with 
200uM of 5-FU for 96 hours.  
Cells were seeded at a density of 50,000 cells per well and treated for 96 h with 200µM of 5-FU. Following 
incubation with treatment the cells were processed for ICC studies of VEGF (green) and BNIP3 (red). 
Immunostaining was carried out using AlexaFluor 488 and 594® conjugated secondary antibody. Nuclear staining 
in Blue from DAPI staining.  Images taken at 100X magnification 
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2.6.3.1  Building a pipeline in CellProfiler  
Before building the pipeline, the images first needed to be treated in order to be 
processed by the software. This involved modifying the file names, identifying a 
size range within which the cells lay and writing a metadata regular expression 
that CellProfiler could use in order to extract information from the file names. As 
the images were uploaded in large cohorts, the file name needed to include all 
information that would be used to distinguish one image from another. Each file 
name was written to include information pertaining to the time point, slide 
number, protein, and drug concentration. An example of this would be 
h24_s4_Ca9_C59, identifying the time point as 24 h (h24), slide number 4 (s4), 
CA9 (carbonic anhydrase 9) as the protein imaged, and treated with 59µM (c59) 
5-FU. 
The metadata regular expression used was 
 ^(?P<Time>[h][0-9]{1,2}_(?P<protein>.*)_(?P<Concentration>[C]) 
Modules were added to the pipeline using the module addition button, indicated 
by the ‘+’ sign. The first module to be added to the pipeline was ‘Identify 
Primary Objects’. Using this module, it was set up to use the DAPI stained 
images to identify cells and label the ‘nuclei’ inclusive of object touching the 
edges of the image. Once the nuclei have been identified, this information can 
be used to perform cell counts, and identify secondary objects, since the 
adjacent cytoplasm of the cells that had been stained with the proteins of 
interest in the linked images. Once the cell margins had been identified with the 
‘identified secondary objects’ module, the fluorescent intensity of both the total 
cell area and the nuclei can be quantified and, using total cell – the nuclei, the 
intensity of the cytoplasm can also be quantified. The area occupied by the cells 
can also be quantified. The full list of modules applied can be found in Appendix 
8.1.1 
2.6.4 Preparation monolayer cultures for Western Blotting  
Following preliminary ICC-based proteomic analysis, western blotting was 
carried out and the results of which were used in the final dataset as the 
proteomic measures.  
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The ICC results showed interesting results for all 6 proteins so western blotting 
was carried out in triplicate on all 6 proteins of interest  (HIF1α, CA9, VEGF, 
BNIP3, NRF2, and pNRF2) and this was narrowed down the three and repeated 
a further 12 times for a total number of 15 replicates for the final dataset. 
Initially this was repeated for a total number of 7 replicates but this was 
increased with a further three experimental batches to provide a wider range of 
external replicates. A comprehensive breakdown of all 15 replicates and the 
internal and external replication can be found in Table 2-7.  
Table 2-7 - Replicates produced for all 6 proteins of interest with western blot 
 The experimental groupings are indicated by colour, showing the number of pseudo replicates produced 
per experimental set. The three final proteins of interest (CA9, pNRF2, and BNIP3) are underlined. These 
were chosen following analysis of all proteins had been performed in triplicate, this decision is discussed in 
the laboratory results chapter. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
CA9 1 2 2 2 2 2+ 2+ 3 3 3 4 4 4 5 5 
pNrf2 1 2 2 2 2 2+ 2+ 3 3 3 4 4 4 5 5 
BNIP3 1 2 2 2 2 2+ 2+ 3 3 3 4 4 4 5 5 
Nrf2 1 1 2             
VEGF 2 2 2+             
HIF1a 1 2 2             
 
2.6.4.1 Seeding of cells for Protein Extraction 
When extracting protein for use in western blotting, cells were seeded at a 
density of 6x105 cells in a 60mm cell culture treated dish (Thermo Scientific). 
Cell were seeded and were incubated in a sterile cell culture incubator for 24 
hours to allow the cells to adhere before treatment. After 24 hours the dishes 
were removed from the tissue culture incubator, the media was aspirated off 
using a sterile pipette tip and a vacuum pump and replaced with 4mL of cell 
culture media containing 1X the relevant drug concentration. The following 
concentrations were used, 0uM (control), 26uM, 59uM, 96uM and 180uM. 
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 59uM and 96uM were the estimated EC75 and IC50 concentrations identified 
in the 96 hour monolayer cell viability experiments (2.4.5). 26uM and 180uM 
were concentrations from the lower and upper ranges of the concentrations 
used in the cell viably assays without using the highest end of the experimental 
range as it was wished that enough cells to still be viable in order to extract a 
large enough quantity of protein. 
 Following treatment the plates were returned to the tissue culture incubator 
until the time point at which protein was to be extracted. At the desired time 
point, the relevant plates were removed from the tissue culture incubator and 
the media removed and stored in a correspondingly labelled 15ml centrifuge 
tube. The plates were washed with 1ml of PBS which was also put into the 
corresponding tube.  0.75ml of trypsin was added to each plate and they were 
returned to the tissue culture incubator for around 5 minutes or until all the cells 
had become un-adhered to the plate surface. The trypsin containing the cells 
was then removed and placed into the corresponding tubes taking great care to 
collect as much of the cells as possible. The tubes were then centrifuged at 
4°C, 1200RPM for 5 minutes to allow the cells to pellet at the bottom. The 
supernatant was poured off and the pellet re-suspended in 1ml of ice cold PLS 
and transferred to a 1.5Ml tube and centrifuged under the same conditions. This 
washing process with ice cold PBS was repeated 3 times in total.  
After the final washing step the PBS was removed and the cell were re-
suspended vigorously in between 100-250ul of ice-cold 
Radioimmunoprecipitation assay buffer (RIPA) containing protease and 
phosphatase inhibitors. The volume of RIPA was dependent on the size of the 
pellet and this volume was recorded. The RIPA containing cells were incubated 
on ice for 10 minutes and then shaken on an orbital shaker on ice at 150RPM 
for 20mins. The cell solutions were then vigorously pipetted and centrifuged at 
0°C at 15,000 RPM for 15 minutes.  Following this final centrifuge step the 
supernatant is very carefully removed using a pipette, taking care to not disturb 
the pellet and moved to a labelled pre-chilled 1.5ml centrifuge tube and stored 
at -80°C.  
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2.6.4.2 Quantifying protein concentration in extracts.  
The colorimetric Bradford Assay, was used in order to estimate the protein 
extracts.  The reagent used in this assay contains the Coomassie Brilliant Blue 
G-250 dye (Sigma-Aldrich) which, when bound to protein within the solution, 
shifts from red to blue. This colour change causes an absorbance shift when 
recorded at a wavelength of 590nm. This quantifies the colour change which 
when compared to a standard of known quantities allows the protein 
concentration to be quantified.  
A 5mg/ml bovine serum albumin (BSA) solution was used, diluted 1:2 for a 
series of dilutions to create this known protein standard. The volumes used 
were 0 (dH2O), 5, 2.5, 1.25, 0.625, 0.3125, and 0.15625 mg/ml. When 
performing the assay, serial dilutions were freshly made each time the assay 
was repeated. A volume of 2µl of the protein standards and the samples was 
pipetted into each well of a clean 96 well plate. Each serial dilution and protein 
sample was repeated in triplicate and the protein standard was repeated every 
time the assay was performed to ensure consistent conditions with the samples 
being quantified against it. 98µl of Bradford reagent was added to each well, 
and 100µl into three background wells. The plate was covered in tin foil to 
protect the reagent and the plate was incubated while shaking for 10 min at 
room temperature. The absorbance of the plate was then read at 595nm using 
an absorbance reader. The results of which were inputted into Microsoft Excel 
and the means of the triplicate protein standards, normalised to the background, 
were plotted on a scatter plot with the known quantity on the x- axis and the 
absorbance value on the y- axis. Using the line equation, y=mx+c, rearranged 
as x=y-c/m, the normalised means of the samples could be substituted in place 
of y and the result of which would give a value on the x-axis relating to the 




Figure 2.16 – Representative image of a protein standard curve by Bradford assay. 
 The absorbance at 595nm has been plotted against known concentrations of BSA (mg/mL). The Line 
equation and R2 value for the trend line are displayed on the graph. 
Mean normalised value of sample ‘n’ was 0.15, when substituted into the 
equation provided (Figure 2.16) gives x=0.15-0.0044/0.0454. The calculated 
value of y, 3.207, is the quantity of sample n = 0.15.  
2.6.4.3 Preparation of protein sampled for gel electrophoresis  
Once the quantity of the protein sampled was known, the volume of each 
sample diluted in RIPA (with 25% of LDS sample buffer was calculated so that 
all samples would have the same running concentration. The samples were 
calculated to have either a concentration of 1.4µg/µL or 1.75µg/µL, with either 
15 or 12µL (depending on gel well size) loaded into the well to give a final 
volume of 21µg. Following quantification the samples were removed from 
storage and defrosted slowly and thoroughly on ice. RIPA was added to pre-
chilled, labelled centrifuge tubes. The total samples were then shaken using a 
bench top orbital shaker and then spun down using a benchtop centrifuge for 15 
sec to ensure that the samples are fully mixed before the calculated amounts 
were pipetted into the corresponding tubes. Finally LDS sample buffer was 
added at a 1 in 4 dilution (25µl to 75µl etc.). The newly diluted samples were 
then placed in the thermomixer at 90°C for 10 min. They were then placed on 
ice for ~10 min in order for any evaporation to condense. Following this the 
samples are either returned to the -80°C freezer for storage or mixed and spun 

























down for loading into the gels. Before loading into the gels the samples were 
defrosted thoroughly on ice if loading from storage and then mixed and 
centrifuged in batches before being loaded into the wells.  
2.6.4.4 Gel Electrophoresis and Gel transfer  
Pre-cast 4-12% Bis-Tris gels (NuPAGE™) were used, in both the mini 12 well 
and standard 26 well sizes. The gels were removed from the packaging and the 
strip removed from the bottom of the cassette before being placed into the gel 
tank and the central well between the gels filled with running buffer to above the 
combs. At this point the combs were very carefully removed taking care to lift 
them straight up and not to disturb the sides of the wells. The samples were 
then loaded into the wells in a pre-determined order and then more buffer 
added to the tank so that the central well was filled to the very top and the 
outside section filled to 50%. When using the ‘mini’ gels, 15µL was loaded at a 
concentration of 1.4ug/µl  and for the ‘midi’ gels 12µL  of 1.75µg/µl was loaded 
both with a quantity of 21µg protein per well. The mini gels were then run at 90V 
for approximately 2 h, and the standard 26 well gels for 110V for 1.5 h, checking 
regularly and topping up the central well with buffer as needed.  
Once the proteins had been run to completion the cassettes were carefully 
removed from the gel tank and the seams broken to access the gel. The top left 
hand corner of the gel was clipped to track lane order and the gel placed into a 
tray containing dH2O.  
For transfer the mini iBlot™2 system (Invitrogen™) was used and the 
corresponding iBlot™2 PVDF Mini and regular sized transfer stacks. The 
transfer stack was placed into the module and the gel placed on top of the 
PVDF membrane and then covered with a piece of damp filter paper. A roller 
supplied with the iBlot™2 system was used to push out any air bubbles before 
the top stack with the copper electrode facing up was placed on top and, again, 
any air bubbles are removed using the roller. The absorbent pad was then 
placed on top with the electric contacts lined up and the lid of the iBlot™2 model 
closed. The transfer was then run at 20V for 7 min. Once transfer had been 
completed the absorbent pad, top stack, filter paper and gel are carefully 
removed, exposing the PVDF membrane which was immediately placed into a 
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dish containing dH2O and the corner corresponding to the clipped corner of the 
gel marked with pencil. 
2.6.4.5 Ponceau Staining and membrane cutting 
After transfer proteins onto the PVDF membrane, a Ponceau S. solution, was 
used to detect protein bands and to confirm transfer. The membrane was 
placed into the Ponceau solution for 2-5 min and then rinsed repeatedly in 
dH2O. If transfer was successful, the proteins were detectable on the 
membrane and stained red. This stain is reversible by continued washing in 
water. An example of a membrane stained with Ponceau can be found in Figure 
2.17. 
 
Figure 2.17 – Representative image of PonceauS staining  
A 26 well standard sized membrane stained using PonceauS to identify proteins and prove a successful 
transfer. The lanes can be seen here as a darker pink than the background 
Using the bands shown by the Ponceau stain and the protein marker the 
membrane was sandwiched between cling film to keep it wet and a scalpel and 
cutting mat were used to section the membrane into its areas of interest 
depending on the molecular weights of the proteins of interest. The top corners 




2.6.5   Western Blotting Protocol 
Once the protein had been transferred from the gel to the membrane and the 
membrane sectioned they were incubated in a blocking solution of 5% skimmed 
milk in TBST 0.1% Tween20 with shaking for 1 h. The membranes were then 
washed with the TBST 0.1% tween20 once as a quick rinse, twice for 5 minutes 
and twice for 10 min. The membranes were then incubated in the relevant 
primary antibody solutions overnight at 4°C with shaking. The following morning 
the washing step was repeated and then the membranes were incubated with 
the relevant secondary antibody solutions for 1 h at room temperature with 
shaking followed by a final wash step with one extra 10-min wash. The probed 
proteins were then detected using an Enhanced chemiluminescence (ECL) 
solution and images using the G: BOX imaging system (Syngene). The ECL 
solution was made in the laboratory using the recipe in Table 2-8.  
Table 2-8 - ECL reagent recipe.  
These solutions were made up in the dark and once made were stable for 1 month after storage under 
light safe conditions at 4⁰C 
Solution A, 50mL Solution B, 50mL 
500ul Luminol (250Mm in DMSO) 32ul Hydrogen Peroxide 
220ul Ρ- Coumaric acid (90Mm IN 
dmso) 
5ml Tris-HCl 1M (Ph 8.5) 
5ml Tris-HCl 1M (Ph 8.5) 45 dH2O 
45ml dH2O   
  
This solution was prepared and stored under light sensitive conditions and is 
stable for up to 1 month when stored in 4°C. When using the ECL solutions, 
solution A and B (Table 2-8) are added at a 1:1 ratio to a tray containing the 
membrane and the membrane covered with agitation for 1 min. The excess 
ECL solution was then removed by holding the bottom right corner of the 
membrane to a piece of clean paper towel. Then the membrane is placed within 
a clear plastic wallet and the air bubble gently removed using a cloth. The 
plastic wallet containing the membrane was then placed on top of the black 
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screen in the Syngene G-BOX Chemi-XX6 Gel Documentation System and 
using the image acquisition software GeneSys (Syngene) the imaging protocol 
for ECL was run with the relevant dimensions of the membrane. Exposure times 
were set at 5,10,15,20, and 30 sec and then 1, 2, 3, and 5 min to capture the 
ECL signal with shorter or longer exposure times if needed. A bright field image 
was also taken and a composite image created to view the protein markers on 
the edges and the orientation of the membranes.  
2.6.6 Densitometry Measure of Western Blots 
 
Using ImageJ, The developed and captured western blot image was opened 
and duplicated to preserve the original. The duplicate was converted into an 8-
bit image and any necessary pre-analysis steps were carried out. These would 
include cropping the image, flipping horizontally, or rotating the image to align 
the bands. The contrast or brightness would not be tampered with at this point.  
The measurements were set to record the mean grey value. A rectangular 
selection was drawn over the first band and a measurement was taken. Using 
the same rectangular section, this action was repeated for all bands, taking care 
to record the bands in a predetermined order (24 h 0-180µM, 48 0-180µM etc.). 
Again using the same rectangular section, a section of each lane above or 
below the band of interest was measured as a background reading. This was 
repeated for both the loading control and the protein of interest. The results file 
was saved and the results copied into an Excel file and labelled with their 
corresponding conditions.  
The following calculations were then used: - The reading of the protein of 
interest (X) was subtracted from 255 (white value on ImageJ) in order to invert 
the mean grey value. Inverting the results causes a value of 0 to correspond to 
completely white, and 255 to correspond to completely black. The images used 
were black bands on a white background. This process was repeated with 
mean grey values of the background, as well as the loading control 
(housekeeping protein) and the background of the loading control. The inverted 
background value was then subtracted from the inverted X value in order to give 
a net value of X (Table 2-9). 
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Table 2-9 – Illustrative table to demonstrate the calculations used to calculate protein densitometry. 
 X is the mean grey value of the protein band. Y is the mean grey value of the background. Both values 
are found using ImageJ. 















Net Value  
(invertedX-
invertedBK) 
1 22.323 232.677 238.094 16.906 215.771 
2 30.625 224.375 240.677 14.323 210.052 
…      
Loading 
control 
     
1 119.443 135.557 231.789 23.211 112.346 
2 114.767 140.233 225.143 29.857 110.376 
….      
 
In order to normalize the protein of interest to the loading control the net protein 
of interest was divided by the net loading control for that lane (lane 1 with lane 1 
etc.). The final step was to normalize the each of the treatment net values by 
the control values for that time point giving the control value as 100% and all 
subsequent treatment values as a percentage relating to the 100% value to 
match the scale of the other measurements gathered such as cell viability and 
diameter.  
2.7 Chapter summary 
The main structure of the experimental data collection focused on variables 
relating to viability, proteomics and morphometric. Viability was recorded using 
ATP based assays suitable for both monolayer and spheroid cultures. 
Morphometric measures of diameter and circularity were recorded from images 
taken of spheroids following treatment with 5-FU over the course of 96 h 
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incubation. Using the same imaging techniques, the percentage change in cell 
confluence was record in monolayer. The proteins of interest included within the 
dataset were pNRF2. BNIP3 and CA9, chosen for their involvement with the cell 
line and therapeutic agent of choice within cell death and hypoxic pathways. 
These proteins of interest were preliminarily investigates through the use of 
ICC, but ultimately quantified through western blotting for the dataset. HIF1α, 
NRF2 and VEGF also underwent quantification but ultimately not being carried 
forward for inclusion with in the model. This selection is discussed in more detail 
in Chapter 4. 
 
The results generated from the variety of experiments detailed in this chapter 
were unified through normalisation to the same scale, being calculated to the 
percentage change of the control for each time point. The data was then 



















Figure 2.18 – Repetition of Figure 2-1  
Flow chart illustrating the elements of biological experimentation that was carried out with both the monolayer 
and spheroid cell cultures. The variables that were included within the final have been shown in red, with the 
three proteins of interest, their expression quantified through Western blotting, shown in green.    
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which variables were collected. Each column represented a separate variable, 
with a column for 5-FU that will act as a grouping factor.   
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3 Chapter Three, Statistical Methodology 
3.1 Chapter outline 
The purpose of this chapter is to discuss the methods used in the preliminary 
statistical analysis of the laboratory collected data as well as the initial validity 
and reliability assessment of the PLS-SEM algorithm using SmartPLS. The 
chapter will begin with an overview of the purpose and methodology behind 
PLS-SEM and a description of the path models that will be featured in the 
results followed by a worked example of an iteration of the PLS-SEM algorithm. 
Followed by the method of model assessment using the SmartPLS software 
and the findings of the preliminary path model. The method for data expansion, 
normalisation and preliminary statistics using the software package SPSS will 
then be discussed.  
3.2 PLS-SEM 
Partial Least Squares Structural Equation Modelling (PLS-SEM) was chosen as 
the statistic model for this project for a number of reasons. The method is 
primarily exploratory and allows several relationships to be explored, it is robust 
enough to handle the relationships we aimed to explored, and it suitable with a, 
relatively speaking, small dataset and its predictive capabilities. Other methods 
were also investigated, further discussed in Chapter 1, but this method was 
carried forward. One such method often used is Principal component analysis 
(PCA). This is a method that has been applied to cellular data for a variety of 
means, one such example was reducing the dimensionality of matrix-assisted 
laser desorption ionization – imaging mass spectrometry (MALDI-IMS) 
generated data set (Weaver, Hummon and Keithley, 2015). PCA is a form of 
multivariate analysis that considers the entire data set to define principal 
components that best capture the covariance in the data. This differs from PLS 
where variables are defined as independent or dependent which allows for the 
exploration of how certain parts of the data set are related to others (Janes and 
Yaffe, 2006). The ability to define variables and their relationships made PLS-
SEM more suitable for this research.  
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The model allowed the combination of many variables associated with 
treatment over time within both monolayer and spheroid cultures and quantified 
the relationships between those variables, providing values related to the 
predictive capabilities of one set of observations on another. The application of 
PLS-SEM in the comparison of monolayer and spheroid experimental derived 
data is novel.  
Prior to the final path-model being decided and structured, a small idealised 
mock dataset was produced to understand the complexities of the modelling 
and the outputs that the algorithm would produce. This data set to calculate an 
iteration of the PLS algorithm without the use of the software to better 
understand the process taking place ‘behind the curtain’ before proceeding with 
the biological data collected in the laboratory.   
3.2.1 PLS-SEM overview 
PLS-SEM is a variance-based form of structural equation modelling (SEM). 
Diagrams that visually represent the relationship and hypothesis of the multiple 







Figure 3.1 - An example of a PLS-SEM model produced using SmartPLS.  
The model has been labelled to identify key areas. Indicators are shown as yellow boxes, and latent variables by 
blue circles. Latent variables 1-3 are classified as exogenous, and 4 is endogenous. 
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generated in SmartPLS (Ringle, Wende and Becker, 2015), a PLS-SEM specific 
software, can be found in Figure 3.1. A latent variable (LV) is a variable that is 
not directly measured, and is shown in the path model as a blue circle. Latent 
Variables are classified as either exogenous, where the latent variable has no 
predecessors, or endogenous where they do have predecessors. The yellow 
rectangles represent indicators, or manifest variables (MVs) represent 
observations taken from raw data.  
 
The path model is made up of two main elements, the inner model representing 
the relationships between latent variables (solid red box in Figure 3.1), and the 
outer model the relationships between indicators and their associated latent 
variable (dashed red box in Figure 3.1). The relationships in the outer model 
can either be reflective (mode A) or formative (mode B). In reflective models, 
the assumption is that the causality is from the LV to the indicators. In formative 
models, the causality is from the indicators to the LV with no requirement for the 
indicators to be correlated. The mode of a LV is demonstrated by the direct of 
the arrow between LV and indicator. The experimentally collected data used 
with this model will all be formative. 
 
The path models can be described by an adjacency matrix, D, illustrated below 
in Table 3-1 is the adjacency matrix for the path model in Figure 3.1. An entry of 
1 indicates that LVi is a predecessor of LVj. If a LV is exogenous, with no 
predecessors, a 1 will appear where the matrix intersects e.g. LV1, LV1.  
Table 3-1 - Adjacency matrix D for the path model described in Error! Reference source not found. 
LVi  LVj > LV1 LV2 LV3 LV4 
LV1 1 0 0 1 
LV2 0 1 0 1 
LV3 0 0 1 1 




The equations used within the PLS-SEM algorithm are details in semPLS: 
Structural Equation Modelling Using Partial Least Squares (Monecke and 
Leisch, 2012). Broadly, the process follows the steps as described in Monecke 
and Leisch (2012). Figure 3.2 shows the steps taken in each iteration of the 
PLS-SEM algorithm. Step one is the initialisation of the model where each latent 
variable (LV) is constructed as a weighted sum of its indicators. Step 2 is the 
approximation of the inner model where each LV is estimated as a weighted 
sum of its neighbouring LVs. Step three involves recalculating the weights, 
using the LV values calculated in step 2. This step differs depending on the 
measurement mode, formative or reflective, used. Step four is the calculating of 
the factor scores using the matrix of weights calculated in step 3 and the means 
of the indicators giving the outer estimation. In step 5 the relative change in 
weights between the previous and current iteration is calculated. If the 
difference is less than a predefined tolerance, typically x10-5 – x10-7, then the 
factor scores from step 4 are taken as final, if not the process repeats until 























3.2.2 Worked example – Idealised datasets using SmartPLS 
In order to carry out these calculations, a mock dataset was constructed for use. 
The datasets used in these trial runs were highly simplified and constructed to 


















Figure 3.3 - Line graph plotting the change in value against treatment concentration for 4 
arbitrary indicators (A-D) 
drug conc A B C D
0 1.16 -1.46 -0.77 1.55
0 1.31 -1.42 -0.21 1.68
0 1.60 -1.26 1.69 1.51
18 1.02 -1.06 0.91 0.95
18 0.87 -0.93 -0.09 0.89
18 0.87 -0.90 -0.88 1.01
26 0.73 -0.69 1.04 0.63
26 0.65 -0.63 -1.67 0.39
26 0.73 -0.53 0.10 0.47
40 0.43 -0.36 -1.34 0.09
40 0.29 -0.33 0.60 0.25
40 0.39 -0.28 0.69 0.23
59 0.00 -0.08 0.06 -0.09
59 -0.09 0.09 0.52 -0.21
59 -0.05 0.11 1.77 -0.07
89 -0.59 0.46 -1.10 -0.39
89 -0.59 0.52 -1.13 -0.49
89 -0.44 0.58 -1.24 -0.35
133 -1.10 1.09 1.45 -1.01
133 -1.02 0.84 -1.06 -1.14
133 -1.17 0.97 0.60 -1.07
200 -1.66 1.48 -0.02 -1.74
200 -1.61 1.93 -0.41 -1.58
200 -1.75 1.84 0.48 -1.52
Table 3-2 - Example of mock dataset used in trialling PLS-SEM  
The data set had been normalised to have a mean of zero and a standard deviation of 1 in order for all of the 




found in Table 3-2 and illustrated in Figure 3.3. The mock dataset consisted of 4 
variables, the relationships between these variables were designed. Variables A 
and D showed a positive correlation, variable B has a negative correlation with 
both A and D, and variables C has no correlations with any of the other 
variables.  Figure 3-3 shows the arbitrary values of these variables plotted 
against drug concentration, and the trend lines of have been colour coded to 
visualise how these variables were designed.  
A mock dataset such as this can be readily altered in order to run various 
iterations of the model, investigate how the different inputs affected the results 
of the PLS-SEM algorithm and also explore important pre-requisites for using 
this model. This type of modelling is primarily used within the business and 
social science sectors, and as such would be used with large cohorts of data 
collected primarily from surveys (Joe F Hair et al., 2014b). As the data used in 
this project would be collected from laboratory experimentation there were 
certain obstacles that needed to be addressed. 
One of these obstacles occurred during the initialisation stage (step 1) where it 
occurred that the dataset was too large to manipulate non-computationally.  
Table 3-3 - Small minimalised data for PLS SEM trial 
The values in this dataset reflecting the slope of the line of each replicate set, calculated from the dataset 
in Table 3-2 
A B C D 
-0.01513 0.015167 0.001867 -0.01483 
-0.01147 0.005167 0.0011 -0.00497 
-0.00323 0.003867 0.001967 -0.0105 
 
Using the data set from Table 3-2 a line was fitted from each mock replicate set 
and the gradient of this line was used as the entry, shown in Table 3-3. The 




Figure 3.4 – Visual PLS-SEM path model used with concise idealised dataset 
 
In the final model, the gradients were not used instead the results of all 
concentrations were included. The gradient of the line was used purely in the 
mock dataset to minimise the amount of values used while incorporating 
information from all of the mock dataset.  
3.2.2.1 Step 1 initialisation 
The first part of Step 1 was to ensure that all values have a mean of 0 and a 
standard deviation of 1 (var=1) as this is a requirement of the algorithm. Using 
Table 3-3, the values were scaled using (
𝑥𝑖−?̅?
𝑠
) to give dataset matrix X, Table 
3-5. This dataset X was then transposed XT, Table 3-6, and the Adjacency 
matrix (M), shown in Table 3-7, is defined based on the model in Figure 3.4. A 





Table 3-4 - Notation used within the PLS algorithm 
Symbol Notation 
N Number of observations 
K Number of observed variables 
G Number of latent variables 
X NxK matrix of observed variables (MVs); each variable standardised 
Xg Block of observed variables (MVs) belonging to latent variable yg 
Fg NxK matrix measurement error for reflective block Xg 
δg Measurement error vector of length N for a formative LV 
Y NxG matrix for LVs 
Z NxG matrix of the structural model error terms 
Ỹ NxG matrix: inner approx./ estimation of factor scores  
Ŷ NxG matrix: outer approx./ estimation of factor scores 
M Adjacency matrix (KxG) for the measurement model 
D Adjacency matrix (GxG) for the structural model 
W KxG matrix of outer weights 
E GxG matrix of inner weights 
B KxG matrix of path coefficients 
T KxG matrix of the total effects 
Ʌcross KxG matrix of cross loadings 
Ʌouter KxG matrix of outer loadings 

















Table 3-7 - Adjacency matrix, M.  
The columns represent the LVs in the path model, and the rows represent indicators A-D. A ‘1’ represents 







In the initial iteration, matrix M will have the weights equal to one or zero, but 
the weights that are initially set to 1 will alter with each iteration of the algorithm 
as convergence through approximation is approached, see step five of Figure 
3.2. Using matrix X and matrix M the following equation Ŷ=XM was computed.  
The results of this calculation were normalised to have unit variance and are 
shown in Table 3-8. 
-0.85 1.15 0.47 -0.96 
-0.26 -0.47 -1.15 1.04 
1.1 -0.68 0.68 -0.08 
-0.85 -0.26 1.1 
-1.15 -0.47 -0.68 
0.47 -1.15 0.68 
-0.96 1.04 -0.08 
 LV1 LV2 
A 1 0 
B 1 0 
C 0 1 
D 0 1 
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Table 3-8 - Matrix Ŷ  





This matrix in Table 3-8, Ŷ=XM (normalised) shows the latent variables as the 
weighted sum of their measured variables and is the final product of step 1: the 
initialisation step and the process could be continued on to the next stage, step 
2: inner approximation.  
3.2.2.2 Step 2 Inner Approximation 
At this point in the algorithm, each latent variable (LV) is estimated as a 
weighted sum of its neighbouring LVs and then the recalculated LVs are scaled 
to have unit variance. This is equivalent to expressing the inner estimate ?̃?, 
Table 3-10, as the product of the outer estimate derived from step 1 and the 
matrix of inner weights Table 3-9 






The inner estimation is obtained using ?̃?= (ỹ1 … ỹg) 
Table 3-9 - Matrix E,  












Table 3-10 - ?̃? Matrix 





As this is a very simplified model with only 1 inner weight between LV 1 and 
LV2, the result is a column of zeros shown in the ?̃? matrix.  
 
3.2.2.3 Step 3 Outer Approximation 
In step 1 all weights were equal with an initial value of one,  
Table 3-7, In Step 3, all weights are recalculated on the basis of the LV values 
that were calculated in step 2. The equations used at this stage depend on the 
measurement mode selected. These measurement modes have been 
described above in 3.2.1.This model has indicators that are formative, and thus 
PLS-SEM operates in mode B. This mode is a multiple regression coefficient 
where the block of indicators are the regressors and the LV as the response. 










If working with reflective indicators, mode A, the equation differs are it is a 
multivariate regression coefficient with the LV as the regressor and the block of 











At this point matrix X was split into two matrices, one for each LV to reflect the 
indicators associated with them. Specifically, LV1 reflects A+B and LV2 reflects 
C+D. LV1 and LV2 will be referred to from now on as X1 and X2 respectively. 
Each LV is calculated separately at this point, and then all of the indicator 









Breaking down the mode B equation into steps, the first step is to 
calculate(𝑋1












−1 is then multiplied with the original 𝑋1
















The same process was repeated with X2, and the weights from C and D were 




These weights were then scaled to have equal variance and used to form the 
outer weights matrix W 
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Table 3-11 - Outer weight matrix W 
1.121 0 0 0 
0 1.118 0 0 
0 0 0.700 0 
0 0 0 -0.008 
 
3.2.2.4 Step 4 Calculating Factor Scores 
Using the means of the indicators and the outer weights matrix W Table 3-11 
from step 3 the factor scores are calculated using the following equation (3.4) 












This give the outer estimation for the model, or latent variable scores. After 
convergence is met and these scores are taken as final, they are used to 
estimate the path coefficients by ordinary least squares (OLS).  
3.2.2.5 Step 5 checking convergence 
The final stage of one full iteration of the algorithm is to assess the relative 
change of all the outer weights from the current iteration to the previous one. If 
the change between the two groups is smaller than a predefined tolerance (x10-
5 – x10-7) then the factor score from the final iteration are taken to be final. If this 
criterion is not met then steps 2-5 are repeated, updating the matrices as 













| < 𝑡𝑜𝑙𝑒𝑟𝑎𝑛𝑐𝑒                      ∀ 𝑘 = 1, … , 𝐾 𝛬 𝑔 = 1, … , 𝐺, 
3.5 
The results of the equation gave a matrix of  
−0.10802 0 0 0
0 −0.10565 0 0
0 0 0.428484 0
0 0 0 −126.628
 
The determinant of the matrix was the found. The determinant of a matrix is the 
scaling factor of the linear transformation described by the matrix and is a single 
value. In this case the determinant was found to be equal to, -0.6192 and was 
not smaller than the predefined tolerance (x10-5). 
After carrying out one full iteration, if the change between iterations of the outer 
weights is not smaller than the tolerance so the process would be repeated. 
When carrying out PLS-SEM computationally a maximum number of iterations 
is also specified and the programme will continue to repeat iterations until 
convergence is met, or this maximum number of iterations is spent. The 
maximum number of iterations carried out is typically 500 or more.  
3.2.3   PLS interation 
The above section details a single iteration of the algorithm with a simple, 
idealised data set. To iterate the model sufficient times for convergence a 
software tool SmartPLS 3 (weblink) was employed. This software allowed 
simulation with a larger number of idealised datasets to gather an 
understanding of how best to structure the developing data as set out in the 
Figure 3.5 - Simplified dummy model shown after running the PLS algorithm.  
The outer weights / loadings are displayed between the indicators and the latent variables, the path coefficients 
between the latent variables and the R2 value in latent variable 2 
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previous Chapter to best represent the information within the data and how 
differing data structures may affect the outcome of the model. Using the dataset 
matrix X shown in Table 3-5 a model was built in the software as shown Figure 
3.4. Figure 3.5 is the output from running the PLS algorithm using SmartPLS. 
The path coefficient is close to the maximum value of 1 (0.819), indicative of a 
strong influence from the exogenous latent variable on the endogenous latent 
variable. In this particular case, and as a result of the highly simplified model, 
the outer weights/loadings are exactly the same value for both indicators related 
to each latent variable. Both A and B of latent variable 1 have scores of 0.553, 
and C and D of latent variable 2 have scores of 2.096. This is not a typical 
outcome as illustrated with more complex models later. Other idealised datasets 
were created and a variety of model structures were developed in order to 
identify the best way to structure the datasets and models. 
3.3 Initial Model formulation 
From the extensive pilot tests it was decided that the best course of action to 
convey the effect of both time and drug concentration on the variables was to 
structure the data in 4 separate data sheets, each one representing one of the 
four time points that data was collected from. Each dataset would have the 
same structure of indicators and be run through the same model independently. 
Each column in the dataset represented an indicator, or measured variables. 
 Table 3-12 - Example of a data sheet used for running the PLS algorithm in for SmartPLS 
5-FU 
Concentration 
Variable 1 Variable 2 Variable 3 … 
0    
26    




The latent variable were designed to each encompass a biological aspect that 
was being experimentally recorded in the lab. In this case monolayer viability, 
proteomics and spheroid viability, later with the addition of spheroid morphology 
as a separate latent variable. The latent variables are derived from linear 
combinations of their indicators. The indicators were representative of 
quantitative measures that could be used to describe an aspect of the latent 
variable, for example the presence of ATP in monolayer culture quantified using 
the CellTitre-Glo® assay is used to quantify monolayer cell viability and the 
observations comprise of the data collected experimentally. The relationships 
between the latent variables were defined biologically and to answer the 
research questions proposed, such as what is the predictive power of quantified 
monolayer cell viability changes on spheroid viability under the same 
experimental conditions. The directionality of the arrows between latent 
variables indicates the endogenous and exogenous latent variables. 
 A column representing drug concentration was also included. The replicates 
from all drug concentrations used were listed under each indicator, and the 
information in regard to the concentration of each replicate was used to set up 
Figure 3.6 - First draft of PLS-SEM Model 
This initial model was constructed based on the biological understanding of the variables. The proteomics 
response to therapeutic insult represented by Latent Variable 2 illustrates the underlying mechanisms that 
ultimately lead to cell death, shown through Latent Variable 1. The relationship between monolayer responses 
to therapeutic insult, LV1 and LV2, and the spheroid responses, LV3, were a focus of this research,  
MCV- monolayer cell viability. SCV – spheroid cell viability. Full list of shorthand can be found in Table 3-23 
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data groups within the total dataset. An example of this set up can be seen in 
Table 3-12. 
Defining the concentrations in data groups this way enables the data to be run 
as a complete set with the inclusion of all treatment dosages taken into account, 
or could be separated by dosages and the results viewed independently. At this 
stage a first version of the model was developed. This model can be seen in 
Figure 3.6. The addition of other indicators were incorporated into the model as 
the data set was developed. Inclusion of these additional indicators allows the 
model to be further fleshed out (see section 3.4).  
Time is not traditionally accounted for within PLS-SEM datasets, making the 
inclusion of data from 4 independent time points was novel to this research 
project. In order to harness the data from the 4 separate time points, each time 
point was used to create 4 separate datasheets. Each one was set up in the 
same manner and populated with the values from the represented time point. 





3.4 Initial model testing and troubleshooting 
3.4.1 Running the PLS-SEM model and testing of the outer/ measurement 
model 
Following on from the development of the PLS initial PLS-SEM model, the 
collection of the laboratory data and the exploratory statistics on SPSS, The 
updated PLS path model shown in Figure 3.7 was created. The PLS-SEM 
algorithm was applied to the datasets using the SmartPLS 3 software and a 
number of initial assessments were carried out to ensure the validity and 
reliability of the outer model. This process was carried out with each of the 4 
datasets. To illustrate the method used to carry out this validity and reliability 
testing, the 96 hour time point datasheet was used as a worked example. Below 
describes a checklist, following the thresholds as recommended in (Joe F Hair 
et al., 2014b) that was utilised to carry out the testing. 
 
Figure 3.7 - Update of PLS path model  
The is the update of the model shown in Figure 3.6, modified to include the monolayer viability indicator, 
confluence and the selected proteins of interest. 
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Outer / Measurement model 
1. Collinearity – VIF of 0.3, acceptable under 0.5 
2. Significant and relevance of formative indicators, outer weights 
significant 
Inner / Structural Model 
1. Collinearity – VIF of less than 3, no more than 5 
2. Path coefficients assessed through bootstrapping – path coefficients 
significant 
3. Coefficient of determination – R2 value of ≥ 0.5 
4. F2 value of ≥ 0.15 
5. Blindfolding to determine Q2 values – weak effect = 0.02-0.15, moderate 
effect = 0.15-0.35, and Strong effect = ≥0.35 
In order to generate the results required in this checklist, two additional 
processes need to be carried out alongside the PLS algorithm. These are 
bootstrapping, and blindfolding. 
The process of bootstrapping is used to test the significance of the coefficients. 
Bootstrapping is carried out by drawing random samples with replacements 
from the original sample. This process is repeated a number of times (~500 for 
initial investigation, ~5000 for final results). After bootstrapping, The T statistic 
and p-values for the path coefficients, outer weights, and outer loadings have 
been calculated. This allows the significance of these values to be assessed. 
For formative indicators, a significant outer weight shows an indicators relative 
importance, and a T statistic of ≥0.5 shows the indicators absolute importance. 
A significant path coefficient denotes stronger relationships between the 
constructs. 
Blindfolding is then carried out to assess the predictive relevance of the model. 
Blindfolding is a sample re-use technique where data points and systematically 
removed and an estimation is provided of their original values.  The difference 
between the original and the estimated results are given as the prediction error 
and the sum of this is used to calculate the Stone-Geisser’s Q2 value. 
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3.4.2 Measurement Model Assessment 
3.4.2.1 Collinearity Assessment – VIF  
Collinearity describes when 2 or more indicators of a construct are highly 
correlated. A high degree of collinearity is problematic as it increases standard 
errors and can cause bias within the indicators weights. The variance inflation 
factor (VIF) is used as an indicator of collinearity and is calculated using the 
following equation (3.6)  





Where 𝑥1is referring to the indicator and 𝑅
2 as the indicator’s variance. An 
acceptable level of VIF is anything below a value of 5, but preferable under 3. 
The results from the worked example are shown in Table 3-13.  
The VIF results shown are from the 24 h and 96 h datasheets. The results from 
24 hours show the values to be ~1, whereas for the 96 hour data sheet the 
values for the diameter and spheroid cell viability indicators show a collinearity 
of 12.478, putting in far above the threshold of 5. 
Table 3-13 - VIF results from the worked example.  
Results with no collinearity issues shown at 24 h and with collinearity issues between diameter and 
spheroid cell viability shown at 96 h. 
 
24 h 96 h 
BNIP3 1.021 1.098 
CA9 1.022 1.158 
Cell Confluence 1.275 2.271 
Diameter 1.001 12.478 
Monolayer Cell Viability 1.275 2.271 
pNRF2 1.001 1.057 




Treatment of collinearity can consist of gathering more data, merging the items 
if this is supported by the model construction, splitting the items by use of a 
higher order model or a combination of these. If after treatment the VIFs are still 
above 5 then it may be necessary to remove the indicator or dismiss the 
formative model.  
In the case of this example, splitting the spheroid measures is supported as one 
is a morphometrically measure and the other a quantitative measure of ATP 
which relates to cellular viability, so the measures can be separated into a 
single item construct containing spheroid viability, and a second latent variable 
representing spheroid morphometric containing diameter and the additional 
indicator of circularity. This evaluation of the model was carried out till 
completion before these changes were implemented and the model assessment 
repeated.  
3.4.2.2 Assessment of outer weights 
The process of bootstrapping, described in section 3.4.1, was used to calculate 
the significance of the outer weights. The outer weight is the results of a 
multiple regression using the latent variable scores as the dependant variable 
and the formative indicator s as the independent variables (Joseph F. Hair et 
al., 2014). The outer weight is representative of the indicators relative 
contributions, and a significant value shows the indicators relative importance. 
When assessing the indicators weights the following flow chart, adapted from 
(Hair, 2013) shown below in Figure 3.8 is followed.  
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Outer weight not 
significant 




Analyse the formative 
indicator’s outer loading 
The outer loading 
T= <0.5 
The outer loading 
T= >0.5 
Test the significance of 
the formative indicator’s 
outer loading 
The outer loading is 
<0.5 and not significant 
The outer loading is 
<0.5 but is significant 
Continue with the interpretation of 
the outer weight’s absolute and 
relative size 
Keep the indicator even 
though it is not significant 
Delete the formative indicator Consider removal of the indicator 
Figure 3.8 - Bootstrapping decision-making tree to test significance of indicators  
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Using this flow chart, the significance of the outer weights was assessed first.  
Table 3-14 - Bootstrapping results for the outer weights in the initial run.  




t Value Significance 
Level 
p Value 
BNIP3 -> Proteomics -0.087 1.122 NS 0.262 
CA9->Proteomics -0.069 1.066 NS 0.287 
Confluence -> Monolayer 
Viability 
0.759 14.757 *** 0 
Diameter -> Spheroid 
Viability 
0.191 1.576 NS 0.116 
MonolayerCV -> Monolayer 
Viability 
0.296 4.935 *** 0 
Spheroid CV  -> Spheroid 
Viability 
0.815 6.886 *** 0 
pNRF2 -> Proteomics 1.007 51.325 *** 0 
Significance of the indicator is based on having a T-statistic of at least 1.965 
and a significance level (p-value) of ≤0.05. Table 3-14 shows the bootstrapping 
results of the worked example. From these values the BNIP3, CA9 and 
diameter indicators are not significant so the outer loadings would then be 
assessed.  
Table 3-15 - Bootstrapping results for the outer loadings in the trial run. 
 NS - not significant, * p=0.1, ** p=0.05, *** p=0.01 
  Outer Loadings t Value Significance 
Level 
p Value 
BNIP3 -> Proteomics -0.119 1.086 NS 0.278 
CA9->Proteomics 0.191 1.524 NS 0.128 
Confluence -> 
Monolayer Viability 
0.981 112.366 *** 0 
Diameter -> Spheroid 
Viability 
0.973 103.106 *** 0 
MonolayerCV -> 
Monolayer Viability 
0.864 37.131 *** 0 
Spheroid CV  -> 
Spheroid Viability 
0.999 498.185 *** 0 




The bootstrapping results of the outer loadings are shown above. In this 
example all the t values are above 0.5 as per the recommendations of the flow 
chart in Figure 3.8 so can be accepted despite lack of significance.  
3.4.3 Structural Model Assessment 
3.4.3.1 Collinearity Assessment, VIF 
The collinearity of the inner model is assessed and treated in the same manner 
as the outer model. The results of which are shown in Table 3-16.  
Table 3-16 - Inner VIF values from worked example 
Path VIF 
Monolayer Viability -> Spheroid 
Viability 
2.683 
Proteomics -> Monolayer 
Viability 
1 
Proteomics -> Spheroid Viability  2.683 
 
In this example the collinearity of the inner structural model meets the 
requirements of being under a value of 5 for all.  
3.4.3.2 Path coefficients through bootstrapping 
The significance of the path coefficients are to be determined through 
bootstrapping, the results of the worked example can be found in Table 3-17. 





Table 3-17 - Path coefficients and their significance following Bootstrapping from the worked 




t Value Significance 
Level 
p Value 
Monolayer Viability -> Spheroid 
Viability  
0.839 19.765 *** 0 
Proteomics -> Monolayer Viability  0.735 19.408 *** 0 
Proteomics -> Spheroid Viability  0.145 2.887 *** 0.004 
 
3.4.3.3 Coefficient of Determination, R2 values 
The R2 value is a measure of the models predictive accuracy and is 
representative of the variance in the endogenous constructs explained by the 
exogenous constructs linked to it. The values will fall between 0 and 1 with the 
higher values relating to a higher level of predictive accuracy. Typically a model 
with an R2 value ~0.25 is considered to have weak predictive reliability, ~0.5 is 
considered moderate predictive reliability, and ~0.75 is considered to have 
substantial predictive reliability. The R2 value is calculated using the following 
formula 
Ra ⅆj
2 = 1 − (1 − R2) ×
n − 1







Table 3-18 - Raw R2 values from worked example.  
Weak - *, moderate - **, strong - *** 
 
24 h 48 h 72 h 96 h 
Monolayer Viability 0.109* 0.365** 0.54** 0.623*** 
Spheroid Viability 0.304** 0.785*** 0.904*** 0.932*** 
 
The results of this worked example show that the strength of the R2 values increases for both latent 
variables over time as indicated in  
Table 3-18.  
3.4.3.4 Effect size, F2 values  
The effect size is the measure of the change in R2 value when an exogenous 
construct is omitted versus when it is included and is used to show whether the 
removal of an exogenous variable has a substantial effect on the endogenous 
variables. The effect size is calculated by running the PLS algorithm twice, once 
with the LV included and once with the LV excluded and the R2 values inputted 
into the below equation, (3.8), to calculate the f2 value.  When evaluating the f2 
Figure 3.9 - R2 values of the inner structural model.  






















values the guidelines are that values 0.02 to 0.15 are considered mild, 0.15 to 
0.35 is considered moderate and 0.35 and higher is considered a large effect 
size. 
              
f 2 =
Rⅈnclu ⅆⅇ ⅆ





Table 3-19 - F2 results calculated during the worked example.  
Mild - *, moderate - **, strong - *** 
 
f2 
Monolayer Viability -> Spheroid Viability 3.652*** 
Proteomics -> Monolayer Viability 1.683*** 
Proteomics -> Spheroid Viability  0.199** 
 
3.4.3.5 Blindfolding to determine the Q2 value 
The method of evaluating the predictive relevance of a formative model was 
carried out using blindfolding to obtain the Stone-Geisser’s Q2 value as 
described in (Andreev et al., 2009). The Stone-Geisser’s Q2 value, a measure 
of predictive relevance from here on referred to as Q2, was calculated through 
the use of blindfolding, as described above in 3.4.1 with a blindfolding distance 
(D) of 7. The equation demonstrating how the Q2 value was calculated is shown 
below (3.9). The rule of thumb in analysing Q2 values is that values between 
0.02 and 0.15 are considered a weak effect, between 0.15 and 0.35 is 
considered a moderate effect and 0.35 and above is a strong effect. The results 
from blindfolding are shown below in Table 3-20. 
Q2 =
Qⅈnclu ⅆⅇ ⅆ








Table 3-20 - Q2 results of worked example 
Mild - *, moderate - **, strong - *** 
 
Q2 
Monolayer Viability 0.51*** 
Spheroid Viability  0.861*** 
 
In this worked example, both of the endogenous variable show strong Q2 
results. 
3.4.4 Conclusions to preliminary analysis of the PLS model 
After carrying out the initial testing of the PLS model, it is showing real potential 
with strong predictive capabilities being displayed but a couple of issue were 
highlighted by carrying out the analysis that need to be addressed before 
moving forward. The collinearity issues highlighted by this initial testing was 
remedied by splitting the two spheroid indicators into two separate latent 
variables representing spheroid viability and spheroid morphology. An indicator 
containing circularity data was also added to provide more data to the spheroid 
morphology and to limit the use of single item constructs to the spheroid viability 
indicator. The process of testing the validity and reliability of the model after 
these amendments was repeated and the results of this are discussed in 
Chapter 5. Overall the preliminary testing of the model at this stage was 
highlighted changes that need to be made and proved beneficial to guiding the 
process moving forward.  
3.5 Data normalisation and creation of databases 
3.5.1 Expansion of Variables 
In order to meet the recommendation of data set size for the statistical model, a 
minimum of 20 replicates was required for each variable (Hair, 2013). For the 
majority of the variables that were collected from the laboratory 
experimentation, these 20 replicates were collected for each condition with the 
exception of monolayer confluence and the proteomic data collected through 
western blotting.  
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The gaps in the cell confluence data occurred because of insufficiently exposed 
images that were considered unsuitable for use. Although the full number had 
been collected, the insufficiently exposed images meant that in some groups, 
the total number of data points fell short of the required 20.  
With the western blotting data the limitation to generating the full set of 
replicates was cost. With the western blotting data, between 4 and 5 
experimental groups were used to extract protein from and between them a 
total of 15 pseudo-replicates were collected. The number of experimental 
groups differed per protein of interest as not all of the experimental groups were 
used to generate replicates for each protein. A graph detailing the pseudo-
replicate groupings for each of the proteins of interest can be found in Table 2-7 
in Chapter 2. The mean of the pseudo-replicates for each group was used to 
create 4-5 representative replicates.  
The process of expanding dataset can been seen throughout the literature, this 
can be carried out for a number of reasons including filling in gaps in 
observational data (Gray et al., 2019) or to avoid the disclosure of personal 
information associated with making a dataset publicly available (Quick and 
Waller, 2018). The process of expanding datasets or the generation of synthetic 
data has been carried out using a number of methods, depending of the nature 
of the data or the goal aiming to be achieved, an example of which generated 
synthetic samples through determining the mean and standard error of 
Gaussian distribution (Yang et al., 2011).   
In order to expand the datasets to meet the replicate requirement, initially the 
data was separate into groups based on their drug conditions in the data 
analysis software Microsoft Excel. Two obvious options for data expansion 
presented themselves: uniform and Gaussian. For a uniform data expansion, 
the replicates could be ordered from highest to lowest values within these 
groupings and the Excel ‘RAND’ function used to expand the dataset to 20. This 
method of expansion would create random values between the predefined 
minimum and maximum values and the values produced would have a linear 




Figure 3.10 - Generation of values using the RAND function on Microsoft Excel,  
A random group of values, shown in red, were used to generate new values using the RAND function in 
Microsoft Excel. The original data set had a mean of 103.47 and a standard deviation of 12.85, the mean 
of the RAND generated values was 107.08 and had a standard deviation of 16.19. The original values 
used to generate the new values are shown in red, and the computationally generated values are shown in 
blue. 
The second method considered to be applied in the expansion of these 
datasets was the use of a Gaussian random number generator (RANDOM.ORG 
- Gaussian Random Number Generator, 2018). This method of producing 
random values uses the mean and standard deviation of a normal distribution 
and applies a Box-Muller Transform to generate a predetermined amount of 
random values. This process is demonstrated in Figure 3.11, where this method 
was used to generate 100 values from the same original data set that was used 
in Figure 3.10.  
The distribution of the datasets was found using the statistical software package 
SPSS. In regard to the western blotting data the distributions of all 15 pseudo-
replicates was found that only 27 out of 48 conditions were normally distributed. 
However, after additional consideration of the underlying structure of the 
replicates and pseudo-replicates, reducing the pseudo-replicates to the true 
replicates by taking the average of the pseudo-replicates to represent each 
experimental group the number of conditions with a normal distribution was 43 
out of 48. This percentage of groups with normal distributions was determined 
to be a large enough majority to employ the Gaussian number generator to 
expand the datasets in a consistent manner. 
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Figure 3.11 - Values generated using an online Gaussian random number generator.  
 Using a small group of random values, shown in red. The mean and standard deviation were calculated. 
They had amean of 103.47 and a standard deviation of 12.85. Using an online Guassian random number 
generator, the mean and standard deviation were used to generate new values, show in blue The mean of 
the Gaussian random number generator values was 104.48 and had a standard deviation of 12.52. 
 
3.5.2 Normalisation of the dataset 
Another prerequisite of the statistical model is that all data must be on the same 
scale (Joe F Hair et al., 2014a) due to the variety of measurements recorded all 
with different values, the dataset required normalisation. This process was 
carried out by transforming each data set to a percentage change based on the 
mean control variable for that time point. This process led to all of the 
measurements being on the same scale and each concentration being related 
back to the untreated values.  
3.6 Preliminary Explorative Statistics using SPSS 
After the collection of experimental data and creation of the database to be 
used in the PLS-SEM software, the first step was to carry out exploratory 
statistics using the statistical programme SPSS v.23. Statistical tests were 
carried out to assess the interaction between time and treatment in the variable. 
Linear Mixed models were used to test this interaction on the repeated variable 
(monolayer confluence, spheroid diameter, and spheroid circularity), for the 
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carried out to assess the distribution of the data and correlations between the 
variables. 
3.6.1 Descriptive Statistics  
Descriptive statistics were carried out to gather an understanding of the shape 
and distribution of the data using the Shapiro-Wilk’s test of normality, identifying 
outliers, and creating box blots and histograms of the data. Although it is not a 
requirement of PLS-SEM to have normally distributed data it is recommended to 
assess the data prior to running the algorithm to have a more extensive 
understanding of the dataset. 
3.6.2 Correlation analysis using Bivariate 
With the data set comprising of 8 variables (Monolayer Viability, Monolayer 
Confluence, Spheroid Viability, Spheroid Diameter, Spheroid Circularity, BNIP, 
CA9, and pNRF2), 5 treatments (5-FU concentrations of 0, 26, 59, 96, and 
180µM), 4 time points (24, 48, 72, and 96 hours) and 20 replicates per condition 
to best approach the correlation analysis the data set was first separated into 
four datasets, each only containing only the data from one time point. Using 
each of these 4 datasets individually, the ‘select cases’ function was used to 
Figure 3.12 - SPSS output showing the results of correlation analysis of indicators treated with 
96µM for 72 h 
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select for each treatment dose in turn. The Bivariate function was then used and 
all variables selected. Pearson Correlation Coefficient was selected for, as well 
as a two-tailed test of significance. An example of the output for this test can be 
seen in Figure 3.12. The results from the preliminary statistics are discussed in 
detail in Chapter 5.  
3.6.3 Linear Mixed Models 
The model contains both fixed effects and random effects within the same 
analysis. Three of the variables – cell coverage, circularity, and diameter – are 
repeated measures with the same spheroid / monolayer being imaged every 
day for the full experiment. With the other variables, the experiments were end 
point assays and the cells were destroyed during the assay so independent 
samples of cells were used for each time point. Linear Mixed Models were used 
for the repeated measures and General linear Model were used for all the end-
point assays. The general linear model method is described in 3.6.4. 
A linear mixed model was performed using SPSS with the measure of choice 
selected as the dependent variable, the replicate number was a random factor, 
as these were repeated measures carried out on the same objects over time, 
and dose and time were selected as covariates. The fixed effects selected for 
were dose and time, and an interaction between dose*time. The predicted 
values and residuals were saved in order to test the assumptions. 
In order to check the assumptions of the linear mixed model, the predicted 
values and residuals that were used to check that the residuals are normally 
distributed, that the model is linear and to check the independence of the 
residuals. To test that the residuals are normally distributed a Shapiro-Wilk test 
was used. The Shapiro-Wilk test was carried out in the same manner as the 
described in 3.6.1 with the residuals listed as a dependent variable. To test 
model linearity scatterplots were produced with the observed variable and the 
predicted to satisfy the assumption of linearity. The final assumption is that the 
residuals are independent. This was tested by creating a scatter plot with the 
residuals and the predicted values. If the plot has a random pattern, then this 
assumption is satisfied.  
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3.6.4 General Linear Model 
For the remainder of the variables (monolayer viability, spheroid viability, and 
the proteins of interest). A general linear model was performed using the 
univariate function in SPSS. The model was set up with the variable of interest 
as a dependent variable, and time and dose as covariates.  Predicted values 
and residuals from this test were saved in order to test the assumptions in the 
same manner as the linear mixed models. To visualise the results of these 
models, line graphs were created on SPSS to show the change in each variable 
over time, with lines showing each drug concentration. The results of this testing 
is discussed in detail in Chapter 5. 
3.7 Displaying results of PLS-SEM model assessment 
With the data used in the PLS-SEM path model the observations from each 
drug concentration used organised into individual groups and the results from 
running each concentration at each time point were generated resulting in 
results from each of the groupings shown in Table 3-21. The control 
observations were not used as when normalising all the data to the control 
involved altering the control to have a mean of 100% and calculating all 
observations to be percentages of this. With the control observations all having 
the same mean, there was not enough variance between the variables to 
generate meaningful results. Biologically it was not necessary to compare the 
controls as they represented un-treated cells in a fixed environment and could 
therefore not provide information on the effect of treatment due to the drug not 
being present.  
Table 3-21 - A list of the groupings used in conjunction with the path model  
These were used alongside the 4, one for each time point, datasheets used to contain all observations 
from all the concentrations including the control. 
24 h, 26µM 48 h, 26µM 72 h, 26µM 96 h, 26µM 
24 h, 59µM 48 h, 59µM 72 h, 59µM 96 h, 59µM 
24 h, 96µM  48 h, 96µM 72 h, 96µM 96 h, 96µM 




The method for best displaying and comparing the results of these 16 sets of 
results was to use the 3D visualisation software, Miner3D (Miner3D, no date). 
This software allowed the production of 3D surface plots showing the results 
from all groupings and allowing the direct comparison of these results in a clear 
visualisation.  
These surface plots were applied to all outer weights between the indicators 
and latent variables, the path coefficients between latent variables, the R2 
values, and the Q2 values.  
3.7.1 Preparing results for Miner3D 
After the PLS-SEM algorithm had been run with the various groupings the 
results were copied into an excel data sheet like the one shown below in Table 
3-22 using the shorthand shown in Table 3-23. 
Table 3-22 - Example of data tables used to organise the outer weights, path coefficients, R2 and Q2 
values for use with Miner3D. 
Dose  Time cc_M.CV mcv_M.CV bnip3_PRO pnrf2_PRO ca9_PRO … 
26 24 0.097 1 0.408 0.845 0.325 … 
59 24 1.026 0.22 0.271 0.922 -0.301 … 
96 24 1.077 2.02 0.614 0.677 0.6 … 
… … … … … … … … 
 
Table 3-23 - List of shorthand terms used to refer to the indicators and latent variables.  
The indicators and latent variables were distinguished by the capitalisation of the later variables. 
Shorthand Full Name 
cc Monolayer cell confluence, indicator 
mcv Monolayer cell viability, indicator 
bnip3 Protein of interest BNIP3, indicator 
ca9 Protein of interest CA9, indicator 
pnrf2 Protein of interest pNRF2, indicator 
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circ Spheroid circularity, indicator 
d Spheroid diameter, indicator 
M.CV Monolayer viability, latent variable 
PRO Proteomics, latent variable 
S.CV Spheroid viability, latent variable 
S.M Spheroid morphology, latent variable 
 
In order to achieve a consistent colour scale across all the surface plots from 
one set of results, eg all outer weights surface plots, the min-max values of all 
results in each set needed to be normalised. This was achieved by find the 
minimum and maximum value for all of the outer weights and adding these to 
the bottom of each outer weight column with blank entries under ‘dose’ and 
‘time’. Path coefficients have set minimum and maximum values of -1 and 1 so 
these were added the same way to the path coefficient columns. This process 
was repeated for the R2 and Q2 values.  
When the data set was opened using Miner3D the axes were specified with the 
desired result group on the Z axis. The ‘objects’ tab was then opened and ‘hide’ 
was selected under ‘null objects’. This process can be seen in Figure 3.13. Due 
to the blank entries under the time and dose columns for the min-max values, 
Figure 3.13 - Screenshot of the Miner3D software showing the selection process of hiding null objects 
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they will not be displayed on the surface plot but their values will be used to 
generate the scale. When specifying the scale, 12 partitions of equal size was 
used for each group. This applied the same colour to value scale for all surface 
plots making them visually comparable. Shown below in Figure 3.14 is a 
demonstration of the benefits to the colour normalisations process. Using the 
monolayer viability indicators as an example, when normalised the monolayer 
confluence outer weight shows far lower values across the results compared to 
the normalised outer weights for monolayer viability. When looking at the un-
normalised colour partitions of monolayer confluence, there are far more data 
points represented in red and orange as the scale is narrower, which visually, 
appear that the results were far more positive than they were in comparison to 
the other indicator. The findings of these surface plot will be discussed in the 





Figure 3.14 - Demonstration of the surface plots before and after colour normalisation.  
A shows the cc_M.CV outer weight and its scale before normalisation. B) mcv_M.CV outer weight 
before normalisation and its scale. C) Shows cc_M.CV after normalisation and D) shows mcv_M.CV 




4 Chapter Four, Laboratory Results 
4.1 Introduction to laboratory results 
The set of Results chapters are presented in three distinct sections: first the 
thesis details the results from the laboratory based experimentation on 
monolayer (2D) and spheroid (3D) cultures, second the statistical analysis of 
the laboratory based data are presented; and finally the main results of the 
PLS-SEM model analysis are considered.  
Here Laboratory Results are set out by experimental method. Section 4.2 
details the measurement of cell viability in both monolayer and spheroid using 
first the MTT method of quantifying reduced formanzan that can be equated 
with cell viability, and second using the CellTitre-Glo® cell viability assay that 
quantifies ATP. The results of image analysis of morphometric features are then 
be discussed, including monolayer confluence, spheroid diameter and circularity 
in Section 4.3. Lastly the results of the proteomic experimentation are 
presented, both the initial immunocytochemistry (ICC) experimentation and 
finally the results of Western Blotting (Section 4.4). 
4.2 Cell Viability 
The purpose of measuring the viability after exposure to therapeutic insult in the 
form of  5-Fluorouracil (5-FU) the chemotherapeutic drug was the assess the 
differences, if any, in the effectiveness of exposure in eliciting cell death 
between the monolayer and spheroid cultures, as the literature has reported 
(Karlsson et al., 2012a). Two methods of detecting viability we trialled for use in 
this research, the methods for which are describe in Chapter 2. The MTT 
method of quantifying the formanzan present as an indicator of viable cells was 
trialled and although yielded successful results with monolayer cultures, was 
unreliable and time consuming when trialled in spheroid cultures. The method of 
ATP quantification using the CellTiter-Glo® assay (Promega) was chosen as it 
yielded reproducible results in both culture systems, and results of this 
experimentation are detailed in the following section.  
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4.2.1 MTT assay 
Initially the MTT colometric assay as described in section 2.4.1 was tested. This 
was used to firstly assess the growth of the colon HCT116+p53 and HCT116-p53 
cell lines cultured as monolayers (Figure 4.1) and preliminary investigation into 
their spheroid growth and appropriate seeding densities. Initial examination of 
responses to treatment with 5-Fluorouracil (5-FU) were also assessed with this 
method.  
 
Figure 4.1 – MTT assay carried out on HCT116 +p53 and HCT 116 –p53 cultures to monitor growth  
Cells were seeded at a density of 5000 cells in 100uL per well. The MTT assay was carried out every 24 
hours for a total of 72 hours days to monitor cell growth patterns in the two cell lines. HCT 116 +p53 cells 
showed steady growth over time, where are there was no significant growth in the HCT 116 –p53 cells. In 
both cases the experiment was performed in triplicate and the error bars represent 1 SD 
 
The growth patterns of monolayer cultures of HCT116 +/+ and -/-p53 over the 
course of 72 h post seeding.  The results showed a steady increase in the wild 
type +/+p53 cell count in comparison with very minor growth of the -/- p53 null 
cell line. The assay was repeated in triplicate with minor variation among 
replicates showing it to be a successful method of quantifying viable cells in 
monolayer.  A similar method was applied to spheroids using the +/+ p53 wild 






































The MTT assay was carried out 48 hours after seeding and the results can 
been seen in Figure 4.2, the results for replicates in each group appeared to be 
varying far more than when this assay was carried out in monolayer. This 
makes the MTT for assay for spheroid viability to be apparently less accurate 
and reliable. 
Nevertheless, this assay was carried out on both monolayer and spheroid 
cultures, to determine the dose response of the wild type HCT116 +p53 cell line 
when treated with 5-FU. Both monolayer and spheroid cultures were seeded at 
a density of 5000 cells per well. While the spheroid cultures were treated with 5-
FU 96 h after seeding to allow the spheroid to form and become compact, the 
monolayer cultures were treated with 5-FU after 24 hours to allow the cells to 
become adherent. Both cultures were exposed to 5-FU for 72 h before being 
assessed for growth or cell viability, the results of this experiment are shown in 
Figure 2.4 in Chapter 2.  
The monolayer cultures the assay again showed reliability through the small 
changes between the replicates of each treatment group. The spheroid cultures, 
however, showed high variance among the replicates of each group with no 






















cell count when seeded
Figure 4.2 – MTT assay carried out on HCT116 +p53 spheroids.  
Cells were seeded with a range of initial seeding densities into 96 well ULA plates (Corning) and allowed 
to incubated for spheroid formation. After 48 h when compact spheroids had formed the MTT assay was 
performed. The experiment was carried out in triplicates, the error bars are representative of 1SD.  
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results it was decided that the MTT assay was not a suitable method to use to 
quantify cellular viability in spheroids. The use of standard colorimetric assays 
not being suitable for use with 3D spheroid cultures has since been reported in 
the literature (Kijanska, 2016) 
4.2.2 CellTitre-Glo® assay 
Literature also suggested that the use of the CellTitre-Glo® assay (Promega) 
(Wenzel, 2014) (Zanoni et al., 2015) was a successful way to quantify cellular 
viability. Initially the assay was used to assess its accuracy and reliability with 
spheroid cultures – since this is where the original data stream problem lay – 
and to determine optimal seeding densities of the spheroids to be used in 
conjunction with the assay. Initial trials of the assay showed that the CellTitre-
Glo® assay was able to produce both accurate and reliable reproducible results 
with the spheroid cultures. Additionally, the experimental time was considerably 
shorter as the MTT assays for spheroids required 24 h to allow the MTT 
solution to penetrate the spheroid. From these results it was decided that the 
optimum cell seeding density for spheroid cultures was 3000 cells, as this 
produced results between the upper limit of the assay (around 10µM ATP) and 
the lower limit to allow recordable growth and decrease of the spheroids. 
(Figure 2.5).  
 
112 





















Figure 4.3 - CellTiter Glo® cell viability assay based on measure of ATP used with monolayer 
cultures of HCT116+/+ cells treated with 5-FU. 
The cells were incubated with 5-FU for a period of 96 hours, after which the CellTiter Glo® assay was 
performed and the data used to generate a drug dose response curve. The IC50 was calculated using the 
analysis software GraphPad Prism and was estimated to be 93µM SE 1.5µM. The experiment was carried 





















Figure 4.4 - CellTiter Glo® cell viability assay based on measure of ATP used with spheroid cultures 
of HCT116+/+ cells treated with 5-FU. 
The spheroids were incubated with 5-FU for a period of 96 hours, after which the CellTiter Glo® assay was 
performed and the data used to generate a drug dose response curve. The IC50 was calculated using the 
analysis software GraphPad Prism and was estimated to be 118µM SE 6.2µM. The experiment was carried 
out with 4 replicates, error bars represent 1 SD. 
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This protocol was used to obtain dose response curves from both monolayer 
and spheroid cultures, these experiments were performed in quadruplicate, and 
the replicates were independent. The IC50 and EC75 values were calculated 
using the method described in Section 2.4.5 
The results were normalised to the mean of the untreated values (100%). 
Although the raw values themselves were very different between culture 
systems, they exhibited similar trends between the spheroids and monolayer 
cultures initially exhibiting very similar responses to treatment at the lower 5-FU 
concentrations but the treatment appears to have less of an effect at higher 5-
FU concentrations from 89µM upwards. The experiment was repeated with an 
additional concentration of 300 µM, this was performed with a total of 20 
replicates to satisfy the requirements of the PLS-SEM path model and the IC50 
values were re-calculated with this larger cohort of observations.  
After the inclusion of 300µM (Figure 4.5), the experiment was able to achieve 
























Figure 4.5 - CellTiter Glo® cell viability assay based on measure of ATP used with monolayer and 
spheroid cultures of HCT116+/+ cells treated with 5-FU, reproduced to include the additional 
concentration of 96µM.  
The monolayer and spheroids were incubated with 5-FU for a period of 96 hours, after which the CellTiter Glo® 
assay was performed and the data used to generate a drug dose response curve. The IC50 was calculated 
using the non-linear regression function in the analysis software GraphPad Prism. For monolayer the IC50 value 
was estimated to be 96µM SE 2.2 µM, and for spheroids it was estimated to be 122µM SE 3.2µM  
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effect of the therapeutic insult is lessened at the higher concentrations. The 
effect of the therapeutic insult in the two culture systems did not differ 
significantly up until the addition of 133µM (p=<0.05). The literature 
demonstrates a marked difference in the viability of HCT 116 spheroid and 
monolayer cultures to 5-FU exposure (Karlsson et al., 2012a).  
The results shown are from the 96 h time point, the maximum exposure to 5-FU 
that was recorded. The results of the earlier time points (24 and 48 h) showed a 
very similar drug effect between the monolayer and spheroid cultures with the 
lines separating over time. At 24h, significant differences were only observed at 
59µM and 89µM, and at 59µM and 300µM at 48h (p=<0.05). Significant 
differences between monolayer and spheroid can be observed at 59µM and 
higher (p=<0.05) at 72h, and from 133µM (p=<0.05) at 96h.  
A one-way ANOVA with Tukey’ HSD post-hoc was used for each time point to 
assess the significant differences between the responses to therapeutic insult in 
monolayer and spheroid cultures. In the case of 48 and 96h the assumption of 
Homogeneity of Variances was not met using Levene’s test of homogeneity of 
variances in which case a Welch F test was run with a Games Howell post hoc 
test. This was carried out using the statistical package SPSS v.25.  
The interaction between time and 5-FU concentration in monolayer and 
spheroid viability, was tested using a general mixed model. The results of which 
can be found in (Section 5.3).  
The significant reduction in cell death in 3D, compared to 2D, can be explained 
by multicellular resistance of spheroid cultures  Spheroids have been 
demonstrated to exhibit higher resistance to therapeutic agents (Olive and 
Durand, 1994). This resistance has a number of underlying mechanisms, as 
outlined in (Desoize and J.-C. Jardillier, 2000) such as the modulation of protein 
expression, presence of hypoxic core, permeability, and a high proportion of 
quiescent cells, these mechanisms contribute to the reduction is functionality of 
the therapeutic agent and can be seen with the significantly higher percentage 
cell survival demonstrated at the higher concentrations used within this 
experiment. This resistance to therapeutic insult is akin to the resistance found 
in vivo (Kobayashi et al., 1993). 
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The statistical analysis package GraphPad Prism (www.graphpad.com) was 
used to generate the dose response curves for both monolayer and spheroid 
viability. The method has been detailed in Section 2.4.5. The mean IC50 
concentration for the 96-hour monolayer replicates was calculated to be 96µM 
with a SE of 2.2µM and the EC75 concentration was calculated to be 59µM with 
a SE of 3.4µM. The mean IC50 value calculated from the 96-hour spheroid 
viability replicates was found to be 122µM with a SE of 3.2µM. This variation 
between the IC50 values for the two culture types demonstrates the differing 
effectiveness of the treatment between 2D and 3D cultures. The difference 
between the IC50 values of the monolayer and spheroid cultures were shown to 
be statistically significant using an Independent t-test (t(38)=-5.114; p=<0.001) 
carried out on SPSS v25. 
The full list of raw data from the ATP-based cell viability experiments, separated 
by experimental group can be found in the Appendix 8.1.2. When compiling the 
datasets together, the mean value of the control from each experimental group 
was used to normalise the results to a percentage of that mean control value. 
This allowed the normalisation of all results within each experimental measure, 
but when applied to all variables it achieved a cohesive scale of percentage 
change from the control, which is necessary with PLS-SEM. 
Although viability assessment was carried out using the larger range of 5-FU 
concentrations over the four days, this number was reduced to four (26, 59, 96, 
180µM) concentrations alongside a control (UT) for the PLS-SEM path model. 
The results of the morphometric and proteomic measures have focused on 
observations at these concentrations.    
4.3 Morphometric Measures 
4.3.1 Monolayer Confluence 
Monolayer confluence is a 2D morphometric measure that is incorporated into 
the Monolayer Viability Variable of the statistical model as a formative indicator 
(Section 3.4). The analysis for the monolayer confluence was originally going to 
be carried out using the pipeline written for the ICC analysis on Cell profiler as a 
cell count and total cell area modules had been included. Carrying out the 
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analysis with this automated process was not viable however as the light source 
intensity and location were not consistent across the cohort of images, meaning 
that the settings that would be suitable for some images would cause inaccurate 
results in others. Examples of these inconsistencies can be found in Figure 4.6. 
Figure 4.6 image A and B shows the same cell culture well, imaged with the 
same microscope at the start and end of the experimental period. There is a 
marked difference in the light source location and intensity.  
A method for recording the confluence change was developed in ImageJ and 
was used to produce data from this cohort of images instead. Similarly to the 
spheroid analysis, the image was converted to 8-Bit and converted to a 
threshold image to create a dark mask over the areas covered in cells. The 
measurements were set to record Area Fraction. This provided the area 
covered by the cells as a percentage. Values were normalised to the mean of 
the control for the 24 h time point. Some of the images were not able to be used 
to provide a reliable measure due. In these cases the total number of replicates 
were inflated using a Gaussian random number generator in order to bring the 
total number of replicates up to 20. This was the same process used to inflate 
the replicates of the proteomic variables and it described in Section 3.5.1. The 
mean values for cell confluence are shown below in Table 4-1. 
Table 4-1 – Mean monolayer cell confluence values over 96 hours following treatment with 5-FU. 
 HCT116+p53 cells were seeded at a density of 3,000 cells and incubated for 72 hours before treatment with 
5-FU. Images were taken of the wells every 24 hours for the duration of treatment. Image analysis was 
preformed using ImageJ where the area occupied by cells was calculated as a percentage of the total 
image. The experiment was carried out with 20 replicates.    





24 h 48 h 72 h 96 h 
0µM 100 102.2059 100 100 
26µM 103.3201 97.79699 102.6765 94.50399 
59µM 104.3327 90.76493 88.30523 73.60247 
96µM 60.17339 52.71342 32.95631 23.98361 




Much like with the ATP cell viability results, both time and increase in drug 
concentration cause a decrease in the confluence of the cells, with the lower 
drug concentrations having very little effect in comparison with the control (no 
treatment) and the higher drug concentrations showing a sizable decrease in 
confluence, from as early as 24 h (Figure 4.7). The significance of the 
interaction between time and 5-FU concentration was tested using a linear 





Figure 4.6 – Representative images of HCT 116+p53 monolayers treated with 59µM.  
Monolayer cultures were seeded at a density of 3,000 cells per 200µL into 96 well plates treated with 59µM 5-FU 
after 72 h. Images were taken every 24 hours post treatment for 96 h.  A) Shows a monolayer culture treated with 
59µM 5-FU for 24 hours, B) Shows the same well after 96 hours treatment. C) Image A following analysis with 
imaging software ImageJ. D) Image B following image analysis. In images C and D, the areas covered by cells, 
the monolayer, have been selected and shown as the black areas. The areas not occupied by cells remain white. 




























































































































































































































































































































































































































4.3.2 Spheroid Diameter 
In some of the samples there were artefacts that affected the spheroid shape 
and structure. These artefacts consisted foreign objects, mostly fibres. For 
consistency across the results, spheroids with a highly visible artefact at the 0 h 
time point were excluded as a replicate from the final data set but imaging and 
subsequent analysis was still carried out for the purpose of consistency (Figure 
4.8.) 
Continuous sampling was possible for both diameter and circularity data from 
the same spheroids following drug treatment, in contrast to the ATP-based cell 
viability assay above which was end-point testing and so different spheroids 
were required for each time points. This continuous imaging afforded the use of 
a linear mixed model as a method of statistical analysis, the results of which can 
be found in Section 5.3.  
At the 0 h time point, where the spheroids had been imaged immediately prior 
to treatment, the spheroids were consistent in shape and size across all wells. 
Over the course of the time period spheroids treated with lower doses of the 
therapeutic agent grew in size over time or remained the same in size. At the 
higher drug concentrations, the diameter of the spheroids decreased and there 
was increase in dead cells leading to a loss of integrity within the spheroid and 
Figure 4.8 - Representative images of spheroids containing artefacts. 
 Cells were seed into ULA plates at a density of 3,000 cells per 200µL 72 h prior to treatment. Both images were 
taken immediately following treatment at 0 h. This is a results of artefacts contaminating the wells during the cell 
counting or seeding stage. During spheroid formation the cells will adhere to the artefact and spheroids will form 
around them.    
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resulting in a loss of the compact spherical shape and the formation of a halo of 







Figure 4.9 – Representative images of spheroid treated with 200µM and 300µM for a period of 96 
hour. 
 HCT116+p53 cell were seeded into 96 well ULA plates at a density of 3,000 cells per 200µl and treated 
with 200 and 300µM of 5-FU for a period of 96 hours. These images illustrate the ‘halo’ of cellular debris 


































































































































































































































































































































































As the drug treatment caused cytotoxic effect 5-FU causes wide-scale cell 
death. The dead cells can no longer maintain the cell-cell interactions that were 
holding the spheroid together. The use of ULA plates creates a closed 
environment to culture the spheroid, with no fluid gradient to carry away waste. 
This means that the dead cells no longer adhered to the spheroid remains in the 
well. This was best demonstrated at the highest drug concentration of 300µM 5-
FU, used in this experiment and can be seen in Figure 4.9. In comparison to the 
cell viability assay which demonstrated cell viability of 22.7% compared to 
untreated when treated with 300µM 5-FU for 96 hours compared to the 
untreated, the spheroid diameter had decreased to 66.3% compared to the 
control (100%) when treated with 300µM 5-FU. 
The difference between the percentage change in diameter and spheroid 
viability. The change in diameter clearly plateaus from around 89µM, and there 
was no significant change in diameter at higher concentrations. This contrasts 
with the percentage change in viability where the decrease in viability continues 




4.3.3 Spheroid Circularity 
Circularity was chosen as a morphometric indicator as it provides a quantifiable 
source of information relating to the formation and integrity of the spheroid. 
Circularity is calculated by ImageJ on an identified object using the following 
formula; 4π(area/perimeter2). The result is a value between 0 and 1, with a 
result of 1 being an object that is perfectly circular. The circularity across all 
Figure 4.12 – Representative images of spheroid to demonstrate loss of spheroid integrity when exposed 
to therapeutic insult. 
 Spheroids were treated with 300µM of 5-FU for 24 hours (left) and the same spheroid after 96 hours (right). Note 






















Figure 4.11 - Spheroids treated with 5-FU for 96 h. Cellular viability was measures using CellTiter-Glo® 
ATP assay and image analysis was performed to observe changes to spheroid ferret diameter.  
Spheroid diameter decreases with the increase of 5-FU concentration, till 96µM, after which the diameter 
does not significantly decrease. Spheroid Viability follows a similar trend of decreasing with the increase of 5-
FU up until 96µM where the decrease in viability become less sharp.  
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drug concentrations used was consistent at the early time points, reducing with 
the increase of drug dosage over time (Figure 4.12).  
The circularity values between 0-1 of the spheroids were normalised to the 
mean value of the control to show each value as a percentage of the control. All 
20 of these values obtained were averaged to give the results shown in Table 
4-2. The full set of normalised results can be found in Appendix 8.1.2. The table 
(Table 4-2) only shows the circularity data from a minimised set of 
concentrations (0, 26, 59, 96, and 180µM).  
Table 4-2 – Mean spheroid circularity values over 96 hours. 
 HCT116+p53 cells were seeded at a density of 3,000 cells into ULA plates and incubated for 72 hours 
before treatment with 5-FU. Images were taken of the wells every 24 hours for the duration of treatment. 
Image analysis was preformed using ImageJ where the circularity of each spheroid was measured. The 
experiment was carried out with 20 replicates (N=20).    
 5-FU concentration (µM) 
Time 
(Hours) 
 0µM 26µM 59µM 96µM 180µM 
24 h 99.8045 107.3294 102.4807 97.4134 75.2226 
48 h 99.7757 107.3791 105.9002 98.0745 95.6857 
72 h 100.2535 100.0362 97.6526 96.9292 80.7950 




These results confirm that exposure to therapeutic insult causes the spheroids 
to suffer a loss in structural integrity that can be quantified using the measure of 
circularity from 2-D images.  
 
By the 96 hour time point at the highest concentration (180µM) the average 
circularity of these spheroids had decreased by 65% compared to the control 
from the same time point. This is comparable to the decrease in spheroid 
viability at 96 h (4.2.2) where the same conditions cause a decrease in viability 
of 61% compared to the control. Over the earlier time points, 5-FU did not 























Figure 4.13 - Spheroids treated with 5-FU for 96 h. Cellular viability was measured using CellTiter-Glo® 
ATP assay and image analysis was performed to observe changes to spheroid circularity.  
Spheroid circularity decreases with the increase of 5-FU concentration as does the viability. For the maximum 
concentration (180µM). The change in spheroid circularity is comparable to the viability.  
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Figure 4.14 - Change in spheroid circularity with the addition of 5-FU over time. 
 Spheroids were treated with 5-FU 4 days after seeding at a approximate cell density of 3,000 cells per well into 
ULA plates. The spheroids were images every 24 hours post treatment up to 96 h and circularity was calculated 
using the imaging analysis software ImageJ. The concentrations of 5-FU used and displayed on the x-axis with 
the mean circularity displayed as a percentage compared to untreated is shown on the y-axis.. Each line 
demonstrates a time point the readings were taken. The addition of 5-FU showed no substantial effect on 
spheroid circularity up until the 96 h time point where the highest dose (180µM) reduced the circularity 





Following the treatment of 2D cell culture with 5-FU, immunocytochemistry 
(ICC) was carried out. The proteins that were probed and stained for were 
HIF1α, BNIP2, CA9, VEGF, NRF2 and pNRF2. The 5-FU concentrations used 
were selected based on the IC50 and EC75 values calculated from the 96 hour 
time point for monolayer viability. The slides were fixed every 24 h, starting from 
24 up to 96 h. A total of 4 slides per condition (time point and 5-FU 
concentrations) were produced. The analysis was carried out using a 
combination of ImageJ (Schneider, Rasband and Eliceiri, 2012) initially, and 
then CellProfiler (Carpenter et al., 2006). The integrated density and corrected 
total cell fluorescence (CTCF) were recorded.  The CellProfiler pipeline and 
ImageJ protocol are presented and discussed in the Chapter 2. When carrying 
out western blotting, the same proteins were probed and stained for, using the 
5-FU concentrations of 26, 59, 96, and 180µM, in addition to a control, and the 
process behind deciding on these concentrations and proteins of interest is 
detailed in Chapter 2.  
4.4.1 Results of Immunocytochemistry Studies 
For ICC experimentation, slides were prepared with cells treated with 59, 96µM 
5-FU alongside a control (UT) and cells were fixed at 24, 48, 72 and 96 h. Each 
set of slides included 2 true replicates per condition. Each replicate was an 
individual coverslip, covered in cells that had been treated in individual wells. 
Following the immunocytological staining the two coverslips per conditions were 
affixed to the same microscope slide side by side. The experiment was 
repeated twice giving 4 replicates (n=4) for each protein of interest for each 
condition.  
The individual greyscale images were used in the measurement of the CTCF 
using ImageJ, the method for this is discussed in detail in Section 2.6.2. From 
each slide, the CTCF of 8 cells was measured and this was averaged to give a 
mean value for that slide.  
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Although this method of measuring the integrated density was straightforward 
and easy to follow there was a degree of human error as the borders of each 
cell would have to be manually identified for each image, instead an automated 
process was implemented using the open source online program CellProfiler. 
The pipeline that was written as part of this thesis allowed each image to be 
analysed with set parameters that would identify each cell in the image and 
provide information on the number of cells, the area covered by cells, and the 
intensity of the fluorescent signal from both the total cell and the nucleus. The 
results of the mean total cell analysis for each protein of interest are discussed 
below. 
Figure 4.15 to Figure 4.18 show representative images of the proteins of 
interest. There is high variation among the images in the strength of the 
fluorescent signal. These images are merged images of the nuclei, with false 
colour in blue, and the proteins of interest in either red or green false colour. 
The colours of each of the proteins is indicated in both the caption and in the 






















0µM 59µM 96µM 
Figure 4.15 - Immunostaining of CA9 and HIF1⍺  in HCT116+p53 monolayers after exposure to 5-FU over 
time  
HCT116 +p53 cell were seeded at a density of 5x104 cells in 2mL of cell culture media. Cells were treated with 
5-FU 24 hours after seeding. Cells were fixed and prepared for immunostaining at 24, 48, 72, and 96 h 
following . Immunostaining was performed using CA9 and HIF1α antibodies with Alexa Fluor 488 and 594 
conjugated secondary antibodies.  These are representative images taken at 100X magnification. Nuclei is 




Figure 4.16 - Immunostaining of VEGF and BNIP3a in HCT116+p53 monolayers after 
exposure to 5-FU over time  
HCT116 +p53 cell were seeded at a density of 5x104 cells in 2mL of cell culture media. Cells were 
treated with 5-FU 24 hours after seeding. Cells were fixed and prepared for immunostaining at 
24, 48, 72, and 96 h following treatment. Immunostaining was performed using VEGF and 
BNIP3 antibodies with Alexa Fluor 488 and 594 conjugated secondary antibodies.  These are 
representative images taken at 100X magnification. Nuclei is shown in blue after being stained 





















   
 

















Figure 4.17 - Immunostaining of NRF2 in HCT116+p53 monolayers after exposure to 5-FU over time  
HCT116 +p53 cell were seeded at a density of 5x104 cells in 2mL of cell culture media. Cells were treated with 
5-FU 24 hours after seeding. Cells were fixed and prepared for immunostaining at 24, 48, 72, and 96 h 
following treatment. Immunostaining was performed using NRF2 antibody with Alexa Fluor 488 conjugated 
secondary antibodies.  These are representative images taken at 100X magnification. Nuclei is shown in blue 






















Figure 4.18 - Immunostaining of pNRF2 in HCT116+p53 monolayers after exposure to 5-FU 
over time  
HCT116 +p53 cell were seeded at a density of 5x104 cells in 2mL of cell culture media. Cells were 
treated with 5-FU 24 hours after seeding. Cells were fixed and prepared for immunostaining at 24, 
48, 72, and 96 h following treatment. Immunostaining was performed using pNRF2 antibody with 
Alexa Fluor 488 conjugated secondary antibodies.  These are representative images taken at 




4.4.1.1 ICC for HIF1α 
In the results of HIF1α protein expression levels there are no significant 
changes in response to either change in drug concentration or treatment time. 
However all conditions tested showed lower levels of HIF1α in comparison to 
the 24 h control to which they are normalised to, this decrease was not found to 
be significant when an ANOVA was performed to assess any significant 
differences between groups (F(11,23)=0.872; p=0.576). This was to be 
expected with the results of a monolayer culture grown in normoxic conditions 
(Wang et al., 1995). When looking at the images, there were variable results 
among replicates, much like the CA9 expression. HIF1α and CA9 were stained 
together on the same slides so the same issues are likely responsible for the 
variation in both.  
  
Figure 4.19 – Percentage change in average total cell HIF1α expression from ICC experimentation, 
 HCT 116 +p53 cells were seeded at a density of close to 50,000 cells, into 6 well plates and exposed to 5-FU 
(96 and 59µM) for a period of 96 h. Cells were fixed and prepared for immunocytological studies at 24, 48, 72, 









































4.4.1.2 ICC for VEGF 
The expression of levels of VEGF protein expression show a decrease in the 
untreated cells over time, with both 72h, 0µM and 96h, 0µM being significantly 
lower than the 24h, 0µM (p=0.037 and 0.0.028 respectfully). There was a 
decrease in the expression of VEGF in the cells treated with 96µM, but this 
decrease was not significant over time. . The cells treated with 59µM 5-FU show 
little change over time.  
 
Figure 4.20 - Percentage change in average total cell VEGF expression from ICC experimentation, 
 HCT 116 +p53 cells were seeded at a density of close to 50,000 cells, into 6 well plates and exposed to 5-
FU (96 and 59µM) for a period of 96 h. Cells were fixed and prepared for immunocytological studies at 24, 




4.4.1.3 ICC for NRF2 
The images showing NRF2 protein expression levels show an overall low 
expression for all concentrations and time points. This can be seen in Figure 
4.21 which shows all replicates collected for the 96µM treated cells for all time 









































visible expression, mostly located toward the nucleus, this expression is difficult 
to see and expression levels are low. This was reflected in the analysis 
conducted for the cells where expression levels do not substantially deviate 
from the control across all time points. There is the appearance of an  increase 
in NRF2 expression with increase in treatment drug concentration over the first 
three time points but the results of a One-way ANOVA showed none of these 




Figure 4.21 - Percentage change in average total cell NRF2 expression from ICC experimentation, 
 HCT 116 +p53 cells were seeded at a density of close to 50,000 cells, into 6 well plates and exposed to 5-FU 
(96 and 59µM) for a period of 96 h. Cells were fixed and prepared for immunocytological studies at 24, 48, 72, 
















































Figure 4.22 - NRF2 expression of HCT116+p53 treated with 5-FU over time. Images taken following 
ICC staining 
The images show the 96µM treated HCT116+p53 replicates at time periods indicated on the left hand 
side, the numbers above indicate the replicate number. Images have not been altered, the expression of 




4.4.1.4 ICC for pNRF2 
Compared with NRF2 total, the results for phospho NRF2 (pNRF2) protein 
expression levels show a much stronger variation in results in response to 
changes in drug treatment concentration and to time, the values that were found 
to be significantly different to 24h, 0µM have been flagged on Figure 4.23.  The 
variation among replicates was minimal when compared to the variation 
observed in CA9 and HIF1α expression levels, moreover there is a clear 
decrease in pNRF2 expression levels at all 5-FU concentrations over time, as 
shown in Figure 4.23. The images show the expression of pNrf2 to be 
predominantly nuclear, this can be seen in the images merged with the DAPI 
staining (Figure 4.18). The clarity of the staining and the clear effect of time and 
treatment made pNRF2 a good candidate to take forward into western blot 
experimentation.  
  
Figure 4.23 - Percentage change in average total cell pNRF2 expression from ICC experimentation, 
 HCT 116 +p53 cells were seeded at a density of close to 50,000 cells, into 6 well plates and exposed to 5-FU (96 
and 59µM) for a period of 96 h. Cells were fixed and prepared for immunocytological studies at 24, 48, 72, and 96 
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4.4.1.5 ICC for BNIP3 
 
Figure 4.24 shows the average BNIP3 expression, expressed as a percentage 
(%) compared to the control, for the total cell. All results have been normalised 
to the 24 h control. Cell profiler records the particular protein expression for all 
cells identified in the image, the mean of all cells in each image was calculated 
and then the mean of all images within a 5-FU drug treatment group was 
calculated. The results from this analysis show no significant change in BNIP3 
expression with the addition of drug treatments from the control, though 
expression in all groups, treated and un-treated, decreased between 24 and 48 
h and then remained flat for the remainder of the time period. 96 h showed a 
slight upregulation in BNIP3 expression in the treated cells from the control, but 
this was not found to be significant, the results of an ANOVA showed that there 
was no significant differences between groups (F(11,28)=1.598; p=0.154).   
 
Figure 4.24 - Percentage change in average total cell BNIP3 expression from ICC experimentation, 
 HCT 116 +p53 cells were seeded at a density of close to 50,000 cells, into 6 well plates and exposed to 5-FU 
(96 and 59µM) for a period of 96 h. Cells were fixed and prepared for immunocytological studies at 24, 48, 












































4.4.1.6 ICC for CA9 
With CA9 the variance between replicates was a lot higher than with BNIP3, 
causing the large error bars particularly at 48 h. The results indicate that the 
total cell average CA9 protein expression is decreasing within the untreated 
cells. The CA9 protein maintains a steady expression in the cells treated with 
59µM 5-FU and in the cells treated with 96µM 5-FU there is a gradual decrease 
in levels of CA9 over the first three time points followed by an increase in 
expression at the final 96 h time point. Due to the high variation between 
replicates, none of these differences were found to be significant 
(F(11,30)=0.355; p=0.964) and there is no way to discern from these results if 
they are a reflection of the true biology. Figure 4.26 shows this high clear 
variation between images, with all 4 replicates placed together for comparison. 
This high variation between replicates could be a product of manual error when 
conducting the ICC protocol or irregularities in imaging over the time period that 
the experiment was carried out, and see Section 4.4.2 for consideration of this 
issue.  
Figure 4.25 - Percentage change in average total cell CA9 expression from ICC experimentation, 
 HCT 116 +p53 cells were seeded at a density of close to 50,000 cells, into 6 well plates and exposed to 5-FU 
(96 and 59µM) for a period of 96 h. Cells were fixed and prepared for immunocytological studies at 24, 48, 72, 












































CA9, 96 h 96µM 
Figure 4.26 - Representative images of CA9 expression taken following ICC staining 
HCT116 +p53 cells were treated with 96µM for 96 hours before fixation and preparation for ICC studies. Cells 
were stained for CA9. The images above show the variations between the 4 replicates in CA9 expression.  
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4.4.2 Conclusions from ICC analysis 
After encountering some initial issues when analysing the images taken of the 
ICC with ImageJ, the analysis using Cell Profiler was able to produce consistent 
results for all images as size and intensity thresholds could be applied 
universally to all images. Despite the improvements to the image analysis 
procedure, some of the protein expression results were still inconclusive with 
large value differences among replicates in some cases, for example with CA9 
and HIF1α. This variation was most likely a product of the variation in the 
images taken, or manual errors that may have occurred while carrying out the 
ICC protocol. The low number of replicates (4) would have exacerbated this 
issue. 
Although CA9 is a marker of hypoxia as it is directly regulated by HIF1α, it is 
downregulated by activated p53 (Kaluzová et al., 2004a) The results from the 
ICC quantification showed no significant differences between treatment groups 
over time, so was unable to confirm the expectation of downregulation from the 
literature. The literature shows that BNIP3 is also downregulated by p53 when 
exposed to 5-FU (Feng et al., 2011b), again no significant difference was shown 
between the groups. From the literature an increase in NRF2 expression was 
expected to be upregulated in the presence of 5-FU, very low expression with 
no significant differences between groups was shown. As the activated form of 
NRF2, the expectation was to see an upregulation in pNRF2, the results of the 
ICC quantification showed a significant downregulation in many groups over 
time and with exposure to 5-FU compared to the 24h untreated control. This 
outcome was later reflected in the results of the Western Blot quantification and 
is discussed in more detail in Chapter 7. As a classical marker for Hypoxia, 
VEGF is upregulated by HIF1α, VEGF has been shown to be unaffected by 
treatment with 5-FU (Fan et al., 2008), but in some cancer cell lines, WT p53 
has been shown to reduce VEGF expression (Zhang et al., 2000). HIF1α is 
activated under hypoxic stress, and by the presence of ROS under oxidative 
stress (Singh et al., 2017). The results of the ICC showed no significant 
differences between treatment groups over time.  
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Overall the results of proteomic expression from ICC were not as expected from 
the reports in the literature and with many of the proteins no significant changed 
in expression could be seen.  
After the completion of the ICC analysis and as a response to the high 
variability in the results, it was decided that it would be beneficial to carry out 
western blotting with all 6 of the proteins of interest for an initial 3 replicates, as 
opposed to selecting three proteins of interest to carry forward from the results 
of the ICC alone. The data from these initial replicates would then be 
considered alongside the ICC data to narrow the scope of the proteomics down 
to three proteins of interest to be included in the statistical model.  
 
143 
4.4.3 Initial Western Blot results 
Before narrowing down the cohort of proteins to three, all six proteins were 
probed by Western blotting in triplicate. Much like the ICC, the proteins were 
paired up relating to the size of band and the species of the antibodies used. 
This process is discussed in more detail within Section 2.6, and cut down on 
both time and consumables required.  
The analysis can be found alongside example images of the membranes in 
section 4.4.3.1 to section 4.4.3.6.   
4.4.3.1 Western blotting for HIF1α 
When probing for HIF1α the antibody produced a number of exogenous bands 
outside the targeted region of interest as demonstrated in Figure 4.27. This 
coupled with a large degree of background noise caused the variation between 
replicate to be quite high and no clear pattern of expression was detected, 
reflecting the results obtained from the ICC experimentation. After carrying out 
the western blotting for HIF1α in triplicate, it was ruled out as a protein of 
interest to be carried forward for the model. The focus was shifted to CA9, due 
to its regulation under HIF1α (Logsdon et al., 2016).  
80kDa 
Figure 4.27 - Representative image of HIF1α protein expression, detection using western blot. 
Cells were treated and prepared for immunoblotting with relevant antibodies following the methods detailed in 
Chapter X. Image of membrane taken using Syngene G-BOX Chemi-XX6 Gel Documentation System.  80kDa 
noted on protein ladder on left hand side, HIF1α expected to be detected at 120kDa.  Β-Actin used as the 




The high number of non-specific bands visible on the blot is a result of the POI 
being targeted, HIF1α. This particular protein is highly degradable (Huang et al., 
1996) and often appears as numerous fuzzy bands (Minamishima et al., 2009). 
For this reason, attention was shifted to the representative markers of HIF1α 
such as CA9 and BNIP3.  
4.4.3.2 Western blotting for VEGF 
Contrasting with the results from the ICC analysis, VEGF quantification through 
western blotting showed an increase in expression with the increase in 
treatment concentration whereas the results in ICC showed little change in 
response to treatment. The VEGF band has the same molecular weight, 43kDa, 
as the housekeeping gene, β-Actin, that was used to normalise the samples. 
This required the membranes to be stripped and re-probed for the 





































Figure 4.28 - Densitometry of HIF1α expression after exposure to 5-FU over time from western blot 
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for western 
blot analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 Gel 
Documentation System. Integrated density of the bands was measures using ImageJ. Each results were 
normalised to the loading control of that lane and then normalised to the UT for each time point. Error bars are 
representative of 1SD. 
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interest of consistency, the requirement of an alternative housekeeping gene 
ruled out VEGF as a suitable protein of interest to be used in the model. 
 
4.4.3.3 Western blotting for NRF2 
Both an increase of 5-FU concentration and incubation time cause an 
upregulation of NRF2 protein levels. These results varied greatly from the ICC 
results, due to the image collected in the ICC showing a very low expression 
and subsequently affecting the image analysis. NRF2 is shown to increase 3-
fold with the addition of 180µM 5-FU for 96 h. This upregulation of NRF2 protein 
levels is in line with predictions. Under normal conditions, NRF2 is readily 
sequestered in the cytoplasm, but an increase in reactive oxygen species 
(ROS) presence causes the release of NRF2 and it is translocated to the 
nuclease (Niture et al., 2010). The irregular cell death caused by exposure to 5-
FU would cause an increase in ROS through the p-53 mediated pathway, 







































Figure 4.29 - Densitometry of VEGF expression after exposure to 5-FU over time from western blot 
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for 
western blot analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 
Gel Documentation System. Integrated density of the bands was measures using ImageJ. Each results 
were normalised to the loading control of that lane and then normalised to the UT for each time point. 










































Figure 4.31 - Densitometry of NRF2 expression after exposure to 5-FU over time from western blot 
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for western 
blot analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 Gel 
Documentation System. Integrated density of the bands was measures using ImageJ. All results were first 
normalised to the loading control, Β-Actin,  of that lane and then the treated values were normalised to the UT 





































































































24 h 48 h 72 h 96 h 
 
Figure 4.30 - Representative image of NRF2 protein expression, detection using western blot. 
Cells were treated and prepared for immunoblotting with relevant antibodies following the methods detailed in 
Chapter X. Image of membrane taken using Syngene G-BOX Chemi-XX6 Gel Documentation System.  80kDa 
noted on protein ladder on left hand side, HIF1α expected to be detected at 120kDa.  Β-Actin used as the loading 




4.4.3.4 Western blotting for p-NRF2 
After the initial three replicates the densitometry results for pNRF2 protein 
expression levels showed a decrease in quantity with both time and 5-FU drug 
treatment concentration, reinforcing the results obtained when carrying out ICC. 
This was determined to be a good candidate for the model as the response to 
time and treatment provides insight into the ROS response pathway as well as 
practically, western blotting was able to produce clean, clear bands consistently 
across the replicates as demonstrated in Figure 4.32. 
 
Protein was extracted from a total of 5 experiments, and western blotting was 
carried out between 2-7 times for each extraction, dependent on the quantity of 
protein obtained per extraction. For the final data analysis, the pseudo-
replicates from each experimental group were averaged, and then the mean of 
these true replicates was then calculated to give the results shown below in 
Figure 4.33.  
The down-regulation of pNrf2 expression with both time and 5-FU concentration 
that was shown with ICC and the initial replicated is further supported and 





































































































24 h 48 h 72 h 96 h 
Figure 4.32 - Representative image of pNRF2 protein expression, detection using western blot. 
Cells were treated and prepared for immunoblotting with relevant antibodies following the methods detailed 
in Chapter X. Image of membrane taken using Syngene G-BOX Chemi-XX6 Gel Documentation System.  
80kDa noted on protein ladder on left hand side, HIF1α expected to be detected at 120kDa.  Β-Actin used as 





Figure 4.33 - Densitometry of pNRF2 expression after exposure to 5-FU over time from western blot 
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for 
western blot analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 
Gel Documentation System. Integrated density of the bands was measures using ImageJ. Each results 
were normalised to the loading control of that lane and then normalised to the UT for each time point. Error 
bars are representative of 1SD. 
4.4.3.5 Western blotting for BNIP3 
 BNIP3 was chosen to be included in the model as a protein of interest, due to 
its associated in cell death pathways, the reported relationships with both p53 



































Figure 4.34 - Representative image of BNIP3 protein expression, detection using western blot. 
Cells were treated and prepared for immunoblotting with relevant antibodies following the methods detailed in 
Chapter X. Image of membrane taken using Syngene G-BOX Chemi-XX6 Gel Documentation System.  
80kDa noted on protein ladder on left hand side, HIF1α expected to be detected at 120kDa.  Β-Actin used as 

























































































































Although there was high variance among the experimental groups, especially at 
increase concentration and time points, the overall effect of 5-FU and time is in 
line with the literature describing a down-regulation of BNIP3 levels when 
treated with 5-FU, and this downregulation has been increased with increase of 
5-FU treatment and the effect of time. The 24 h time point showed little variation 
between the treatment groups indicating that this downregulation of BNIP3 
levels requires exposure of cells to drug treatment for longer time periods than 
24 h.  
There was a high amount of smearing visible on the blots, this has been 
previously reported with the use of the antibody, with multiple cell lines including 
HCT116 (Tracy et al., 2007) (Feng et al., 2011c) (Bellot et al., 2009). BNIP3 
migrates as a monomer at 30kDa and a dimer at 60kDa, and multiple 




































Figure 4.35 - Densitometry of BNIP3 expression after exposure to 5-FU over time from western blot 
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for western blot 
analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 Gel Documentation 
System. Integrated density of the bands was measures using ImageJ. Each results were normalised to the 




4.4.3.6 Western blotting for CA9  
After the initial CA9 densitometry performed in triplicate the results showed high 
variance between the replicates at the 72 h time point (Figure 4.36). The high 
error bars at 72 hours were due to one replicate showing low quantities of 
protein within the control lane. This was due to a pipetting error at the 
electrophoresis stage of the protocol. As the normalisation process involved 
normalising each treatment to the control for that time point this error effected 
the whole time point. Despite this, CA9 was chosen to be continued as a protein 
of interest within the statistical model. CA9 was included in the statistical model 
as its regulation under HIF1α makes it a representative marker of hypoxia, as 
an alternative to the inclusion of HIF1α itself. Its use as an indicator of survival 





































Figure 4.36 - Densitometry of CA9 expression from three replicates after exposure to 5-FU over time 
from western blot  
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for western 
blot analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 Gel 
Documentation System. Integrated density of the bands was measures using ImageJ. Each results were 
normalised to the loading control of that lane and then normalised to the UT for each time point. Error bars are 
representative of 1SD. 
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After data expansion to include a larger number of replicates, the results 
showed a down regulation of CA9 protein expression levels with both and 
increase in 5-FU concentration and treatment time, this down regulation of CA9 
levels supports and confirms the ICC results (Figure 4.15). Western blotting 
showed a decrease in CA9 quantity with the increase in 5-FU concentration and 
treatment duration (Figure 4.37).  
This downregulation of CA9 was expected from the review of the literature that 
reports a downregulation of CA9 in the presence of p53, this is discussed in 
Section 4.5. The smearing visible around the bands is potentially a result of the 
composition of the running buffer being incorrect, or too high a voltage used 
during electrophoresis (Mahmood and Yang, 2012). The smearing was not 










































































































24 h 48 h 72 h 96 h 
Figure 4.37 - Representative image of CA9protein expression, detection using western blot. 
Cells were treated and prepared for immunoblotting with relevant antibodies following the methods detailed 
in Chapter X. Image of membrane taken using Syngene G-BOX Chemi-XX6 Gel Documentation System.  
80kDa noted on protein ladder on left hand side, HIF1α expected to be detected at 120kDa.  Β-Actin used as 















































Figure 4.38 - Densitometry of CA9 expression after exposure to 5-FU over time from western blot  
Cells were treated with 5-FU over time, at each time point proteins were extracted and prepared for western blot 
analysis. Images of the membrane were taken using the using Syngene G-BOX Chemi-XX6 Gel Documentation 
System. Integrated density of the bands was measures using ImageJ. Each results were normalised to the 




4.5 Chapter Findings  
After the completion of the experimental data collection and before the input of 
the data to the PLS-SEM model, a preliminary statistical analysis comprising of 
normality testing, correlation analysis, and significance testing to show the 
effect of treatment and time on the variables. The results of this analysis will be 
discussed in Chapter 5 and the relationships and correlations between the 
variables will be explored further.  
The results of the viability experimentation when exposing monolayer and 
spheroid culture to 5-FU over time demonstrated that the effect of 5-FU differs 
between the two culture systems, confirming the findings of the literature. This 
is confirmed by the variation in IC50 values that were calculated from the 96 h 
data sets. Monolayer cultures had an IC50 value of 96µM SE 2.2µM and the 
spheroid culture had an IC50 of 120µM SE 3.2µM.  
The results of the morphological analysis of the spheroids showed a reduction 
in spheroid diameter and circularity with the increase in 5-FU concentration over 
time. This demonstrated that shape morphometric indicators can inform the 
effect of therapeutic insult in spheroid cultures. It is worth noting that although 
spheroid viability reduced further at higher concentrations, the diameter of the 
spheroids reduced to a minimum of 66% compared to the control indicating that 
the size of the spheroid will only reduce so far, and without the removal of dead 
cells will not continue to decline in line with the number of viable cells. In the 
case of spheroid circularity these results found that that at the circularity 
decreased with the increase of 5-FU concentrations at later time points. At 
earlier time points there was no substantial change in circularity with the 
addition of 5-FU (Figure 4.14), it was not until 96 h that the circularity of the 
180µM treated cells decreased.  
The results of the protein expression quantification used western blotting 
showed that both NRF2 and VEGF (not to be included as proteins of interest in 
the PLS-SEM model along with HIF1α) showed upregulation with increase in 5-
FU over time. HIF1α did not show any substantial changes with the addition of 
5-FU over time.  
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BNIP3, CA9 and pNRF2 the three proteins of interest that were included in the 
model all showed a downregulation from the control with the addition of 5-FU 
over time. The expectations of how the proteins of interest were to respond to 
the introduction of 5-FU over time were based on a review of the literature. 
The downregulation of BNIP3 is a response to the upregulation of p53 by 
exposure to 5-FU. This downregulation has been demonstrated in the literature 
(Feng et al., 2011c), and the BNIP3 gene was shown to be downregulated with 
exposure to 5-FU in HCT 116 cells (Kho et al., 2004). Although there was 
variation between replicates, the predicted downregulation of BNIP3 when 
exposed to 5-FU, due to the presence of wild type p53, was shown in the 
results of this experimentation.  
Similarly to BNIP3, CA9 is a regulated under HIF1⍺ under hypoxic conditions. 
The presence of hypoxia leads to the upregulation of CA9 through the 
stabilization of HIF1⍺ (Wykoff et al., 2000). Upregulation of CA9 has also been 
shown independent to HIF1⍺ when cells are cultured at a high density (Kaluz et 
al., 2002). A downregulation of CA9 has been reported, this mechanism was 
shown to be caused by p53 upregulation due to DNA damage (Kaluzová et al., 
2004b). The therapeutic agent in this experimentation, 5-FU, causes DNA as 
part of its mode of action (De Angelis et al., 2006). The downregulation of CA9 
shown by the Western blot reflected this prediction.    
From a review of the literature, it is known that treatment with 5-FU leads to an 
increase in mitochondrial ROS (Hwang et al., 2007), from this increase in ROS 
an upregulation in NRF2 was expected, and demonstrated, with the results of 
the Western blot. There is significant crosstalk between p53 and Nrf2, covered 
in the review by Rotblat et al (Rotblat, Melino and Knight, 2012), which 
highlights both the positive and negative co-regulation between NRF2 and p53, 
(Kalo et al., 2012) demonstrated a decrease in NRF2 in the p53 null variant of 
HCT116 compared to the wtp53 variant. An upregulation of pNRF2 similar to 
the upregulation of NRF2 (total) was expected, as pNRF2 is the active form of 
NRF2 (Chen et al., 2016). This contrasting downregulation of pNRF2 and 
upregulation of NRF2 (total) have be discussed in further detail in Chapter 7 
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The significance of these finding and the interactions between 5-FU 
concentration and time have been explored statistically in the statistical results 




5 Chapter Five, Statistical Analysis of biological results and 
validity testing of PLS-SEM path model 
5.1 Introduction 
The overall aim of this study was to investigate whether drug responses in 2D 
cell cultures reflect drug effects in 3D spheroid cultures. The initial objective of 
this study was to establish the response of 5-FU used with 2D and 3D cultures 
of the cell line HCT116 +p53. Following this, the relationships between the 2D 
and 3D measured variables were explored using PLS-SEM to see of the results 
from the 2D system reflect results from 3D spheroid culture.  
The measurements used to record cell viability in both monolayer and spheroid 
cultures was the presence of ATP, using the CellTitre-Glo® assay kit. The 
methods behind this assay have been described in the Chapter 2. 
Morphological measures pertaining to cell viability were also recorded through 
image analysis of both monolayer and spheroid cultures. The diameter and 
circularity of spheroids were measured, as was the confluence of the monolayer 
cultures. Proteomics measures were also recorded with the use of western 
blotting analysis for three proteins of interest; pNRF2, CA9 and BNIP3. The 
specific results of these experiments and comparisons have been discussed in 
the Chapter 4.   
Within this Chapter the focus is the PLS-SEM model used to explore the 
relationships between measurements from both monolayer and spheroid 
cultures and to determine relationships, and investigate which are the strongest 
and hold the most predictive relevance.  It is equally interesting to note those 
relationships that are particularly weak. 
This Chapter will discuss the results of the initial statistical analysis on 
experimental results before the parameterisation of the PLS-SEM path model 
with that data. 
The validity and reliability testing of the model will then be discussed, alongside 
the predictive accuracy and relevance of the PLS-SEM path model. 
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5.2  Formation of biological database for PLS-SEM path model  
After collection of the different biological data streams, the data set was 
integrated into a single format taking account of the pre-requisites of the PLS-
SEM path model. The software used for running the PLS-SEM path model 
requires the data to be normalised to the same scale, with each variable is 
represented as a column (see Table 3-22 for reference). The measured 
variables included in the final model were monolayer viability, monolayer 
confluence, spheroid viability, spheroid diameter, spheroid circularity, pNRF2, 
CA9 and BNIP3 expression levels.  
As described in Chapter 3 the distribution of the proteomic measurements had 
already been assessed prior to the expansion of the data using a Gaussian 
random number generator. Descriptive statistics were also carried out to 
confirm the shape of the other variable distributions.  
Although PLS-SEM is a non-parametric method that does not require the data 
to have a normal distribution, it is recommended to be aware of the distribution 
of the data as extremely non- normal data can inflate the standard errors when 
carrying out bootstrapping and in turn may reduce the significance of some 
relationships (Henseler, Ringle and Sinkovics, 2009).  
Out of the variable groups, 79% had a normal distribution, with only two 
conditions being consistently not normally distributed across all time points. 
These were Spheroid Viability at 0µM, and Circularity at 59µM across all time 
points (Figure 5.1 and Figure 5.2). In the case of Spheroid viability at 0µM 5-FU 
, there are a number of outliers identified by SPSS which are causing the non-
normal distribution, and with Spheroid circularity at 59µM 5-FU the data appears 
skewed towards to top end of the distribution, causing it to not be normal. The 





Figure 5.1 – Distribution of Spheroid viability results in the absence of 5-FU over time. 
 Box plot showing the results, and outliers of the spheroid viability experimentation. The graph demonstrates 
the identified outliers of the untreated spheroids (0µM 5-FU). The outliers have been identified and indicated 
with a circle and the values entry number. 
Figure 5.2 – Distribution of Spheroid viability results in the absence of 5-FU over time. 
 Box plot showing the results, and outliers of the spheroid circularity experimentation. The graph 
demonstrates the identified outliers of the spheroids treated 0µM 5-FU. The outliers have been identified and 
indicated with a circle and the values entry number. 
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5.3 Mixed Model analysis of the interaction between 5-FU treatment 
and time 
A combination of Linear mixed models (LMM) and general linear models (GLM) 
(Section 3.6) were conducted to test the interaction between treatment with 5-
FU and time.  
Some of the variables were repeated measures, where the observations were 
taken from the same subject (monolayer or spheroid) for all time points making 
them suitable for a LMM. The variables are monolayer confluence, spheroid 
diameter, and spheroid circularity.  
The other variables (monolayer and spheroid cell viability, and expression of 
pNRF2, CA9 and BNIP3) were end point experiments, where the observations 
were taken from different experiments for each time point, so a GLM model was 
more suitable. Both were carried out using the statistical package SPSS. 
Each variable had been normalised as percentages of the mean control values 
prior to carrying out the statistical analysis so that all variables were on a 
comparable scale (Section 3.5).  
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5.3.1 Linear Mixed model results of monolayer confluence 
experimentation  
The monolayer confluence refers to the percentage of a surface that is covered 
by adherent cells. This variable was measured by imaging the wells of a 96 well 
plate every 24 hours from treatment to the 96 hour time point. The images were 
then analysed in ImageJ software package (https://imagej.net/) to calculate 
what percentage of the image the cells were adherent. When treated with 5-FU 
it is expected that the area occupied by cells would decrease in the presence of 
the drug over time, as the drug has an effect the cells undergo cell death, 
causing them to detach from the surface and therefore decrease the confluence 
over time. This temporal decrease in confluence in all but the control 
Figure 5.3 - Linear Mixed model showing the effect of drug over time on mean monolayer confluence (%). 
 Main effect of drug F(1,396)=16.107, p=<0.001. Main effect of time F(1,396)=1.658, p=0.199. Main effect of 
drug*time F(396)=36.761, p=<0.001. The points of the graph represent the time points at which monolayer 
confluence was recorded. The lines are representative of the concentration of 5-FU used. The error bars 
represent 1 SD. 
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experiment is shown in Figure 5.3. Confluence decrease as drug dosage 
increases up to 96µM where a saturation effect is observed.  
 
A linear mixed model (LMM) was used to test the significance of the interaction 
between 5-FU treatment and time (drug*time) with both dose and time listed as 
covariates and the replicate ID as a random factor, as the same wells were 
imaged over the course of treatment. 
The results of the testing show a significant interaction of drug*time (Figure 5.3). 
Fig. 1.3 shows that the main interaction of drug*time F(396)=36.761, p=<0.001. 
The main effect of drug was also shown to be significant, but as the first time 
point used in this dataset was 24 h, the treatment with 5-FU had already had 
time to take effect.  
The assumptions of normality of residuals will be discussed for monolayer 
confluence in detail, but for the remaining independent variables, the results of 
the tests of the assumption will summarised.  
The predicted values and residuals were recorded in order to test the 
assumptions of the model. The results of the Shapiro-Wilk test of normality of 
the residuals show a significant result, p=<0.001, indicating that the null 
hypothesis of the residuals being normally distributed should be rejected. When 
viewing the Q-Q plots of the residuals, such as that shown in Figure 5.4(A) a 
linear trend in all but two of the residuals was observed, indicating a normal 
distribution with the exception of these outliers. When repeated with the 
exception of these outliers the Shapiro-Wilk test was still significant at an alpha 
level of 0.05, p=0.003, (Figure 5.4B). 
The Shaprio-Wilk test is reported to be over sensitive with large samples, where 
even a minute deviation from normality will result in significance. The central 
limit theorem suggests that sample sizes of >30-40 tend to have a normal 
sampling distribution (Ghasemi and Zahediasl, 2012). A visual inspection of the 
Q-Q plots and histograms was used to confirm the normal distribution of 
residuals.   
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The assumptions of linearity and independence were satisfied with the 
assessment of scatter plots generated using the collected values alongside the 
predicted values and residuals as detailed in Chapter 3. These graphs are given 
in Figure 5.4 C and Figure 5.4 D.  
 
5.3.2 General Mixed model results of monolayer viability experimentation  
The results of monolayer viability were collected using the CellTiter-Glo® assay 
from Promega using the method described in Chapter 2, Section 2.4.4 The 
luminescent signal recorded in the experiment is proportional to the amount of 
A B 
C D 
Figure 5.4 - Testing the assumptions for a LMM carried out on the monolayer confluence observations. 
A) Linear normal Q-Q plot of Monolayer Confluence residuals (CCres), indicating a normal distribution. B) 
Histogram of monolayer confluence residuals (CCres) following the removal of identified outliers and is a 
characteristic symmetrical distribution i.e. a normal distribution of residuals (CCres). C) Shows the assumption of 
Linearity, with predicted values (CCpred) plotted against observations (confluence %). The plot shows the linear 
relationship between the observed (confluence %) and predicted values (CCpred) D) Shows the assumption of 




ATP, a viability marker, present in each sample. The same method was used to 
measure viability in the spheroid cultures.  
The results from each well were normalised to a percentage change from the 
untreated giving the percentage change in viability. It was observed that the 
viability of the monolayer cultures decreased with the addition of 5-FU, with the 
viability decreasing over time and with the increase in concentration of 5-FU.  
Monolayer viability in the presence of various 5-FU concentrations was 
assessed at various time points (Figure 5.5). Both time and 5-FU concentration 
were fixed factors (covariates) in this GMM. There was a significant interaction 
between drug concentration and time (F(1,396) =171.906, p=<0.001). This 
indicates that over the time period studied the cell viability declined significantly 
Figure 5.5 - General linear model showing the effect of drug over time on mean monolayer viability, 
measured using the CellTiter-Glo ® assay of ATP quantification.  
Main effect of drug F(1,396)=0.081, p=0.776. Main effect of time F(1,396)=2.860, p=0.092. Interaction between 
drug*time F(1,396)=171.906, p=<0.001. The points of the graph represent the time points at which monolayer 
confluence was recorded. The lines are representative of the concentration of 5-FU used. The error bars 




and the rate of decline increased with the concentration of 5-FU. The 
assumptions of normality of residuals, linearity of the relationship between 
predicted and observed values and independence between residuals and 
predicted values were all met. Homogeneity of variance was also satisfied 
(Levene’s test F(19,380) = 0.650; p=0.866). 
5.3.3 General Mixed model results of spheroid viability experimentation  
Spheroid viability was assessed using the same method as monolayer viability, 
with the spheroid being treated with 5-FU and the viability being assessed at 24 
hour intervals after treatment till 96 h. It was predicted that the effect of 5-FU in 
the spheroid cultures would have less of an effect than in the monolayer culture 
to due to the morphological differences between the two. Monolayer cultures by 
design have all cells (broadly) equally exposed to therapeutic agents where as 
in spheroid cultures only the outer layer of cells are directly exposed meaning 
therapeutic agents need to penetrate into the spheroid to access further viable 
cells. The diffusion rate of drugs into a spheroid is reduced in comparison to 
monolayer cultures under the same conditions due to the extracellular matrix 
(ECM) that exists between the cells in spheroid cultures (Schütze et al., 2015). 
The ECM in spheroids more closely resembles that on an in-vivo-tumour. The 
presence of this barrier contributes to the reduction in drug diffusion (Achilli et 
al., 2014)   
This was shown in viability experimentation with the observed IC50 differing 
between the two culture methods; monolayer cultures having a lower IC50 
concentration; monolayer IC50 = 96µM SE 2.2µM, spheroid IC50 = 120µM SE 
3.2µM.  
The results of the general linear model on the effect of time and drug 
concentration (fixed factors) on spheroid viability show the combined effect of 
time*drug concentration is significant (F(1,369) =142.766, p=<0.001) (Figure 
5.6). The assumptions of normality of residuals, linearity of the relationship 
between predicted and observed values and independence between residuals 
and predicted values were all met. Homogeneity of variance was also satisfied 





Figure 5.6 - General linear model showing the effect of drug over time on mean spheroid viability, 
measured using the CellTiter-Glo ® assay of ATP quantification  
There was no significant main effect of drug F(1,396) =3.162, p=0.076. Main effect of time F(1,396) =1.766, 
p=0.185. Interaction effect of drug*time F(1,396) =142.766, p=<0.001. Lines represent concentration of 5-Fu, and 
the points are representative of treatment time. Error bars represent 1SD.  
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5.3.4 Linear Mixed model results of spheroid diameter experimentation  
In this study, spheroids were treated with the 5-FU concentrations and the 
diameter of each spheroid was measure at 4 time points (Figure 5.7). Since this 
was a repeated measure the data were analysed using a linear mixed model 
(LMM). Each spheroid was assigned an ID number and spheroid ID was used 
as a random variable as described in Section 3.6.3. Time and drug 
concentration were fixed factors (covariates). 
The results of the LMM showed that the main effects of time and drug 
concentration were not significant but the interaction between time and 
treatment (time*drug) was significant (F(1,396) = 130.642; p=<0.001). 
Figure 5.7- Linear Mixed model showing the effect of drug over time on mean spheroid diameter (%).  
Main effect of drug F(1,396)=0.523, p=0.470. Main effect of time F(1,396) = 0.228, p=0.633. Interaction between 
drug*time F(1,396)=130.642, p=<0.001. Lines represent concentration of 5-Fu, and the points are representative 
of treatment time. Error bars represent 1SD. 
 
167 
The assumption of normal distribution of the residuals were met through visual 
assessment of the Q-Q plots and histogram (as discussed in section 5.3.1 
above). The assumptions of linearity and independence were also met. 
5.3.5 Linear Mixed model results of spheroid circularity experimentation  
The circularity was used as a morphological measure since when spheroids are 
exposed to therapeutic insult the cells undergo cell death. As a result, the 
structure of the spheroid has been shown to lose integrity. The circularity of the 
spheroid was calculated following the method describe in Section 2.5.  
It was expected that treatment with 5-FU would cause the circularity of the 
spheroid to decrease over time as spheroid viability decreases. 
Figure 5.8 - Linear Mixed model showing the effect of drug over time on mean spheroid circularity 
(%).  
Main effect of drug F(1,377)=0.787, p=0.376. Main effect of time F(1,377)=0.002, p=0.964. Interaction 
between drug*time F(1,377)=37.440, p=<0.001. Lines represent concentration of 5-Fu, and the points are 
representative of treatment time. Error bars represent 1SD. 
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In this study, spheroids were treated with the 5-FU concentrations indicated and 
the circularity of each spheroid was measure at 4 time points (Figure 5.8). Since 
this was a repeated measure the data were analysed using a linear mixed 
model (LMM). Each spheroid was assigned an ID number and spheroid ID was 
used as a random variable. Time and drug concentration were fixed factors 
(covariates). 
The interaction between time and drug (F(1,377) = 37.440; p=<0.001) was 
significant. The main effects of treatment and time on spheroid circularity was 
not significant.  
The residuals were normally distributed and the assumptions of linearity and 
independence were both met. 
5.3.6 General Mixed model results of pNRF2 expression in monolayer  
The expression of pNRF2 was quantified using western blot. Monolayer cultures 
were treated with 5-FU and the protein extracted at 24, 48, 72 and 96 h 
following treatment. Proteins were prepared and quantified prior to western blot 
following the method describe in Section 2.6.4.2. Results of western blot were 
normalised to the loading control β-Actin, and then normalised to the control 
group (0 𝜇M) for the time. A General mixed model was performed using the 
statistical package SPSS with time and 5-FU concentration as covariates.   
The effect of time and 5-FU concentration on pNrf2 show that the interaction 
between time and treatment (drug*time) was not significant (F(1,316) = 0.192; 
p= 0.661). The GLM assumptions of normality or residuals, linearity between 
predicted and observed values and independence of residuals were met. The 
assumption of homogeneity of variance was also met (Levene’s test, F(19,300) 
= 1.761 p=0.027).  
The graph shows that although all concentrations are causing a decrease in 
pNRF2 expression over time the concentrations do not appear to be causing 
significantly different results to one another. This suggests that the 
concentrations of 5-FU used are all stimulating the maximum response in 
pNRF2 expression. From the literature a wide range of concentrations and time 
points have been used (Kim et al., 2014), (Boyer et al., 2004), (Focaccetti et al., 
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2015). The concentrations of 5-FU in this research were informed by the IC50 
and EC75 values calculated from the results of the monolayer cell viability 




5.3.7 General Mixed model results of BNIP3 expression in monolayer  
The expression of BNIP3 was measured in the same manner as pNRF2 as 
described in 5.3.6. A general mixed model was carried out using the statistical 
package SPSS with time and 5-FU concentration listed as covariates. There 
was a significant interaction between treatment and time F(1,316)=14.215, 
Figure 5.9 – General linear model analysis showing the effect of drug over time on mean pNRF2 (%). 
 Main effect of drug F(1,316)=0.007, p=0.002. Main effect of time F(1,316)=336.129, p=<0.001. Interaction 
between drug*time F(1,316)=0.192, p=0.661. Lines represent concentration of 5-Fu, and the points are 
representative of treatment time. Error bars represent 1SD. 
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p=<0.000. The GLM assumptions of normality of residuals and independence of 
residuals were met. The assumption of homogeneity of variance was also met 
(Levene’s test F(19,300) = 0.679; p=0.839).  
The literature shows that BNIP3 is upregulated under hypoxic conditions 
(Burton and Gibson, 2009) and over expression of BNIP3 can induce 
autophagic cell death (Bristow et al., 2011). Under both normoxic and hypoxic 
conditions, p53 the tumour suppressor protein has been shown to inhibit the 
activity of BNIP3 when exposed to 5-FU (Feng et al., 2011c).  
 
 
Figure 5.10 - General linear model showing the effect of drug over time on mean BNIP3 (%).  
Main effect of drug F(1,316)=5.429, p=0.020. Main effect of time F(1,316)=1.297, p=0.256.  Interaction 
between drug*time F(1,316)=14.215, p=<0.000*.  Lines represent concentration of 5-Fu, and the points are 
representative of treatment time. Error bars represent 1SD. 
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5.3.8 General Mixed model results of CA9 expression in monolayer  
The expression of CA9 was measured following the same protocol as described 
in section 5.3.6. The results of the general mixed model for CA9 expression 
showed that there was no significant interaction between drug*time (F(1,316) = 
1.127; p=<0.289). The GLM assumptions of normality or residuals, and 
independence of residuals were found to be met. The assumption of 
homogeneity of variance was also met (Levene’s test (F(19,300) = 1.398; 
p=0.126). The literature reports that activated p53 downregulates CA9 in the 
presence of therapeutic insult (Kaluzová et al., 2004a). Similarily to BNIP3, 
although not significant, CA9 expression appears to be downregulated with the 
increase in 5-FU concentration after the 24 h time point.  
 
Figure 5.11– General linear model showing the effect of 5-FU over time on mean CA9 concentration (%). 
Main effect of drug F(1,316) = 2.083, p=0.150. Main effect of time F(1,316) = 50.557; p=<0.001.  Interaction 
between drug*time F(1,316) = 1.127; p=0.289. Lines represent concentration of 5-Fu, and the points are 




Treatment with the drug (5-FU) induced a variety of concentration and time-
dependent effects on the cell viability, spheroid morphology and protein 
expression variables selected. These variables were selected because cell 
viability were chosen to show broadly the response to therapeutic insult on the 
viability of cells and outline the comparison between monolayer and spheroid 
cultures. Morphological variables such as diameter and circularity provide a 
visual representation of the effect of therapeutic insult on spheroid cultures such 
as reduction in size and loss of integrity. The proteins of interest selected for the 
model were chosen on their involvement within the hypoxia response pathway, 
a pathway shown to be upregulated within spheroid cultures in comparison to 
monolayer cultures (Mischiati et al., 2015) and their reported responses to 5-FU 
exposure and cell death. The responses to therapeutic insult differed between 
variables, as expected, with significant drug time interactions shown in the 
viability and morphometric variables.  
It was important to confirm and assess the effect of treatment and time on 
variables that reflect the protein expression, morphological and viability of the 
cells in 2D and 3D prior to developing the PLS model. The PLS model will 
explore the relationships between these variables in 2D and 3D formats and 
how the strength and direction of these relationships vary with time and 
concentration of 5-FU. 
 
5.4 Correlation analysis between the biological variables 
Prior to building the PLS-SEM model, the strength of the correlations between 
the dependent variables for protein expression, cell viability and morphology 
were examined. The purpose of carrying out this investigation before applying 
the data set to the model was to provide prior understanding and knowledge of 
the relationships between pairs of variables and to help interpret the model.  
The Pearson’s’ Correlation coefficient (r) was determined for pairs of dependent 
variables and for this analysis, the data was segregated by time point, with data 
points from all 5-FU concentrations.  
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The correlations between the variables varying greatly depending on the time 
point, treatment concentration and the variable themselves (Figure 5.12).  
Some of the most notable correlations from examining the protein expression 
data are that there are moderate - strong correlations (significant at the 0.01 
level) between CA9 and pNRF2 and all the other variables at 96 h except 
BNIP3. CA9->BNIP3 has Pearson correlation (r=0.012) p=0.902 and pNRF2-
>BNIP3 has Pearson correlation (r=0.017) p=0.864. BNIP3 shows very few 
significant correlations with the other variables with the exception of a moderate 
correlation with pNRF2 at 72 h, (Pearson correlation (r=0.334) p=0.001). 
Between the spheroid and monolayer viability and morphometric variables there 
are consistently significant correlations across all time points, typically showing 
weak correlations at earlier time points and the strength of the correlation 
increasing toward the 96 h time point. These results gave a good indication that 
the relationships explored between monolayer viability, and the spheroid latent 
variables in the PLS-SEM model will give strong results.  
The lack of correlations between BNIP3 and other variables, may influence the 
proteomic latent variables relationships within the model. When assessing the 
morphometric vs proteomics correlations with CA9 and pNRF2, both proteins 
showed moderate correlations (r = 0.538 – 0.675) with spheroid diameter from 
48 h onwards, and moderate (r = 0.29 – 0.48) correlations with spheroid 
circularity at 72 and 96 h.   There was only one negative correlation, weak, 
between spheroid circularity and spheroid diameter at 24 hours (r = -0.214) p = 
0.032) was significant at the 0.05 level.  
The strength and significance of the correlations between the monolayer 
proteomic variables of CA9 and pNRF2 and the spheroid morphological 
indicators of diameter and circularity gives strength this projects hypothesis that 






Not significant at 0.01 level
Significant at the 0.01 level
r = 0.100 0.300 0.700
p =
Positive Strength Negative
0 < r < 0.1  none 0 < r < -0.1
0.1 < r <0.3 weak -0.1 < r < -0.3
0.3 < r  < 0.7 moderate -0.3 < r  < -0.7
0.7 < r  < 1 strong -0.7 < r  < -1
Figure 5.12 – Results of Pearson’s correlation coefficient analysis of biological measurements.   
The results of each biological variable from each time point were tested for correlations against one 
another using the Pearsons correlation coefficient (r ) using the statistical package SPSS v23 (SPSS). 
The strength of r is denoted by colour as shown in the key (above) with the strength of the correlation 
ranging from white, ≥0.1, for a weak positive correlation, yellow, ≥0.3, for a moderate correlation, to red, 
≥0.7, for a strong correlations. Evidence for these correlations is indicated by the significance, with 
values not significant at the 0.01 level written in grey and the significant values in black. The strength of 
the correlations between the variables increases over time.  
VAR1 VAR2 24 h 48 h 72 h 96 h 
monolayer viability cell confluence 0.465 0.629 0.811 0.748
monolayer viability spheroid viability 0.514 0.729 0.796 0.831
monolayer viability spheroid diameter 0.050 0.791 0.893 0.754
monolayer viability spheroid circularity 0.564 0.332 0.488 0.706
monolayer viability BNIP3 -0.073 0.079 0.622 0.371
monolayer viability pNRF2 0.314 0.510 0.670 0.581
monolayer viability CA9 0.261 0.463 0.594 0.527
cell confluence spheroid viability 0.400 0.693 0.860 0.937
cell confluence spheroid diameter 0.186 0.770 0.903 0.939
cell confluence spheroid circularity 0.263 0.295 0.434 0.676
cell confluence BNIP3 -0.145 0.029 0.550 0.442
cell confluence pNRF2 0.113 0.583 0.605 0.652
cell confluence CA9 0.156 0.474 0.518 0.615
spheroid viability spheroid diameter 0.030 0.893 0.886 0.959
spheroid viability spheroid circularity 0.540 0.417 0.460 0.696
spheroid viability BNIP3 -0.105 0.054 0.533 0.741
spheroid viability pNRF2 0.332 0.496 0.594 0.702
spheroid viability CA9 0.110 0.411 0.527 0.665
spheroid diameter spheroid circularity -0.214 0.361 0.400 0.625
spheroid diameter BNIP3 -0.151 0.080 0.616 0.457
spheroid diameter pNRF2 -0.045 0.613 0.675 0.667
spheroid diameter CA9 0.033 0.538 0.584 0.651
spheroid circularity BNIP3 -0.078 -0.047 0.390 0.264
spheroid circularity pNRF2 0.295 0.044 0.350 0.418
spheroid circularity CA9 0.183 0.168 0.310 0.295
BNIP3 pNRF2 -0.021 -0.080 0.670 0.322
BNIP3 CA9 -0.041 -0.141 0.697 0.358
pNRF2 CA9 0.178 0.650 0.697 0.823
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5.5 Path Modelling between dependent variables from 2D and 3D 
cell culture.  
Path models were developed to explore in more detail, the complexity of the 
relationships between the measured, dependent variable in 2D and 3D cell 
culture. Preliminary studies examining individual measured variables in turn 
(Chapter 4) demonstrated that when treated with 5-FU, many of the measured 
variables varied in magnitude in a time and dose-dependent manner. The 
Pearson’s correlation co-efficient revealed significant associations of different 
strengths between pairs of variables. However, neither of these statistical 
analysis individually capture the full complexity of the relationships between all 
measured variables over time and concentration range.  
Following the development of the initial PLS-SEM path model (Figure 3.7, 
repeated in Figure 5.13) the validity testing of the PLS-SEM path model was 
carried out, this was shown as a worked example in Chapter 3. The results of 
this initial testing showed that the model had real potential with strong predictive 
capabilities being displayed but a couple of issue were highlighted by carrying 
out the analysis that need to be addressed before moving forward. 
There was collinearity issues highlighted by the initial testing were remedied by 
splitting the two spheroid indicators into two separate latent variables 
representing spheroid viability and spheroid morphology. Spheroid circularity 
data was also added to provide more data to the spheroid morphology latent 
variable and to limit the use of single item constructs to the spheroid viability 
indicator. These modifications led to the final path model design moving 
forward. 
PLS-SEM is a path modelling approach that is widely used in business for 
exploring relationships between abstract business constructs and it has been 
applied here for the first time to explore the complexity of the relationships 
between measured variables from cellular data.  
Once the PLS-SEM algorithm has been run, the validity and reliability of the 
model is tested. This was done following a procedural check list developed and 
detailed in Chapter 3, Section 3.4 which was used to discover issues within the 

































































































































































































































































































































































































































































































































































































































































































































































5.6 Outer Measurement model Assessment  
5.6.1 Collinearity Assessment – VIF  
The validity testing of the first version of the model (Figure 5.13) showed 
collinearity issues (Section 3.4.2.1) at the higher time points between the 
spheroid indicators, and this led to their separation into two independent latent 
variables in subsequent versions of the model. The same checklist was used to 
check the validity and reliability of the updated model (Figure 5.14).  
In the initial development of the model (Figure 5.13), the collinearity between 
diameter and spheroid viability was higher than the accepted threshold (VIF<5) 
leading to the redesign of the path model to separate the two indicators. When 
assessing the new path model, the first thing addressed was the collinearity of 
the new model. 
  
The results of the outer model VIF values of the final path model, calculated by 
the SmartPLS software using the method described in (Equation 3.6, Section 
3.4.2.1) can be seen in Figure 5.15. All VIF values were under the threshold of 
Figure 5.15 - Results of collinearity assessment on the outer model (final path model).  
Each indicator is shown and labelled across the bottom, the colour of the bars represent the results of the 
4 time point datasets. The height of the bars represents the VIF values.  A VIF value of under 3 is desired, 
















5, and with the exception of the CA9 and BNIP3 indicators at 96 hours with a 
value of 3.092 all values were below the desired threshold of 3 (Hair, 2013). 
These results show that the separation of the spheroid diameter and spheroid 
viability indicator has fixed the collinearity issues associated with the previous 
model version.  
The results of the inner collinearity assessment yielded similar results with no 
value exceeding the threshold of 3 across all 4 of the time points.  
5.6.2 Outer model weights and loadings 
The outer model comprises the outer weights and loadings between the 
indicators and its associated latent variable and indicate how well the indicator 
variable described the latent variable. The bootstrapping procedure was used to 
assess the significance of these outer weights and loadings.  
In a formative model the outer weights are first tested for significance, and if a 
weight is found to not be significant at p=0.1 then the indicator’s loading t-
statistic is then analysed. If the loadings t-statistic is ≥0.5 then the indicator is 
kept, if not then the significance of the loading is tested. If the outer loadings t-
statistic is ≤0.5 but is significant (p=0.1), then the indicator can be kept. It is 
recommended at this stage that if the outer loading is not significant that the 
indicator could be removed. This process has been described in Section 
3.4.2.2.  
The outer weights of a few of the indicators are not significant (Table 5-1) and, 
these are indicated in red. In these cases the outer loadings are then 
considered (Table 5-2). All indicators across all time points had outer loading 
values of >0.5. The outer loadings of BNIP3 at 24 and 48 h were not significant, 
but are retained in the model due to meeting the criteria for the T-value.  
When working with formative indicators (where causality is from the indicator to 
the LV and are not required to be correlated), deleting indicators based purely 
on statistical outcomes is not advised if the indicators are theoretically important 
to the model. The removal of indicators and the effect on the path model 




Table 5-1 – Values of outer weights of the indicators on their corresponding LVs following 
bootstrapping.  
* p=0.1, ** p=0.05, *** p=0.01. Values that are not significant are indicated in red. The majority of the outer 
weights were significant which is representative of them have a significant relative contribution to the 
model 
 
   



































































Table 5-2  - Table showing Values of outer loadings of the indicators on their corresponding LVs 
following bootstrapping  
* p=0.1, ** p=0.05, *** p=0.01. Loadings that are neither ≥0.5 nor significant are indicated in red. The 
majority of the outer weights were significant which is representative of them have a significant absolute 
contribution to the model 
 






































































5.7 Inner Structural Model Assessment  
5.7.1 Determination of path coefficients 
Path coefficients are the relationships between the latent variables in the 
structural model. The structural model is defined as the relationships between 
the LVs (Figure 3.1). This has been demonstrated visually in Figure 5.17.  
The path coefficients for the four time points vary greatly across the latent 
variable relationships. The path coefficients between ‘Monolayer viability  
spheroid morphology’; ‘Monolayer Viability  Spheroid Viability’ and 
‘Proteomics Monolayer Viability’ (Figure 5.16), increase over time. The 
greatest path coefficient values are between monolayer viability and spheroid 
morphology, followed by the relationship between monolayer viability and 
spheroid viability. The path coefficients between proteomics and the other latent 
variables are consistently lower, though only by a margin in regard to the 
relationship between proteomics and monolayer viability. As shown in Figure 
5.16, not only are the path coefficients between proteomics and the spheroid 
latent variables considerably less than that of the others, these path coefficients 
also have larger values at earlier time points compared to the other path 





Figure 5.17 Representative image of path model displaying path coefficient values.  
Following the PLS algorithm the path model is updated to include the path coefficient values next to their 
corresponding relationships between latent variables (blue circles). These values were calculated from the 24 h 
data sets, shown in Figure 5.16 
Figure 5.16 – Final Model path coefficients at different time points.  
The results are from dataset including observations from all 4 5-FU concentrations and the controls. The 
path coefficients between the latent variables are shown, with each colour representing the results from the 



































To assess the significance of the path coefficients bootstrapping was carried 
out. The process of bootstrapping has been described in Chapter 3.  The 
bootstrapping confirms that of the path coefficients generated by the PLS 
algorithm from the monolayer viability latent variable to both spheroid latent 
variables, and between the proteomics and monolayer viability latent variables 
are significant for all time points (Table 5-3). However the majority of path 
coefficients between the proteomics latent variable and spheroid morphology 
and viability latent variables were not significant.  
Note, these results were from a bootstrapping procedure carried out with no 
sign changes option selected. Including individual sign changes is an option for 
bootstrapping that will reverse the sign if the results of bootstrapping is different 
compared to the original sample. This makes the signs consistent across the 
bootstrap samples and avoids sign change issues that may occur and provides 
a more conservative empirical t-value (Hair, 2013). When bootstrapping 
procedure was repeated to include individual sign changes the path coefficient 
between the proteomics and spheroid viability latent variables at 24 h, became 





Table 5-3 - The significance of the path coefficients following the bootstrapping procedure with no 
sign changes.  
* p=0.1, ** p=0.05, *** p=0.01. Values not significant at 0.1 level are marked with red.  
 
 
Table 5-4 - The significance of the path coefficients following the bootstrapping procedure repeated 
to include individual sign changes.  
* p=0.1, ** p=0.05, *** p=0.01. Values not significant at 0.1 level are marked with red. 
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5.8 Assessment of the predictive accuracy and relevance of the 
latent variables  
The predictive accuracy and relevance of this model was assessed based on 
the R2, F2 and Q2 values (Equations 3.7, 3.8, and 3.9 in Methods). A detailed 
explanation of these values is given in the Chapter 3. 
 For reference the R2 value is a measure of predictive accuracy generated by 
the PLS-SEM algorithm. The predictive capability of the model is considered 
weak if the R2 values are is ≤0.25, moderate if between 0.25 and 0.5, and a 
strong indicator of predictive accuracy if ≥0.5. The f2 value measures effect size 
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5.1 
The f2 value assesses how strongly an exogenous construct is contributing to 
the explanation of an endogenous construct in terms of the R2 value. 
The Stone Geisser’s value, Q2, is a value of predictive relevance and is 
described in Section 3.4.3. As a rule of thumb, a value between 0.02 and 0.25 is 
considered weak, between 0.15 and 0.35 is considered moderate, and ≥0.35 is 
considered a strong value of predictive relevance. 
As shown in Figure 5.18, the R2 values for all three endogenous latent variable 
become greater with an increase in time period. Moreover, the spheroid latent 
variables exhibit similar results across the time period whereas monolayer 
viability exhibits what would be considered a weak result at 24 hours, and 
moderate results for the remaining time points. Similarly the spheroid latent 
variables increase from moderate results at 24 h to a strong results for the 




Figure 5.18- Visual representation of the R2 values generated by the PLS-SEM algorithm of all 
four time points  
The R2 values of predictive accuracy were generated by the PLS-SEM algorithm on all 4 of the 
datasets, each representing a different time point shown in the above graph. Each colour of bar 
represents the R2 value for each endogenous latent variable and the size of their values are shown 
by the height of the bars. The values of the spheroid latent variables (morphology and viability) from 




















The f2 are displayed below in Table 5-5. The majority of relationships exhibit an 
effect size in the range weak to strong with the exception of ‘Proteomics → 
Spheroid Morphology’ 96 h as well as ‘Proteomics → Spheroid Viability’ 48 and 
72 h with values lower than the threshold for a weak effect size. The largest 
effect sizes were recorded between monolayer viability the spheroid latent 
variables at the later time points of 72 and 96 hours. As these results are 
derivative of the R2 values, they reflect the trends of the R2 results (Figure 5.18). 
Table 5-5 - f2 value of effect size calculated by the PLS-algorithm.  
*= weak result ** = moderate result, *** = strong result. Red indicates that are lower than the threshold for 
weak. The f2 values assesses how strongly an exogenous construct is contributing to the explanation of an 
endogenous construct and was calculated after running the PLS-SEM algorithm using the software 
SmartPLS. The relationship between monolayer viability and spheroid morphology latent variables show 
string effect sizes at all time points where as the proteomic latent variables relationships to the spheroid 
latent variables shows small effect sizes.  
 
Relationship 24 h 48 h 72 h 96 h 
Monolayer Viability -> Spheroid 
Morphology 
0.397*** 1.433*** 4.127*** 4.514*** 
Monolayer Viability -> Spheroid 
Viability 
0.289** 0.924*** 1.471*** 4.777*** 
Proteomics -> Monolayer Viability 0.16* 0.694*** 1.063*** 1.047*** 
Proteomics -> Spheroid 
Morphology 
0.027* 0.078* 0.051* 0.017 





Following completion of the PLS-SEM algorithm calculation. The blindfolding 
procedure was carried out, using an omission distance of 7 to calculate the 
Stone Geisser’s Q2 value of predictive relevance. (Section 3.4.3.5) 
The results of Stone Geisser’s Q2 values can be seen in Figure 5.19 with strong 
(>0.5) results indicated by a double asterisk. All results have values which are 
at least considered weak. Having high values relating to the predictive accuracy 
and relevance indicate that the measures used in monolayer have the capability 
of predicting the outcomes of the measures from spheroid cultures using this 
path model and relationships. 
  
Figure 5.19 - Stone Geisser's Q2 values calculated using the bootstrapping procedure in 
SmartPLS 
A strong result is indicated by **. The colour of the bars represent the Q2 values of each endogenous 
latent variable and the height relates to the strength of that value. The values were calculated using the 
4 time-based datasets and are displayed on the graph. The calculated values all gave results that 


























5.9 Interpretation of PLS-SEM model results 
When using the data inclusive of all treatments collected the results show 
promising predictive capabilities, especially at the higher time points where 
there is more variation in effects on the variables in relation to the treatment. 
The results detailed in section 5.8, provided an understanding of the validity and 
reliability of the model as well as an indication of the predictive accuracy and 
relevance of the model through the calculation of the R2, f2, and Q2 values. 
These results were generated by viewing the dataset in its entirety including the 
results of all 5-FU concentrations and the controls. Note these concentrations 
were later split into their respective groups based of 5-FU concentration and the 
findings of this modelling are discussed in detail in the next Chapter.  
The strongest relationships in regard to the predictive capabilities are between 
the Monolayer Viability latent variable and the spheroid latent variables, as well 
as between the Proteomics and Monolayer Viability latent variables. This 
indicates a potential indirect effect being exhibited of the Spheroid related latent 
variables through Monolayer Viability by proteomics. Biologically this is 
expected as the proteomics results were taken from monolayer cultures and the 
proteins of interest included within the model are related to cell viability and 
drug response. The changes in these protein levels would naturally inform the 
survival of the monolayer culture, and the change in the indicators included in 
the monolayer viability latent variable. This indirect effect is further explored in 
Chapter 6 alongside the breakdown of the results when viewing each 5-FU 
concentration individually.  
A miscalculation in the dataset had caused a previous iteration of the PLS path 
model to give non-significant outer weights and loadings for the BNIP3 
indicator, as well as weaker predictive results for the relationships between the 
proteomic latent variable and the spheroid morphology and cell viability latent 
variables. This was remedied and although the BNIP3 indicator is significant in 
the iterations displayed in these results, in order to test the assumption that a 
non-significant indicator does not influence the results of the model, the PLS 
algorithm was performed on the model with different arrangements of the 
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proteomic indicators. The results of this have been discussed in the Chapter 6. 
This gave a more in depth understanding of the interactions of each individual 
protein on the model as a whole and inform the driving indicators amongst the 




6 Chapter Six, Findings from the PLS-SEM path model 
6.1 Chapter outline 
In previous chapters the validity and predictive assessment of the PLS-SEM 
path model has been discussed in terms of the observations from all of the 5-
FU concentrations. In an effort to delve further into the differences amongst the 
individual drug concentrations and any conditions that may be driving the values 
of the complete dataset, this Chapter will be exploring the results of the PLS-
SEM model in more detail with a breakdown of the individual drug 
concentrations results, including the predictive accuracy and relevance of the 
PLS-SEM path model under these specific conditions. 
As outlined in Chapter 3 the datasets were split into groupings for each 
concentration and time, this resulted in 16 sets of results and it is these that will 
be covered in sections 6.4 - 6.6. This phase of model assessment outlines the 
role of each drug concentration at each time point in the PLS-SEM path model, 
considering their individual effect on the strength of the relationships both 
between indicators and latent variables, between the set of latent variables, and 
the predictive value of the latent variables.   
This Chapter begins with the impact of the individual proteomics results as well 
as the proteomics latent variable’s indirect effect on the model after issues of 
certain indicators contribution to the model were brought up during initial 
iterations of the model validity testing discussed in the previous Chapter 5. 
6.2 Results of proteomic exemption in the PLS-SEM path model 
During an initial assessment of the PLS-SEM path models validity and reliability 
of the model, one indicator, BNIP3, at 48 hours was found to have outer weights 
and loadings that were neither significant nor had values higher than the 
predetermined threshold. This was a result of a miscalculation and was 
remedied in the reported results. When outer weights and loading values are 
not significant it means that the indicator makes no significant contribution to the 
latent variable. Hair et al.  (Hair, 2013) recommends that formative indicators 
should not be removed on the basis of statistical outcome if the surrounding 
theory, in this case the biological literature, backs up that it has relevance. The 
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removal of a formative indicator that is not contributing will not substantially alter 
the parameter estimates.  
When the non-significant values were encountered, the contribution of each 
protein on the model was tested. The data from the previous non-significant 
datasets has been used as an example in this case. In addition to the results 
using the combination of all three proteins, as shown in the path model in the 
previous Chapter, the same path model was run a number of times with the 
following combinations of proteins of interest linked to the proteomics indicator:- 
1. BNIP3 and CA9 
2. CA9 and pNRF2 
3. BNIP3 and pNRF2 
4. CA9 only 
5. pNRF2 only 
6. BNIP3 only. 
The model validity assessment was carried out on the results of each of these 
alternative models following the method described in Chapter 5 and the results 
are summarised in section 6.2.1.   
6.2.1 Comparison of outcomes of PLS-SEM results using alternative 
proteomic LV structure 
The comparisons of the PLS algorithm results with alternative combinations of 
protein expression indicators were carried out on all time points. For brevity the 
48 h time point is shown as an example as this was the time point where the 
BNIP3 indicator did not meet the threshold of contribution. Note that the 
comparisons showed the same trends reflected across all time points. The path 
coefficients were calculated and shown below in Table 6-1 with the original 
model results containing all three proteins of interest in the first column. 
Focusing on the proteomics latent variables (the final three rows in Table 6-1), 
the models using combinations made up of two of the three proteins, as well as 
the models comprising of CA9 and pNRF2 expression indicators only differ 
slightly in the results “proteomics → monolayer” viability, but when the BNIP3 
indicator was run as a single item construct the path coefficient value dropped 
from ~0.5-0.6 to a value of 0.041. This means that when only the BNIP3 values 
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are contributing the proteomics latent variable at this time point, the relationship 
between the proteomics and monolayer latent variable is no long significant.  
The same pattern occurs with “the proteomics → spheroid morphology” and 
“spheroid viability” path coefficients as well with the BNIP3 indicator alone 
values being considerable lower that the others, and in the case of “proteomics 
→ spheroid” viability, producing a negative value. A negative path coefficient 
indicates a negative relationship between the latent variables.   
The values for the model containing CA9 and pNRF2 indicators with the 
removal of BNIP3 indicator differ very little from the initial model confirming that 
the removal of BNIP3 indicators does not markedly affect the results. 
Table 6-1 – Comparison of Path Coefficients for the 48 h time point, recalculated with various 
combinations of protein indicators.  
The first column represents the original model. Path coefficients that differed substantially from the original 
model are indicated in red.  





























































Monolayer Viability → 
Spheroid Morphology 
0.765 0.804 0.780 0.766 0.866 0.804 1.612 
Monolayer Viability → 
Spheroid Viability 
0.764 0.784 0.762 0.772 0.790 0.787 0.988 
Proteomics → Monolayer 
Viability 
0.631 0.519 0.609 0.627 0.041 0.519 0.579 
Proteomics → Spheroid 
Morphology 
0.160 0.120 0.141 0.158 0.001 0.119 0.052 
Proteomics → Spheroid 
Viability 
0.037 0.009 0.042 0.025 -0.049 0.003 0.002 
 
The R2 values of predictive accuracy were compared together with the path 
coefficients and the results for this comparison can be found in Table 6-2. The 
48 h time point is used again as an example here and the comparison was 
carried out for all time points. The R2 values for spheroid morphology and 
spheroid viability differ very little from the original path model despite the protein 
 
195 
combination, showing that the proteomics latent variable is contributing very 
little to these endogenous constructs directly, as is shown in the path 
coefficients above in Table 6-1. As proteomics are the only exogenous latent 
variables to monolayer viability, the R2 values for monolayer viability are the 
ones of interest in this case. Similar to the results of the path coefficient 
comparisons, with the exception of BNIP3 alone, all path models produce weak 
to moderate R2 values of predictive accuracy. BNIP3 as a single item construct 
had a value of close to zero (-0.009) which can be interpreted as it as having no 
predictive value. 
Table 6-2 – Comparison of R2 for the 48 h time point recalculated with various combinations of 
protein indicators.  
The first column represents the original model. Values that differ substantially from the original model have 






























































Monolayer Viability 0.398 0.269 0.371 0.393 -0.009 0.269 0.367 
Spheroid 
Morphology 
0.764 0.761 0.761 0.764 0.745 0.761 0.761 
Spheroid Viability 0.621 0.622 0.621 0.621 0.616 0.621 0.621 
 
The conclusion drawn from this testing confirms that the removal of a formative 
indicator has little effect on the model at large and as the protein of interest 
BNIP3 is considered to be biologically relevant to the model, it justifies it’s 
continues inclusion in the path model.  
The results of the final data sets after corrections had been made showed that 
the BNIP3 expression indicator was significant. When considering the results of 
some of the western blots, BNIP3 expression showed a downregulation over 
both time and with an increase in treatment dosage (see Figure 4.35), a 
significant contribution is what was expected.  
6.3 Indirect effect of proteomics on spheroid latent variables 
When looking at the path model assessment the path coefficients between the 
Proteomics latent variable and the Spheroid Endogenous latent variables were 
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often lower in value and not significant in comparison to the path coefficients 
between proteomics and monolayer viability, and in turn compared to the path 
coefficients between monolayer viability and the spheroid latent variables (see 
Figure 5.16). From a biological stand point it can be presumed that the 
monolayer viability latent variable is acting as somewhat of a mediator in this 
process.  The protein expression changes shown in the proteomic indicators 
were quantified from monolayer cultures, from a biological standpoint it would 
be expected that the monolayer protein expression profile is more closely 
related to the monolayer viability indicators as they were recorded from the 
same culture type. All three proteins of interest show a downregulation over 
time with the addition of 5-FU, which aligned with the decrease in cell viability 
under the same conditions (see sections 4.2.2 and 4.4.3  
This mediating effect was tested using the path coefficient values and 
significance generated through bootstrapping. These results are shown in 










Figure 6.1 - Isolated components of the PLS path model used to test the mediating effect of the 
monolayer viability latent variable.  




Table 6-3 – Results of the path coefficients from the PLS path model  
These results were reported in Chapter 5 but are repeated here for reference. The value of the path 
coefficients are displayed per time point alongside the results of bootstrapping (t value, significance and 












24 0.54 7.422 *** <0.001 
48 0.752 14.131 *** <0.001 
72 0.88 23.651 *** <0.001 





24 0.48 5.202 *** <0.001 
48 0.77 13.566 *** <0.001 
72 0.857 17.435 *** <0.001 





24 0.371 3.233 *** <0.001 
48 0.64 11.698 *** <0.001 
72 0.718 18.625 *** <0.001 




24 0.141 1.404 NS 0.161 
48 0.176 2.681 *** 0.009 
72 0.098 2.225 ** 0.037 




24 0.159 1.514 NS 0.131 
48 0.028 0.546 NS 0.746 
72 0.018 0.383 NS 0.803 




Table 6-4 - Mediation effect present within the path model,  




Proteomics -> Monolayer Viability -> 
Spheroid Morphology 
Proteomics -> Monolayer Viability -> 
Spheroid Viability 
24 Indirect, full Indirect, full 
48 Complementary, partial Indirect, full 
72 Complementary, partial Indirect, full 
96 Indirect, full Complementary, partial 
 
Isolating the components shown in Figure 6.1, the mediating effect of 
monolayer viability between the proteomics latent variable and the spheroid 
Yes No 


























Figure 6.2 - Decision making tree for testing mediating effect,  
Reproduced from Zhao yet al, 2010. The green boxes indicate the type, if any, of mediation taking place. The 
path numbers (p1, p2, p3) are shown in Figure 6.1. 
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latent variables was testing using the decision tree adapted from (Zhao et al., 
2010)  (Figure 6.2). Using this tree and the results of the path coefficients 
shown in Table 6-3. The following conclusion can be drawn: that there is either 
full of partial mediation between proteomics and both spheroid LVs via 
monolayer viability at all of the time points.  
6.4 Surface plots of outer weights / loading values 
The path model shown in Figure 5.14 contains only formative indicators so the 
outer weights are the focus. The outer weights for each indicator for all 16 
separate data groupings were recorded using the method outlined in Chapter 3. 
The ‘spheroid viability indicator → spheroid viability’ latent variable have a score 
of 1.00 for all points as it is a single item construct so has not been included.  
The dependence of outer weight was represented as 3D plot where time and 5-
FU concentrations are displayed on the X and Y-axis respectively. The Z-axis 
represents the outer weights with high peaks representing large positive values 
and low peaks representing large negative values. Shown below in Figure 6.3 
the highest outer weight value is at 96µM, 24 hours and can be seen clearly as 
a high red peak; a similarly high value can be seen at 180µM, 24 hours. The 
outer weight value is relative to the formative indicators relative contribution to 
the latent variable and can therefore be compared to contribution of the other 
indicators in a construct. The other indicator within this construct was cell 
confluence, the results of which are shown below in Figure 6.4 where the two 





Table 6-5 - Raw data for all outer weights.  
The relationships are shown using the short hand described in Table 3-23, and the time and concentration 
for each outer weight are shown in the left most columns. cc – Cell confluence indicator, m.cv – monolayer 
viability indicator, circ – circularity indicator, d – diameter indicator, M.CV – monolayer viability LV, S.M – 



























































26 24 0.097 1 0.408 0.845 0.325 0.91 -0.35 
59 24 1.026 0.22 0.271 0.922 -0.301 -0.482 0.925 
96 24 1.077 2.02 0.614 0.677 0.6 1.2 0.434 
180 24 0.649 1.5 0.826 0.065 0.483 0.8 -0.334 
26 48 0.763 0.643 0.967 0.126 0.173 0.522 0.843 
59 48 0.428 -0.894 -0.528 0.842 0.003 -1.025 -0.111 
96 48 0.148 0.901 0.745 0.547 0.83 0.202 1.012 
180 48 -0.283 0.974 -0.569 -0.038 0.767 -0.032 0.996 
26 72 0.527 1.047 -0.71 0.072 0.89 0.928 -0.306 
59 72 0.536 0.942 0.795 -0.981 1.056 0.962 0.33 
96 72 0.159 0.898 0.232 0.836 0.389 -0.034 0.997 
180 72 -0.01 0.997 0.726 -0.939 0.744 0.114 0.985 
26 96 0.9 0.59 -0.308 0.701 0.679 0.907 0.314 
59 96 0.999 1.324 0.614 0.951 -0.447 0.908 -0.299 
96 96 1.053 0.07 -0.928 1.116 0.431 0.296 0.954 









Figure 6.3 – Surface plot of the monolayer viability →Monolayer Viability Outer weights, showing the 
effect of time and 5-FU treatment. 
The outer weights between monolayer viability indicator and the monolayer viability latent variable, Y-axis 
shows the concentration, ‘dose’, the X-axis shows time in hours and the outer weight values are represented 




Figure 6.4 - Surface plot of the monolayer confluence →Monolayer Viability Outer 
weights, showing the effect of time and 5-FU treatment. 
The outer weights between cell confluence indicator and the monolayer viability latent variable, 
Y-axis shows the concentration, ‘dose’, the X-axis shows time in hours and the outer weight 




The outer weights of “cell confluence → monolayer viability” also has a high 
peak at 96µM, 24 h showing that both indicators are have high relative 
importance to the latent variable at this concentration and time point. Another 
large outer weight value for cell confluence is at 96µM, 96 h where it has a 
value of 1.053, this contrasts with monolayer viability that has a low contribution 
at this point with an outer weight value 0.07.  
When looking at the biological results of cell confluence and monolayer viability 
at these points, confluence had a mean of 20.61% confluence compared to the 
control with a standard deviation of 4.5, and monolayer viability had a mean 
value of 52% compared to the control with a standard deviation of 21.33. The 
results of the cell confluence values lie within a smaller range and this will have 
increased their impact on the indicator as the observations have a closer 
relationship to one another in comparison to the cell viability results where there 
is a much larger range in the observations.  
  
Figure 6.5 - Surface plot of the pNRF2→Proteomics outer weights, showing the effect of time and 5-FU 
treatment.  
The outer weights between the pNRF2 indicator and the proteomics latent variable. The Y-axis shows the 
concentration, ‘dose’, the X-axis shows time in hours and the outer weight values are represented on the Z-axis. 
The highest outer weight value is at 59µM, 72 hours 
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When looking at the 96µM, 24 h monolayer viability has a mean of 80.52% and 
a standard deviation of 1.93, and cell confluence had a mean of 59.19% and a 
standard deviation of 13.40. Here there is a very high contribution to the latent 
variable from monolayer viability.  
Other notable outer weights are those between the protein of interest pNRF2 
and its latent variable ‘Proteomics’. This indicator has the highest outer weight 
out of the proteomic indicators at 59µM, 72 h with a value of 1.056 and the least 
amount of negative values. At this particular data point the CA9 indicator has a 
very negative outer weight, and BNIP3 has an outer weight value of 0.795. After 
performing bootstrapping, the 72 h time point had the largest t value out of all 
“the pNRF2-> outer weights” (Table 5-1) with all the concentrations together out 
of all the time points. And the highest value out of all the proteomic indicators at 
the 72 h time point when combining all the concentrations. This indicates that it 
is the concentration (59µM) that is driving the outer weights at this time.  
6.5 Surface plots of path coefficient values 
The path coefficients are used in PLS-SEM path models to describe the links 
between latent variables within a path model. The results of path coefficients 
when including observations from all concentrations was discussed in Chapter 
5, Table 5-3.  
The path coefficients between monolayer viability and the spheroid latent 
variables, and between proteomics and monolayer viability were significant 
across all time points but only half of the time points were significant between 
proteomics and the spheroid latent variables (PRO→S.M = 24, 96 h and 
PRO→S.CV = 48,72 h).  
The raw values used to construct the 3D surface plots in Miner3D (Miner3D, no 
date) can be found in Table 6-6. These surface plots were constructed using the 
method described in Chapter 5, Section 3.7, as per the surface plots shown in 
the above section 6.4. 
Path coefficients can have a maximum value of 1 and a minimum value of -1 so 
the colour scale used on the surface plot was partitioned evenly between there 
too value for all path coefficient plots for consistency amongst plots. A path 
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coefficient value of 1 shows the strongest positive effect; values close to 0 have 
the least effect, neither positive nor negative.  
 
Table 6-6 - Raw data for all path coefficients used to construct 3D surface plots.  
The relationships is shown using the short hand described in Chapter 3, and the time and concentration for 












































26 24 0.063 -0.612 0.379 0.416 0.239 
59 24 -0.511 0.048 0.481 -0.267 -0.169 
96 24 0.74 -0.289 0.115 0.109 0.318 
180 24 0.873 0.911 0.397 0.174 0.145 
26 48 0.591 -0.217 -0.451 -0.032 -0.269 
59 48 0.357 -0.402 0.613 -0.862 0.145 
96 48 0.745 0.276 -0.195 0.054 -0.315 
180 48 0.924 -0.001 -0.331 -0.033 -0.525 
26 72 0.538 0.068 0.015 0.47 -0.169 
59 72 0.056 0.19 0.546 0.276 0.023 
96 72 1 -0.983 0.519 -0.121 0.096 
180 72 0.823 -0.901 0.387 0.041 0.102 
26 96 -0.35 0.102 0.526 0.329 0.189 
59 96 -0.176 -0.116 0.581 -0.313 0.206 
96 96 0.648 -0.276 -0.443 -0.112 -0.19 





The surface plot below in Figure 6.6 shows the path coefficient between 
monolayer viability and spheroid morphology. The path coefficients have 
consistently higher values with the 96µM and 180µM drug doses across all time 
points with the exception of 180µM, 96 hours where there is a substantially 
lower value. The path coefficients between monolayer viability and spheroid 
morphology were the highest at all of the time points out of the path coefficients 
calculated using the observations from all 5-FU concentrations and this 
reinforced with this path coefficient have the largest number of high values 
when considered by individual concentration groups. The high path coefficient 
values using all concentrations appear to be being driven by the higher 
concentrations within the observations.   
 
  
Figure 6.6 – Surface Plots of path coefficients between monolayer viability and spheroid morphology 
latent variables. 
 Y-axis shows the concentration, ‘dose’, the X axis shows time in hours and the path coefficient values are 
represented on the Z axis. This relationships shows the most consistently high path coefficients across the 5-FU 





Figure 6.7 shows the path coefficient between monolayer viability and spheroid 
viability is also interesting to note. There is one ‘peak’ at 180µM, 24 hours which 
has a very high value of 0.91 and is the only very strongly positive path 
coefficient value out of this grouping. The majority of the path coefficients 
shown in this surface plot are closer to 0 than the min or max values. There are 
some very strongly negative values at 96µM and 180µM, 72 hours which 
contradicts the strongly positive values at these point between the monolayer 
viability latent variable and spheroid morphology.  
From the analysis in section 6.3 it can be concluded that there is an indirect 
effect, either full mediation, or partial complementary mediation, by monolayer 
viability between proteomics and the spheroid latent variables. When looking at 
the results of the proteomics → monolayer viability (Figure 6.8) path coefficients 
Figure 6.7 - Surface Plots of path coefficients between monolayer viability and spheroid viability latent 
variables.  
Y-axis shows the concentration, ‘dose’, the X axis shows time in hours and the path coefficient values are 
represented on the Z axis. The path coefficients in this relationship are consistently lower with a high number of 
negative results, the exception being the relationship between the two latent variables at 180µM, 24 hours. This 
is also a high value in the monolayer viability → spheroid morphology relationship. 
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there is a strong result at 96µM, 72 h. This value is the highest value between 
monolayer viability and spheroid morphology, giving indication that this 
concentration is the driving force in the indirect effect between proteomics and 
spheroid morphology through monolayer viability. 
 
 
6.6 Analysis of Predictive values R2, f2, and Q2 
The predictive capabilities of the PLS-SEM model can be shown using the R2 
value of predictive accuracy and the Q2 value of predictive relevance (Equations 
3.7 - 3.9.in Chapter 3). The f2 value measures the effect size of an exogenous 
variable on the endogenous latent variable. All three of the values were 
reported in detail in the previous chapter and can be found in section 5.8. 
Previously they had been calculated from datasets including observations from 
all concentrations. Similarly to the outer weights and path coefficients, the 
results of the R2 and Q2 values were calculated using each concentration 
independently, the raw results were then used to create 3D surface plots for 
Figure 6.8 - Surface Plots of path coefficients between proteomics and monolayer viability and latent 
variables.  
Y-axis shows the concentration, ‘dose’, the X axis shows time in hours and the path coefficient values are 




comparison. The raw data can be found in Table 6-7, and the threshold for 
interpreting the strength have been repeated in Table 6-8.   
Table 6-7 – Raw results of individual groupings R2 and Q2 values.  




(hours) MCV_R2 SM_R2 SCV_R2 MCV_Q2 SM_Q2 SCV_Q2 
26 24 0.143 0.197 0.321* 
-0.144 
-0.124 0.12* 
59 24 0.231* 0.464** 0.023 -0.013 0.059* -0.078 
96 24 0.013 0.578** 0.164* n/a -0.069 -0.169 
180 24 0.158 0.913*** 0.957*** n/a -0.057 0.519*** 
26 48 0.203 0.367* 0.067 -0.062 -0.054 -0.346 
59 48 0.375* 0.493** 0.111 -0.126 0.141* -0.221 
96 48 0.038 0.542** 0.209* -0.071 -0.009 0 
180 48 0.109 0.876*** 0.276* -0.042 0.298** 0.019* 
26 72 0 0.518** 0.033 -0.066 0.035* -0.023 
59 72 0.298* 0.096 0.042 -0.013 -0.214 -0.153 
96 72 0.27* 0.894*** 0.877*** 0.139* 0.366*** 0.799*** 
180 72 0.15 0.705*** 0.752*** -0.013 0.301*** 0.66*** 
26 96 0.277* 0.109 0.067 -0.268 -0.119 -0.078 
59 96 0.338* 0.193 0.028 -0.21 -0.084 -0.782 
96 96 0.196 0.496** 0.066 -0.076 0.013 -0.476 
180 96 0.002 0.656** 0.161 -0.3 0.182** -0.424 
 
6.6.1 R2 value of predictive accuracy 
The R2 value (Equation 3.7) of predictive accuracy can be applied to all the 
endogenous latent variables and is the value of predictive accuracy. These 
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values will be between 0 and 1. The method of calculating the R2 values has 
been discussed in previous chapters along with the thresholds of determining 
their strength but have been repeated here for both the R2 and Q2 values to aid 





Table 6-8- Thresholds to interpret the strength of R2 and Q2 values 
 R2 Q2 
Weak (*) ~0.25 0.02-0.15 
Moderate (**) ~0.5 0.15-0.35 
Strong (***) ~0.75 ≥0.35 
 
The R2 value for spheroid morphology has can be seen as a 3D surface plot in 
Figure 6.9. The highest values can clearly be seen 96µM, 72 hours, and at 
180µM, 24 and 48 hours. The R2 values for 180µM were high across all four 
time points, with 24-72 hours have strong values and 96 hours being classified 
as a moderate value at 0.656. This trend was reflected in the results for the 
spheroid morphology latent variable (Figure 6.9). The strongest values were at 
180µM, 24 hours and 96µM, 72 hours same as spheroid morphology. This 
shows that the explanatory power of both latent variables is being driven 
Figure 6.9 – Surface plots of R2 values for the latent variable spheroid morphology.  
Y-axis shows the concentration, ‘dose’, the X axis shows time in hours and the R2 values are represented 
on the Z axis. 
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strongly by the predecessors in the path model at these points and as 
mentioned previously in section 6.5, the path coefficients between monolayer 
viability and the spheroid latent variables are highest under these conditions.  
 
6.6.2 Analysis of Q2 value of predictive relevance 
The Q2 value of predictive relevance for the spheroid cell viability construct is 
shown below in Figure 6.11. Using the threshold defined in the previous 
Chapter 5, the strength of the results have been indicated in the raw results 
table (Table 6-7). The highest Q2 values are seen at 96 and 180µM, 72 hours. 
When looking at the path coefficients between monolayer viability and spheroid 
viability at these two points they have very strongly negative values (-0.983, and 
-0.901) respectively. A high value can also be seen at the 180µM, 24 hours 
which when looking at the same patch coefficient at this value it has a very 
strong positive value (0.911). This reinforces that the monolayer viability latent 
variable is the driving force behind the predictive capability of the spheroid 
viability latent variable. 
Figure 6.10 - Surface plots of R2 values for the latent variable spheroid viability.  
Y-axis shows the concentration, ‘dose’, the X axis shows time in hours and the R2 values are 




The 96µM, 72 hours value is also the highest value out of “the proteomics -> 
monolayer viability” path coefficients, indicating that the particular concentration 
and time point is an important observation in regard to the model relationships 
and predictive capabilities of the path model.  
The Q2 values for spheroid morphology can be found below in Figure 6.12. Half 
of the Q2 values were negative meaning no predictive relevance for with the 
majority of significant values being at higher concentrations and later time 
points. The highest values of this construct is at 96µM, 72 h. These same 
conditions had the highest value of predictive relevance for the spheroid viability 







Figure 6.11 – Surface plot of The Q2 values for the latent variable spheroid viability.  
Y-axis shows the concentration, ‘dose’, the X axis shows time in hours and the Q2 values are represented on the 
Z axis. 
Figure 6.12 - Surface plot of The Q2 values for the latent variable spheroid morphology.  





6.7 Conclusions on findings of PLS path modelling 
The indirect effects of the model were testing with a focus on the mediation of 
monolayer cell viability between the proteomic latent variable and the spheroid 
latent variables. Analysis of “Proteomics → monolayer cell viability → spheroid 
morphology / cell viability” showed that that there was a mediator effect by 
‘monolayer viability’ between the proteomics latent variable and the spheroid 
endogenous latent variables. The mediation was either partial complementary 
mediation or full mediation. Mediation is the process of an indirect effect 
between constructs via one or more intermediary constructs. A partial 
complementary mediation refers to a relationships between the exogenous 
latent variable and endogenous latent variable, as well as the relationships 
between the exogenous and mediator, and mediator and endogenous are all 
significant. A full indirect only mediation refers to when the only significant 
relationships are via the mediator between the exogenous and endogenous 
variable and there is not a significant relationship directly between them.  
In terms of the biology, this confirms the theory that the results of the monolayer 
proteomic profile is only influential on the results of spheroid endogenous latent 
variables either completely, or partially through its significant relationship with 
the monolayer viability indicators. 
 The results of this testing were shown in section 6.3 and found that at all time 
points, there was either full or partial mediation by monolayer viability in the 
above relationships. These results confirm the hypothesis that as the proteomic 
indicators were obtained using monolayer cultures, that there would be a strong 
relationship between proteomics and monolayer viability. The results of the 
proteomics indicators generate information about the response to therapeutic 
insult and in turn monolayer viability, and there is a correlation between the 
responses to therapeutic insult in monolayer and spheroid cultures which is 
causing this mediation. 
This chapter also covered the results of the PLS-SEM path model was the 
datasets were not only separated by time point but by concentration of 5-FU. 
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The results from each of the 16 path model result sets were displayed visually 
using 3D surface plots and the colour scales normalised for comparison.  
There were reoccurring themes throughout this testing, such as the 96µM, 72 h 
point repeatedly showing high values across a number of relationships. When 
carrying out analysis on the monolayer cellular viability data, 96 µM was 
identified as the IC50 concentration at 96 h, and was included as an observed 
concentration for this reason.  
There were strong relationships between “proteomics → monolayer viability”, 
and “monolayer viability → spheroid viability / morphology”, confirming the 





7 Chapter Seven, Discussion and Conclusions 
7.1 Results of Biological Experimentation 
The aim of this research was to integrate data streams from 2D and 3D systems 
through computationally modelling using PLS-SEM path modelling and to 
explore the relationships between the two culture systems (monolayer and 
spheroids) with a focus on the ability of the responses to 5-Fluorouracil (5-FU) 
treatment in monolayer cultures to predict the responses to the same conditions 
(5-FU treatment and time) in spheroids. The first phase of this research project 
was dedicated to the creation of a data set to enable comparison of monolayer 
and spheroid cultures in regard to response to 5-FU insult, for a range of doses, 
and over time resulting in the creation of a dataset consisting of replicates 
relating to viability and protein expression in 2D, and to viability and morphology 
in 3D. This data set was as input to the PLS-SEM path modelling developed 
during the second phase of this project to explore the relationships between the 
data sets arising from the two different culture methods. In this final Chapter, 
the findings from the biological experimentation and the PLS-SEM path 
modelling are discussed, with a note on the future work would be required and 
final conclusions.  
7.1.1 Results of monolayer and spheroid comparison 
From the literature review of drug responses in monolayer and spheroid 
cultures, with a focus on the results of the chosen therapeutic insult, 5-FU, and 
selected cell line, HCT116+p53 broad trends in responses could be predicted. 
Overall, a reduction in response to therapeutic insult in spheroid cultures 
compared to monolayer was expected (Friedrich, Eder, Castaneda, Doss, 
Huber, Ebner and L. A. Kunz-Schughart, 2007) (Karlsson et al., 2012b). 
However, here the modelling work required more detail than that overall 
expectation: temporal data at a range of dosages. After completion of the 
experimentation, results showed that the spheroid cultures were less 
susceptible to 5-FU therapeutic insult compared to monolayer cultures, with less 
cell death occurring at higher drug concentrations over time. This broad trend 
was as expected, although results showed that the cytotoxicity and killing 
effects at lower dosages of 5-FU against spheroids closely matched that of the 
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monolayer cultures. Thus results of 2D and 3D systems diverge with increasing 
dosage. The final time point of 96 h, 300µM 5-FU in the experiment caused 
almost total cell death within the monolayer culture, while the spheroid cultures 
still maintained 20% cell viability when respectively compared to the untreated 
spheroid. These results have been repeated for reference in Figure 7.1  
 
Dose response curves were generated in Graphpad Prism using the (‘[Inhibitor] 
vs. normalised response – Variable slope’ function. From the 96 h data, the 
IC50 in monolayer was calculated to be 96µM with a SE of 2.2µM and that of 
spheroid cultures was found to be 122µM with a SE of 3.2µM. This is a 
difference of around 26 µM between monolayers and spheroids. Friedrich et al 
(2007) reported IC50 values of 7.4 ± 2.9 µM in monolayer and 28 ± 19.4 µM in 
spheroid, a difference of around 21 µM. Although the absolute values 
Figure 7.1 - Duplicated from Figure 4.5 in Laboratory Results  
CellTiter Glo® cell viability assay based on measure of ATP used with monolayer and spheroid 
cultures of HCT116+/+ cells treated with 5-FU, reproduced to include the additional concentration 
of 96µM.  
The monolayer and spheroids were incubated with 5-FU for a period of 96 hours, after which the CellTiter 
Glo® assay was performed and the data used to generate a drug dose response curve. The IC50 was 
calculated using the non-linear regression function in the analysis software GraphPad Prism. For 
monolayer the IC50 value was estimated to be 96µM, and for spheroids it was estimated to be 122µM. 
Concentration of 5-FU (µM) is shown on the X axis and the change in viability expressed as percentage compared to 
the un-treated control is on the Y axis. 
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themselves differ, the observed difference between the IC50s is similar for this 
experiment and for the literature. 
A multicellular resistance to therapeutic insult has been observed in spheroid 
cultures, resulting in a reduction in cytotoxic effect (Desoize and J. C. Jardillier, 
2000). A similar multicellular resistance phenomenon can be observed within 
confluent monolayer cultures, causing a similar drug response to that of 
spheroids (Steadman et al., 2008). The monolayer cultures were incubated for 
72 h post cell seeding before treatment, to match the experiments in spheroids 
and the raw mean confluence values before normalisation, of the 24 h (96 h 
post seeding) untreated cells was 45% ±19.5 SD confluent in the monolayer 
cultures, and which increased to an average of 75% ± 19.4 SD by 48 h. The 
confluence values for the lowest 5-FU concentrations (26 and 59µM) did not 
deviate far from the untreated up until 72 h of treatment. This high level of 
confluence at lower concentration could explain the similarity between the 
responses to lower concentrations of 5-FU through the multicellular resistance 
observed in confluent monolayer cultures.  
Spheroid morphometric indicators were chosen for inclusion within the PLS-
SEM path model as the introduction of therapeutic insult has been recorded in 
the literature to have an effect on the size and shape of a spheroid (Sirenko et 
al., 2015). The morphometric variables that were included were the ferret 
diameter of the spheroid as an indicator of size and circularity as an indicator of 
the spheroid shape. These variables were chosen due to their ease of 
measurement for high throughput repetitive measurements, and to reduce 
experimental time. Both indicators could be calculated form a single top down 
image of a spheroid using the imaging software ImageJ, and such single 
images can be used for high throughput screening.  
High throughput capability is important within cancer research as it allows for 
large cohorts of data to be curated in a timely manner. This can be used to 
screen large amounts of potential treatment candidates for their efficiency as an 
anti-cancer drug. Image analysis can be streamlined with the use of automated 
imagers where pre-set parameters can be implemented for repeated measures 
over a designated period. Unlike most viability experimentation approaches, 
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which cause the destruction of spheroid cultures and can only be carried out 
once per culture, imaging is non-invasive and can be repeated on the same 
subject repeatedly for a direct start to end point comparison.  
Monolayer cell confluence was also used as an indicator of monolayer viability. 
Monolayer confluence closely reflected the results of the viability assessment as 
demonstrated by the comparison in Figure 7.2. Concerning the 96 h time point, 
the viability and confluence of monolayer cultures when normalised to represent 
the change (%) from the mean of the untreated cells, are highly representative 
of one another, for most of the concentrations used. The exception being the 
cells treated with 96µM, where the recorded monolayer viability was found to be 
double that of the monolayer confluence. This comparison was reflected in the 
comparisons from all time points.  
Across all time points, 96µM was observed to be a ‘tipping point’, in terms of cell 
confluence with lower concentrations not deviating far from the untreated 
control in regard to confluence values. When observing the treated wells, 
changes in cell adherence was first observed in the centre of the wells with the 
edges of the wells maintaining higher levels of cell coverage, this is known as 
the ‘edge effect’ (Lundholt, Scudder and Pagliaro, 2003). The wells were 
typically imaged close to the centre and with the 96µM concentration of 5-FU 
the cytotoxic effect would have been high enough to drastically reduce the 
confluence of the imaged areas but may not have been representative of the 
well as a whole. This could be corrected by imaging the whole well to give a 
more representative result.  Note at 180µM the correlation between monolayer 






When comparing the results of the spheroid viability experimentation and the 
results of the spheroid morphology variables, the decrease in spheroid size was 
far less than the decrease in recorded viability in the spheroid cultures. The 
initial diameter of the spheroids immediately prior to treatment with 5-FU was 
0.530mm (SD = 0.039mm). This was reduced to an average of 0.499mm (SD = 
0.093mm) with the addition of 180µM of 5Fu after exposure for 96 h. This was 
around 75% as a percentage of the control from that time point. Untreated 
spheroids increased in diameter by around 16% compared to the mean 
spheroid size at the time of drug delivery. When treated with the highest drug 
concentration, 300µM of 5-FU (not included in statistical model) spheroids 
showed a reduction in mean diameter to 0.395mm (SD= 0.022mm), and so 































Monolayer viability Monolayer confluence
Figure 7.2 - Direct comparison of monolayer viability and monolayer confluence treated with 5-FU 
over 96 h.  
Cells were seeded into 96 wells to at an approximate density of 3,000 cells per well. After a period of 72 
hours the monolayer cultures were exposed to the therapeutic agents 5-FU. CellTiter Glo (Promega) ATP 
based cell viability assay was carried out at 24, 48, 72, and 96 h intervals. Cultures from the 96 h time 
point were imaged every 24 h for the duration of this treatment period. Image analysis to calculate the 
surface area occupied by cells (confluence) was carried out using ImageJ. The results from both 
experiments were normalised to represent the change from the mean of the untreated cells as a 
percentage. This demonstrates that with the exception of the 96µM treated cells, the confluence of the 




In the results of the 96 h time point, the diameter stopped decreasing 
significantly with concentrations of 89µM 5-FU and higher. This same trend was 
observed by (Kessel et al., 2016) who have also reported no further reduction in 
spheroid size when exposed to higher concentrations of therapeutic agent 17-
AAG.  
Comparison of the reduction of spheroid diameter to the spheroid viability 
variables with the larger data set of 5-FU concentrations demonstrated that at 
the 96 h time point both variables underwent a linear reduction between 40µM 
and 96 µM. There was a continued reduction in viability at higher 5-FU 
concentrations but at a slower rate. Furthermore, the decrease in spheroid 
diameter appeared to plateau until 300µM where the diameter decreased 
marginally further. The similarity between drug responses in the two variables 
(spheroid diameter and spheroid viability) is reflected by these results. The 
results of the Pearson’s correlation coefficient testing confirms this with 
significant strong correlation values from 48 h onwards (Figure 5.12).   
As an indicator of spheroid integrity, spheroid circularity varied very little from 
the control over the initial time points of 24-72 h and following 5-FU treatments, 
as discussed in Chapter 4. It was not until 96 h, 180µM that the circularity was 
significantly different from the control. The spheroid circularity, expressed as a 
percentage compared to the mean of the control value, more closely resembled 
the viability value under these conditions following the same normalisation. The 
maintenance of spheroid circularity at lower concentrations of 5-FU and time 
points demonstrates the ability of a spheroid to maintain integrity as cell death is 
occurring. As the reduction in spheroid viability begins to plateau, this is when 
circularity is substantially reduced. The maintenance of spheroid integrity when 
exposed to therapeutic insult is a result of the extra cellular membrane 
remaining intact, even following the loss of viability (Baek et al., 2016). The 
reduction in circularity values at higher drug concentrations after 96 h indicating 
the breakdown of the extracellular matrix under these conditions. 
When comparing the results of the viability assessment and the morphology 
indicators in both monolayer and spheroid cultures, the spheroid and monolayer 
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viability indicators most closely resembled one another in terms of 5-FU drug 
effect over time. This comparison has been demonstrated in Figure 7.3. 
The results of the correlations analysis, tested using the Pearson’s Correlation 
Coefficient are discussed fully in Chapter 5, showed strong positive correlations 
(r = >0.7) between the results of these four indicators (monolayer viability, 
spheroid viability, spheroid diameter, and spheroid circularity) at the 96 h time 
point. The correlations between monolayer and spheroid viability and spheroid 
circularity were expectedly lower with values that would be considered weak to 
moderate (0.1 < r < 0.7) at the earlier time points of 24 and 48 h. This was 
expected as circularity showed little to no change from the untreated control 
when treated with 5-FU at these times, whereas the viability variables did. As an 
indicator of spheroid integrity and morphological change after therapeutic insult, 
the circularity of a spheroid is a valuable indicator, however as an indicator of 
viability it may only hold value at higher drug concentrations and time points in 
this case. The use of ‘roundness’ as a morphological indicator of dug effect was 
investigated by (Monjaret et al., 2016), with differing results between the three 
therapeutic agents used, and suggested that effect on morphological 
parameters such as circularity are dependent on the mode of action of the drug.   














































































































































































































































































































































































































































































































































































7.1.2 Proteomic assessment of monolayer cultures 
The proteins chosen for the proteomic profiling were chosen due to their roles in 
the hypoxic response and cell death pathways and their reported relevance to 
the chosen therapeutic agent, 5-FU, and cell line, HCT116+p53. (Logsdon et al., 
2016) (Riedl et al., 2016) (Akhdar et al., 2009b) (Feng et al., 2011a)  
The results of the mixed model analysis to test the interaction of time vs 5-FU 
concentration showed significant interaction in all the viability and morphological 
variables, but not in the protein expression indicators. The change in 5-FU 
concentrations did not cause a significantly different change in protein 
expression suggesting that the concentrations used were super maximal. In the 
experimental design, the time points and concentrations of 5-FU were kept the 
same in experiments in both monolayer and spheroid in order to maintain a 
level of consistency when incorporating all the data into the PLS-SEM path 
model and for comparative purposes. The time point and concentrations used 
within the path model were informed by the results of the viability 
experimentation in monolayer. The super maximal effect of 5-FU in the protein 
expression indicators may cause a reduction in contribution to the statistical 
model. The individual drug concentrations are not significantly different to one 
another at each individual time point, and the data set were separated by time 
point. The impact of the proteomic variables is discussed further in section 7.3.2 
The results of the total NRF2 expression from western blots (not included in the 
model) showed an increase in total NRF2 expression over time with the 
introduction of 5-FU. In contrast to this, the results of western blot analysis 
showed a decrease in pNRF2 expression when exposed to 5-FU. The antibody 
for pNRF2 is this experimentation was NRF2 phospho at serine 40 (Ser40). The 
phosphorylation of NRF2 at Ser40 is mediated by protein kinase 3 (PK3). 
Phosphorylation of NRF2 at ser40 is involved in importing of NRF2 to the 
nucleus by freeing NRF2 from KEAP1 in the cytoplasm before translocating to 
the nucleus (Niture, Khatri and Jaiswal, 2014). Although this activation of NRF2 
by phosphorylation at Ser40 allows for NRF2 to be released from KEAP1, it is 
not necessary for the accumulation of NRF2 in the nuclease (Bloom and 
Jaiswal, 2003). With pNRF2 Ser40 involvement in the induction phase after 
expose to ROS it is likely that the upregulation of pNRF2 Ser40 had already 
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occurred prior to the first time point recorded, 24 h. The subsequent decrease in 
pNRF2 expression levels could be as a response of NRF2 accumulation in the 
nuclease occurring through alternative mechanisms beyond the initial induction 
phase, causing a decrease in phosphorylation at Ser40.  
BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, is involved 
with cell death pathways and is upregulated under Hypoxia Inducible Factor ⍺ 
(HIF1⍺) (Guo et al., 2001). From the literature it has been shown that p53 is 
upregulated in HCT116p53 cells, and caused a reduction in BNIP3 expression 
after exposure to 5-FU in both normoxic and hypoxic conditions (Feng et al., 
2011a). The anti-BNIP3 antibody (Table 2-6) used in the western blot 
experimentation produced a number of endogenous bands between 30-60kDa, 
(Bellot et al., 2009). When measuring the expression of the bands, this may 
have resulted in some manual error when selecting the region of interest and 
could explain for the high variance between the replicates of BNIP3 expression. 
However, although not significant, there is a pattern of BNIP3 expression 
decreasing with the addition of 5-FU over time as was expected and reported in 
(Feng et al., 2011a).  
The third protein of interest included within the PLS path model was Carbonic 
Anhydrase 9 (CA9) considered to be an endogenous marker of Hypoxia 
Inducible Factor ⍺ (HIF1α) (Guan et al., 2015). CA9 is upregulated in the 
presence of hypoxia within the cells. The results of western blot analysis 
showed a decrease in CA9 expression over time with the addition of 5-FU. This 
was expected as DNA damage, in this case caused by treatment with 5-FU (De 
Angelis et al., 2006), activates p53 which in turn causes a downregulation in 
CA9 (Kaluzová et al., 2004a). This was shown to be a non-significant interaction 
with a general mixed model.  
When selecting proteins to include within the PLS-SEM path model, the proteins 
of interest were selected for their roles within hypoxia response, response to 
therapeutics, or involvement in cell death. The time points at which the 
expression levels were recorded was the same as the time points of the 
variables relating to viability and morphology. With pNRF2, measuring the 
expression levels at earlier time points may have demonstrated a clearer 
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understanding of the effect of therapeutic agent but a comparison between 
monolayer and spheroid drug responses was key and changes to the 
morphology occur some time after the introduction of treatment.  
Potential future work would include western blot analysis of protein extracts 
from spheroid cultures, and a comparison with the results of monolayer. The 
PLS-SEM path model would be modified to include a latent variable of spheroid 
protein expression as an intermediary between the monolayer and spheroid 
sides. Increasing the proteomic profile of the monolayer culture to include more 
proteins of interest that could be selected and removed from the model 
interchangeably, could also be considered. This would provide an enhanced 
picture of the inner workings of the cell that could be tailored to the drug-action 
and expression profile of the cell line of choice. This proposed future model is 
schematically demonstrated in Figure 7.4.   
Figure 7.4 - Proposed updates to PLS-SEM path model.  
The proposed phase 2 of the PLS-SEM path model would include a latent variable of spheroid 
proteomics. This would sit as an intermediary between the monolayer proteomics and the spheroid 
latent variables of morphology and viability. This would provide a comparison of protein expression 
profiles between monolayer and spheroid, as well as the relationship between the protein expression in 
spheroid cultures and the morphology.  
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If presented with a situation to expand the model, a number of techniques could 
be applied to increase the variables to give a more in-depth look at the 
contrasts between monolayer and spheroids responses to therapeutic 
insult. Matrix-assisted laser desorption/ionization (MALDI) imaging mass 
spectrometry (IMS) has been used to investigate drug penetration in spheroid 
cultures (Liu, Weaver and Hummon, 2013). Often spheroids are shown to be 
more resistant that monolayer cultures, and a factor for this is the penetration 
rate of therapeutic agent into spheroids compared to monolayer cultures in 
which the full surface area is exposed. This more closely mimics clinical 
situations with tumours in-situ (Mehta et al., 2012). 
As an alternative to Western Blotting, a range of techniques could be applied to 
generate proteomic quantification for the spheroid cultures including traditional 
frozen or paraffin embedded Immunohistochemistry (IHC) (Mikhail, Eetezadi 
and Allen, 2013), whole spheroid immunostaining with confocal imaging 
(Weiswald et al., 2010), or flow cytometry (Grässer et al., 2018) with the first 
two techniques offering not only quantification but localisation of the protein 
expression within the spheroids. 
 
7.2 Using PLS-SEM path modelling with biological data  
The rationale for using PLS-SEM modelling was laid out in the introduction 
chapter. The benefits to using this technique is in the focus on exploratory 
research suitable for the prediction of key target constructs (Hair, 2013). For this 
research, the prediction of the effect of 5-FU treatment on the morphometric 
and viability indicators of spheroids.  
The aim of the PLS path modelling was the explore relationships between the 
biological variables collected from both monolayer and spheroid cultures and to 
use these relationships as a basis to inform the outcome of complex 3D 
spheroid experiments with simple 2D monolayer experiments to better direct 
effort in 3D. The biological data was first tested statistically to highlight 
correlations between the biological variables at different time points and the 
effect of 5-FU concentration over time on these variables.  
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The path model was developed as a way to explore these relationships with a 
focus on relationships from the monolayer to the spheroid variables. This is to 
best address the questions being asked: (1) are there meaningful relationships 
between the experimental results of therapeutic insult on viability in monolayer 
cultures and the responses of their spheroid counterparts; (2) are there 
relationships between the proteomic profile of a monolayer culture and the 
morphology of a spheroid culture; and (3) can these relationships be quantified 
in such a way that allows scope for prediction of the endogenous (spheroid) 
variables from the exogenous (monolayer) input. 
A feature of PLS-SEM is that it enables the use of formative constructs. The 
model in this research was developed in the formative style, where there is no 
required common cause for the indicators and they do not have to correlate. 
The latent variable (LV) is defined by a combination of the indicators (MV), 
rather that the LV explaining the indicators. As the LVs were defined by a 
combination of the MVs, this model style suited the data set and all LVs were 
designed in this style, with the exception of spheroid viability, which was a 
single item construct and consisted of only one MV.  
The data sets (one for each time point consisting of viability, morphometric and 
proteomic variables) were applied to the PLS-SEM path model in a way that 
allowed results of the PLS-SEM algorithm to be observed per time point. With 
either the observations from all 5-FU concentrations used, or to view the groups 
individually by concentrations. This resulted in 20 sets of PLS-SEM results for 
comparison. The results of the PLS-SEM modelling for the 4 time points with all 
observations included was discussed in Chapter 5, and the results of the 
individual concentrations at each time point were discussed in Chapter 6. The 
biological data was first tested statistically to highlight correlations between the 
variables at different time points and the effect of 5-FU concentration over time.  
 
The application of PLS-SEM to biological data (as opposed to survey data) 
required some consideration of the inherent structure of that data. PLS-SEM 
reads each row of the data sheet as an input. If considering a questionnaire, the 
likely source of most PLS-SEM data inputs, each column would represent either 
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participant information or a question asked and each row would represent the 
information and responses of one participant. The adjustment made to account 
for biological data was that each row represented a replicate number and each 
column a variable that was measured. The drug concentration was used to 
group the data, the same way gender or age group would in a questionnaire.  
 
One of the reasons for choosing PLS-SEM is its ability to handle smaller sample 
sizes (Avkiran, 2015). One of the suggested methods for determining sample 
size is the 10 times rule, where the samples sizes should exceed 10 times the 
maximum number of formative indicators associated with one latent variable, or 
10 times the maximum number of paths pointed at a single construct (Barclay, 
Higgins and Thompson, 1995). In the case of this model, the maximum number 
of paths was 2, so the minimum data size should be 20. The number of 
observations for all the concentrations was 100 for each time point so this 
satisfied that 10 times rule. However, while the sample size requirements are 
considered small, that does not necessarily translate in terms of experimental 
replicates with a ‘small’ number of replicates not being considered small in 
terms of this research outside of high throughput testing. This should be 
considered when using this modelling technique. In this research the need for 
this volume of replicates in western blotting was solved through the expansion 
of the data using Gaussian random number generation based on the means 
and standard deviations of the true replicates groups (method in Section 3.5.1). 
This in itself had issues as the high variance between replicates was inflated 
when the dataset was expanded.  
7.3 Results of the PLS-SEM path modelling compared with the 
results of biological testing 
The aim of the PLS path modelling was the explore relationships between the 
biological variables collected from both monolayer and spheroid cultures and to 
use these relationships to guide better questions in regard to the similarities and 
differences between these responses of 2D and 3D cultures systems to 
therapeutic insult. The biological data was first tested statistically to highlight 
correlations between the variables at different time points and the effect of 5-FU 
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concentration over time. The results of the PLS path model have been outlined 
in Chapters 5 and 6. This section ties together the findings of the model with the 
biology of the observations used to generate the model results.  
A main focus of this research was to consider the relationships among the 
variables collected from therapeutic insult in monolayer cultures with the results 
of the same therapeutic insult in spheroids generated with the use of a 
multivariate statistical model. These relationships were explored through the 
outer weights, an indicators relative contribution to the model, and the path 
coefficients, estimated path relationships between the latent variables. The 
predictive capabilities of monolayer variables in predicting the responses in 
spheroid cultures was a consideration. This was evaluated through the 
predictive indicators R2 values (coefficients of determinations) and the Stone-
Geisser’s Q2 value of predictive relevance (Stone, 1974)(Geisser, 1974).  
7.3.1 The contribution of monolayer viability indicators to the model and 
to the spheroid latent variables   
The results of the time-based data sets showed that the indicators of monolayer 
viability, monolayer cell confluence, spheroid viability, and spheroid diameter 
and pNRF2 expression were making a significant relative contribution to their 
corresponding latent variables in regard to the outer weights, across all 4 data 
sets. Circularity was not shown to be making a significant contribution (p=0.992) 
to the latent variable at 48 h, in line with the biological results that showed no 
substantial change from the control across all concentrations of 5-FU at this 
time point. At this time point, it is thus assumed that the addition of 5-FU is 
causing no change to the circularity of the spheroid, and therefore not 
contributing towards the change in the morphology unlike diameter that showed 
a decrease when compared to the control. 
In the individual concentrations of 5-FU the 96µM concentration at 24 h caused 
the highest outer weight value for not only the monolayer cell viability indicator 
but for all the indicators. This particular value had a mean of 80%. There was 
very little variance among the replicates at this point (± 1.9 SD). The outer 
weights are the results of a multiple regression with the indicators as the 
independent variables and the latent variable as the dependent (Monecke and 
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Leisch, 2012). The low variance between replicates in the monolayer viability 
indicator can be interpreted as a high level of agreement between observations, 
leading to increased impact on the variable. The high outer weights values 
shows that the results of the monolayer viability are explaining the results of the 
monolayer viability latent variable the most at this point, which links in with the 
biological results of the monolayer viability being a direct measure of viable cells 
within the sample, whereas the cell confluence was a representative image of 
the area covered with adhered cells.  
The path coefficients are calculated using ordinary least squares (OLS) (Lee et 
al., 2011), where the exogenous latent variable scores are used as independent 
variables to estimate the endogenous latent variables, or dependent variables. 
The path relationships between the monolayer viability LV and the spheroid 
morphology LV were the strongest at all of the time points with the exception of 
48 h, where the path coefficient between monolayer viability and spheroid 
viability was marginally larger but overall the path coefficients between 
monolayer viability and both of the spheroid LVs were largely comparable. This 
means that changes in the exogenous variable map closely to the changes in 
the endogenous variables. This is confirmed by considering the results of the 
correlations analysis using Pearson’s correlations coefficient that showed strong 
correlations between the monolayer and spheroid viability and morphometric 
indicators at the later time points. 
When looking at the individual drug concentrations the path coefficients varied 
significantly among them. There were higher path coefficients (0.64 – 1) 
between the monolayer viability indicator and the spheroid morphology indicator 
at higher concentrations and later time points. This reflected the results of the 
complete data set with the higher path coefficients being seen at later time 
points.  These high path coefficients at higher concentrations and later time 
points indicate that these conditions are more suitable for mapping the 
responses of morphometric measures from spheroids from multiple viability 
variables in monolayer than the results of low drug concentrations at shorter 
exposure times. The strong relationships between the monolayer viability LV 
and the spheroid morphology latent variable, alongside the strong correlations 
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reported in Section 5.4 support and confirm that monolayer viability can be used 
to map the morphometric response of spheroid cultures.  
The effects of 5-FU treatment on the morphology in spheroid cultures showed 
no substantial effect in the initial stages of treatment, indicating that the effect of 
therapeutic insult altering the morphology of spheroid cultures is time 
dependant, as changes to the morphology come as a result to viability loss. 
The R2 value of predictive accuracy is the coefficient of determination, and 
refers to the extent at which the endogenous latent variable is explained by the 
exogenous variable (Avkiran, 2015). The values for both the spheroid viability 
and morphology latent variables increase from moderate results at 24 h to 
strong results for the remaining time points. When considering the results of the 
individual concentrations, the values of most concentrations of the spheroid 
morphology variables are moderate to strong with the exceptions being at lower 
concentrations. In the spheroid viability indicator results at every time point, with 
the exception of 72 h, the R2 values are highest in the 180µM group. In the 72 h 
time point, although 180µM is not the highest value, the values from both 96µM 
and 180µM groups have values that are considered strong. These results show 
that the amount that the endogenous spheroid variables can be explained by 
the exogenous constructs is driven by the results in the higher concentrations.   
The Q2 value of predictive relevance uses the blindfolding analysis procedure, a 
sample reuse technique described in Chapter 3, Section 3.4.3.5. A high Q2 
value refers the ability to predict the endogenous latent variables indicators 
(Hair, Ringle and Sarstedt, 2011). This value is therefore only generated for the 
endogenous latent variables within the model. The results of the Q2 values for 
the spheroid latent variables closely reflect that of the R2 values and the 
interpretation stands (Section 5.8). When considering the individual 
concentration breakdown of the data set, only one data group gave a weak Q2 
value (0.139) for the monolayer viability LV and this was the 96µM, 72 h group 
(a reoccurring theme throughout the analysis), all other concentrations groups 
were negative values so even as a weak result it is the strongest in the 
groupings. Standout groupings from the spheroid viability and morphology latent 
variables were the 96 and 180µM, 72 h groupings. The 96µM concentration was 
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included within the model, as it was the IC50 value for monolayer calculated 
from the 96 h cell viability data set. The implication being that this concentration 
at this time point is high enough to cause a substantial change from the 
untreated in the variables without being high enough to cause very substantial 
or total diminishment.  
The results of this analysis indicate that 96µM is acting as a form of tipping point 
from little effect to substantial effect within the variables, especially at the later 
time points. 
In summary: 
 ATP-based viability contributes more than confluence to explaining the 
latent variable for viability of monolayer cultures in the model, which in 
turn drives the relationships of the monolayer viability variable with the 
endogenous spheroid variables: 
 When considering the individual 5-FU concentration groupings, the 
results of higher 5-FU concentrations at higher time points have stronger 
relationships between latent variables, and higher predictive indicators. 
For future work, the attention would be shifted to focus in on these 
concentrations and time points that have been highlighted within the 
model.  
 A reoccurring theme throughout the analysis was strong values in the 
96µM, 72 h grouping compared to the other concentration and time 
groupings. These conditions appear to be the key parameters in terms of 
balancing drug effect and exposure time for the majority of the variables.  
 
7.3.2 The contribution of protein expression indicators to the model and 
to the spheroid latent variables   
The CA9 protein expression indicator showed a non-significant outer weight 
value at 96 h (p=0.146), whereas the results of both BNIP3 and pNRF2 are 
significant (p=0.003***, p=0.001***). When considering the raw values for this 
time point, the difference between the 26 and 180µM (min-max) mean values is 
14% change in CA9 expression. BNIP3 had an average change between min-
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max concentrations of 28%, and for pNRF2 expression, this was 20%. The 
smaller range between the effects of the minimum and maximum 5-FU 
concentrations for CA9 is causing the decrease in relative contribution in 
comparison to the other indicators of the proteomic latent variable. Biologically 
this can be interpreted as the effect of differing 5-FU concentrations at later time 
points are more similar to one another suggesting that the drug effect on CA9 
occurs more substantially at earlier time points.  
The BNIP3 protein expression indicator was shown to only make a significant 
relative contribution towards the overall Proteomics indicator only at the later 
time points of 72 and 96 h. However it was shown to have a significant absolute 
contribution to the model at all time points with the values of the outer loadings 
The relative contribution of BNIP3 through the outer weights is estimated in 
comparison to the other indicators of the proteomics latent variable, which at the 
lower concentration had more significant outer weights. The absolute 
contribution through the outer loadings is considered without factoring in the 
other indicators and often gives higher values. Much like the values for 
circularity, the effect of 5-FU at 24 and 48 h caused no significant change in 
BNIP3 expression.  
The proteomic expression indicators, as discussed above in section 7.1.2, 
among lower correlations with other variables had a larger reported variance 
between the replicates and in the case of CA9 and pNRF2 did not show a 
significant interaction between treatment and time in the results of the GLM 
statistical analysis. The responses of pNRF2 can be attributed to the 
concentrations of pNRF2 being super maximal at all concentrations resulting in 
the low variance between drug effect of the difference concentrations, or that 
the time event for protein expression fluctuations had been exceeded by the 24 
h time point. This indicated that the effect of the proteomic values on the 
monolayer drug response had not been captured within the parameters of this 
experiment. However, the relevance of the protein expression latent variable on 
the monolayer viability was significant at all of the time points, with strong effect 
sizes from 48 h onwards. The conclusions to be drawn from this are that the 
results of the protein indicators, despite the above points, were able to generate 
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strong values of predictive accuracy and contribute strongly to the explanation 
of the monolayer viability latent variable. 
The path coefficients between the proteomic latent variable and the monolayer 
viability latent variable were also strong, indicating the strong relationship 
between them. The direct relationships between proteomics and the spheroid 
variables however were not as strong and, in some cases, not significant. There 
is a mediating effect by monolayer viability between the proteomics and 
spheroid variables: these effects were either complementary partial mediation 
or full mediation. Mediating effects can be either full (indirect only, where the 
direct relationship is not significant, but the indirect relationships are), 
Complementary / competitive partial mediation or direct only. There may also be 
no mediation, which can be classed as direct only, or no effect. The type of 
mediation, if present, is decided through the significance (or lack thereof) of the 
path coefficients both directly and indirectly via the mediating construct, and 
whether those path coefficients are positive or negative. The method is 
illustrated in Figure 6.2. When considering the biological origin of the model, the 
proteins of interest were quantified from monolayer cultures. Since both the 
protein expression and monolayer viability indicators were quantified using the 
same culture system they have more immediate relevance. Thus, the protein 
expression is more relevant to the viability of the same culture system as 
opposed to with the spheroid indicators. In the case of the complementary 
partial mediation, where both the direct and indirect relationships are significant 
and the same sign (+ or -), there was a significant relationship between the 
proteomics and spheroid variables, but the relationships ‘proteomics → 
monolayer viability’ and ‘monolayer viability → spheroid morphology / viability’ 
were far more significant and contributing more to the spheroid latent variables. 
The R2 values of monolayer viability were observed to be high at 72 and 96 h, 
with strong effect sizes from 48 h onwards showing a strong capability of the 
proteomic indicator to explain the monolayer viability latent variable. This was 
hypothesised to be due to the selection of proteins that were involved in cellular 
death pathways and in cellular response to therapeutic insult, this and the 
underlying biology is discussed in more detail in section 7.1.2. When 
considering the spheroid latent variables, they have moderate to strong R2 
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values across the board indicating a high level of predictive accuracy. The f2 
values of effect size, however, show at best a weak interaction between the 
proteomics and the spheroid latent variables. This shows that the contribution of 
proteomics in explaining the results of these endogenous variables is low to 
insignificant and that the R2 values of the spheroid variables are being driven by 
the monolayer viability latent variable. A similar pattern is observed in the Q2 
values of predictive relevance.   
It was hypothesised in this research that the proteomic results in monolayer 
culture would have predictive relevance to the morphological responses of 
spheroid cultures. The findings of this model show that this is not the case, and 
that the predictive capabilities via the additional monolayer viability variables 
have a much higher ability in performing this task than proteomics. 
In summary: 
 The values between proteomics and the spheroid latent variables were 
consistently lower in comparison to the relationships between the 
monolayer viability latent variable and spheroid latent variables, in 
particular the F2 effect size which showed that the proteomics latent 
variable is not contributing directly to the prediction of the spheroid 
indicators as hypothesised; 
 The mediation effect between proteomics and the spheroid latent 
variables through monolayer viability shows that the proteomics variables 
contribution to the model is most significant within the context of 
monolayer viability. A comparison to the proteomic expression in 
spheroid cultures may complement this model and help to bridge the gap 
between monolayer proteomics and spheroid variables.  
 Supermaximal issues in the protein expression levels of pNRF2 caused 
the change in response to different concentration to not vary 
considerably. The strong relationships between the proteomics and 
monolayer viability indicators highlight that this was not an issue 




7.3.3 The predictive capabilities of PLS-SEM  
The results of this model show that there were strong predictive capabilities 
both in terms of the R2 value of predictive accuracy and through the Stone 
Geisser’s Q2 values. This was especially prevalent between the monolayer 
viability latent variables and the spheroid latent variables indicated by the f2 
value of effect size, although the predictive capabilities of the proteomics were 
not as prominent. Within the literature the predictive capabilities of PLS-SEM 
have been questioned (Ratzmann, Gudergan and Bouncken, 2016) (Rigdon, 
2014). In the former, the abilities of three alternative PLS-SEM methods were 
tested as alternatives. These options were PLS prediction-oriented 
segmentation (PLS-POS), a hybrid approach PLS-PATHMOX  (Sánchez and 
Aluja, 2006) and PLS-SEM latent interaction effect (PLS-LIE). The benefits to 
using an alternative method such as PLS-POS, is that it is suitable for 
discovering unobserved heterogeneity within the structural model (Becker et al., 
2013), identification of which would inform where in the model would benefit 
from additional indicators or latent variables to improve the results of the model. 
Future work could look to test the predictive capabilities of the PLS-SEM model 
further, and cross-reference the results with the suggested alternative 
approaches. A test sample of data consisting of the concentrations not used 
within the PLS-SEM model would then be used to perform out-of-sample 
prediction (Ebbes, Papies and van Heerde, 2011). The PLS-SEM model would 
be re-run with the inclusion of observations from addition 5-FU concentrations 
for the monolayer indicators, withholding the observations from these 5-FU 
concentrations in the spheroid indicators in order to compare the predictions 
against the true values. The variation between the predicted and true values 
would be compared to analyse the predictive strength in each indicator. This 
process would be repeated using one or more of the suggested methods and 
comparison of the variance between the predicted and true values would 
indicate which methods may be more suitable to the task.  
The ability to closely predict the outcome of therapeutic insult on spheroid 
morphometric variables from the results of 2D experimentations could allow the 
continued experimentation using the well-established 2D systems and 
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appropriate assays with an estimate of a 3D outcome that is more similar to the 





There is a scale gap often illustrated between 2D monolayer cultures routinely 
used in cancer research and drug development and the responses of tumour in 
clinical setting. Thus, this research looked into and compared the connectivity 
and responses in 2D monolayer and 3D spheroid cultures to (1) understand and 
closing that gap based on the findings of the literature, and (2) examine and 
demonstrate whether the responses in monolayer cultures could be used to 
predict the responses in spheroid cultures. The use of PLS-SEM path model 
was employed to explore and quantify the relationships between variables 
collected in 2D and 3D systems with an emphasis on morphometric indicators 
from spheroid cultures. A range of experimental conditions over different time 
points and 5-FU concentrations were used to develop data sets to be used with 
the proposed model. 
The findings of the model demonstrated the strong relationships between the 
monolayer viability latent variable, consisting of input from cell viability (ATP-
based) and cell confluence indicators, and the spheroid viability and 
morphology latent variables. High predictive values were also demonstrated 
especially at later time points within the experimentation. 
 When assessing the effects of the individual 5-FU concentrations, higher 
concentrations often yielded higher correlation values, both as path coefficients 
and in the measures of the models predictive capabilities. This indicates that 
higher concentrations of 5-FU with longer exposure times would be preferable 
for the prediction of responses in variables from spheroid cultures using 
variables collected in monolayer. 
The impact of the proteomic expression on the model was significantly less in 
regards to the endogenous spheroid variables. However, monolayer viability 
was shown to be a mediator in the relationship between proteomic expression 
and spheroid variables, either by strengthening the already significant direct 
relationship through partial mediation, or completely providing a significant link 
between the two where there was no significant direct link. This implications of 
this are that although the ability of monolayer proteomic indicators to direct 
predict the responses in spheroid cultures to therapeutics insults over time is 
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weak, they can indirectly predict these responses via the additional indicators 
related to monolayer viability and have values within the path model.  
The findings of the model was in agreement with the findings of the biological 
data. In addition the model identified new knowledge: that the IC50 
concentration of monolayer, 96µM, at 72 h served as somewhat of a tipping 
point in the relationships between a number of the variables. Higher drug 
concentrations with increased drug exposure provided stronger predictive 
capabilities between the monolayer and spheroid variables. These parameters 
can serve as a focus for any future work with this model. The results of the 
protein expression levels showed a non-significant interaction between drug 
concentration and time when tested using the standard statistical method of a 
general linear model but despite of this significantly contributed to the model.  
The use of the PLS-SEM path modelling technique is well established in other 
disciplines, but this research shows and supports its potential application to 
biological data. Here, this research investigated the relationships between 
variables and through exploitation of the predictive capabilities of PLS-SEM and 
PLS based approaches. This model could be applied more routinely than other 
multivariate statistical methods discussed in the general introduction, Chapter 1, 
it has the applied advantage of requiring relatively far fewer data points to 
achieve statistical power and with the use of purpose-built software such as 
SmartPLS or the semPLS package in R it can be carried out and interpreted 
with relative ease.  
Future work could potentially include expanding the proposed path model to 
include a spheroid proteomic latent variable. This would aim to better (1) explain 
the link between the monolayer proteomics and the current spheroid latent 
variables, (2) the application of out-of-sample prediction to test the predictive 
capabilities of the model on the endogenous spheroid latent variables; and (3) 
the application of the model to other cell lines and therapeutic agents in order to 





8.1 Supplementary results and methodologies 
8.1.1 Modules used in CellProfiler Analysis of ICC  
 
 
Screen shot of the CellProfiler pipelineand the modules used, listed on the left 
hand side, featured is the metadata regular expression used to identify and 
group images based on the file name. The models included  
 ‘Identify Primary Objects’ used to identify the nuclei from the images of 
the DAPI staining 
 ‘Identify Secondary Objects’ to identify the areas stained for the proteins 
of interest 
 ‘Measure Image Area Occupied’ to provide a cell count and the area of 
the image occupied by cells  
 ‘Measure Object Intensity’ to measure the intensity of the fluorescent 
signal produced by the proteins of interest 
 ‘Export to Spreadsheet’ the location at which the output would be saved. 
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8.1.2 Full datasets from all variables used with the PLS-SEM model 
 
 
All ATP-based viability results from monolayer cultures. The results have been 
normalised to the mean of the untreated controls for each time point and 
expressed as a percentage (%). The Time point is indicated in the top left-hand 
corner of each data group, 5-FU concentration is indicated above each column 





All results of monolayer confluence. The results have been normalised to the 
mean of the untreated controls for each time point and expressed as a 
percentage (%). The Time point is indicated in the top left-hand corner of each 
data group, 5-FU concentration is indicated above each column and the 




All ATP-based viability results from spheroid cultures. The results have been 
normalised to the mean of the untreated controls for each time point and 
expressed as a percentage (%). The Time point is indicated in the top left-hand 
corner of each data group, 5-FU concentration is indicated above each column 




All results of spheroid diameter. The results have been normalised to the mean 
of the untreated controls for each time point and expressed as a percentage 
(%). The Time point is indicated in the top left-hand corner of each data group, 
5-FU concentration is indicated above each column and the replicate number is 




All results of spheroid circularity. The results have been normalised to the mean 
of the untreated controls for each time point and expressed as a percentage 
(%). The Time point is indicated in the top left-hand corner of each data group, 
5-FU concentration is indicated above each column and the replicate number is 





All results of pNRF2 protein expression levels, quantified from Western blot,  
used within the PLS-SEM model. The results have been normalised to the 
untreated control of the time point and expressed as the percentage change 






All results of CA9 protein expression levels, quantified from Western blot, used 
within the PLS-SEM model. The results have been normalised to the untreated 
control of the time point and expressed as the percentage change from the 





All results of BNIP3 protein expression levels, quantified from Western blot, 
used within the PLS-SEM model. The results have been normalised to the 
untreated control of the time point and expressed as the percentage change 




8.1.3 PLS-SEM algorithm results 
 
R2  24 h 48 h 72 h 96 h 
Monolayer Viability 0.134 0.41 0.515 0.511 
Spheroid Morphology 0.367 0.767 0.909 0.91 
Spheroid Viability 0.312 0.621 0.753 0.921 
 
 The R2 values, calculated each time-based dataset inclusive of all 5-FU 
concentrations used to generate Figure 5.18 
 
Q2 24 h 48 h 72 h 96 h 
Monolayer Viability 0.074 0.314 0.44 0.411 
Spheroid Morphology 0.125 0.414 0.547 0.665 
Spheroid Viability 0.252 0.6 0.731 0.899 
 
The Q2 values, calculated each time-based dataset inclusive of all 5-FU 
concentrations used to generate Figure 5.19.  
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8.2 List of Equipment used in this Research 
 
Equipment Makers 
96 well absorbance and 
luminescence plate reader  
Modulous Microplate, Turner 
Biosystems UK 
Centrifuge 5417 R Eppendorf 
Centrifuge 5804 R Eppendorf 
CO2 Incubator DH autoflow Air-Jacketed CO2 
Incubator Nuaire 
Gel and membrane documentation 
system 
G-BOX Chemi-XX6 Gel 
Documentation System, Syngene 
Gel and membrane image capture GeneSys (Syngene) 
Gel electrophoresis  XCell SureLock™ Mini-Cell 
Electrophoresis System 
 NuPAGE™, Invitogen 
Gel transfer mini iBlot™2 system, Invitrogen 
Imaging system though microscope iXonEM +867 EMCCD, Andor 
Technologies 
Microscope Leica DM-IRE2 inverted fluorescent 
microscope 





8.3 Reagents and kits used during this research 
Product Manufacturer 




Anti Carbonic Acid IX (CA9) antibody Ab15086, abcam 
 Anti HIF1α antibody Ab1, Abcam 
Anti-mouse seconday antibody Ab205719, Abcam 
Anti-Mouse AlexaFluor (594, red) Invitrogen 
Anti-Rabbit seconday antibody #7074, Cell Signalling 
Anti-Rabbit AlexaFluor (488, green) Invitrogen 




Anti BNIP3 antibody Ab10433, Abcam 
Bradford reagent Pierce Biotechnology 
BSA Sigma-Aldrich 
Anti Carbonic Acid IX (CA9) antibody Ab15086, Abcam 
CellTiter Glo® Promega 
DMEM Glutamax™ Gibco 
Fluorosheild™ mountant with DAPI Sigma-Aldrich 




Anti HIF1α Antibody Ab1, Abcam 
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NRF2 Ab137550, Abcam 
NuPage®  LDS sample buffer Invitrogen 





Penicillin Streptomycin Glutamine 
(100X)  
Gibco 
Anti pNRF2 antibody Ab76026, Abcam 
RIPA  Thermo Scientific 
Trypsin Gibco 
Anti VEGF antibody Ab46154, Abcam 






8.4 Ethical approval E1 form 
Form E1 
 
Research – Ethical Considerations        School Of Science, Engineering & 
Technology 
This form must be completed for all research projects: undergraduate, 
postgraduate and staff. Following submission to an Ethics Rep (see page 7), 
the form will be returned to the Proposer/Supervisor, indicating the outcome 
(see pages 8-9). 
This form must be completed electronically and submitted by email.  
To enter information, please tab between the grey field boxes.  
Responsibilit ies 
 Where the Proposer is STAFF: completion of this form and submission to 
Ethics Rep. 
 Where the Proposer is a STUDENT (conducting a project within the 
University): completion of this form and submission to Supervisor or 
designated programme contact1. 
 Where the Proposer is a PLACEMENT STUDENT (conducting an EXTERNAL 
project, outwith the University): completion of this form and submission to 
designated programme contact2. 
 Supervisor: check and complete student’s form and submit to Ethics Rep. 
HELP NOTES: where applicable, important help notes are provided in the Word 
status bar (at the foot of your screen) when you move to an entry field. Please 
look out for these notes. 
Section A General Information 
                                            
1 Some programmes may designate an alternative person (e.g. project module tutor) as the 
recipient of completed E1 forms. The Programme Tutor concerned should be consulted if in 
doubt. 
2 Note that for external projects the completed E1 form should be forwarded to the designated 
recipient (as advised by the Programme Tutor concerned); the form should NOT normally be 
forwarded to either the internal (University) Supervisor or the external (placement) Supervisor. 
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A1 Name of Project Proposer: 
 Stefanie Wilson 
A2 Matriculation No. (where applicable):   
 1007291           
A3 Programme (where applicable):   
 PhD student 
A4 Module Code/Title (where applicable):  
 - 
A5 Supervisor (if not the Proposer): 
 Dr Yusuf Deeni 
A6 Title of Project:  
 Bridging the scale gap: linking 2D behavioral and 3D morphometric 
data   
A7 Main aim of study (max. 80 words):  
The aim is to integrate 2D and 3D systems in a novel way in order to 
be able to predict a range of responses in 3D spheroids from 2D cell 
line experimentation.  This will involve building a form of multivariate 
classifier by using statistical modelling to map 2D proteomic data as 
input against 3D spheroid morphometrics as output. If successful this 
model would enable the ability to predict, at least approximately, the 3D 




A8 Site of the Research: 
 Abertay University  
A9 For external projects  
i.e. projects conducted fully or partly outwith Abertay University  
A9.1  Name of external local ethical approval body: 
       
A9.2  Local ethical application status:   Approved      Pending       
Declined  
A9.3  Reference                                                    Date (dd/mm/yy) 
       
Please note that, in the case of external projects, both external ethical 
approval and University approval are required.  
 
A10 Outline of Research Proposal  
Please supply a brief outline of the research proposal in the field below 
(max. 300 words).  
 Ensure you highlight any areas of potential ethical relevance.  
 If you consider there to be no areas of ethical relevance, please make 
this clear. 
 
2D cell culture systems are a popular choice within drug efficacy testing as 
they are relatively easy to work with and with the use o f proteomics intra-
cellular signalling can be quantif ied. The use of monolayer cell cultures may 
have its advantages but several studies over the years starting with 
Sutherland and his colleagues in the early 1970s have shown that spheroids 
are a much better model for tumours In vivo  due to their shape and 
microenvironment being similar.  This project will aim to connect 2D 
proteomic data and 3D morphometric data in a novel way with the aim to 
build a statistical model which will allow the prediction of a 3D response from 
2D cell line testing.  
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This will be carried out by first initiating the culture of the colon cancer cell 
line HCT 116 as both a monolayer and in spheroids. The cells will then be 
insulted by a clinically relevant drug, in the case 5-Fluorouracil (5-FU) and 
the effects of this will be recorded for both culture systems. Cell survival, 
invasion, protein expression, and drug metabolism will all be recorded using 
a variety of assays on both the monolayer and spheroid cultures. Where 
viable the same assays will be run on both culture but in some cases this is 
not possible due to the difference in morphology. This data will then be 
collected on a database and a variety of statistical tests will be run in order 
to find a correlation and produce a statistical model. This model will then be 
tested on another independent cell line in order to test the accuracy of the 
model and the specificity of the model to HCT 116. This cell line will probably 
be of either ovarian or pancreatic origin.  
 
 
                                            
3 The University permits ‘expedited approval’ for research involving only literature review; such 
applications are normally given automatic approval. 
A11 Is this a ‘Knowledge Transfer Project’ (KTP), i.e. commercial / 
consultancy work commissioned by an external company or body, for which 
a three year generic approval is sought? 
 
A12 Is the research entirely ‘literature review’ (with no empirics)?3 




Section B Ethical Aspects 
 
# Please answer the following questions:  YES NO 
B1 
Does a significant risk of physical or psychological 








Will the research involve animals of a type requiring 
a Home Office licence? 
  
B4 Will the research involve genetic modification (GM)?    
B5 
Will the research involve stored human samples, for 
example organs, tissues, cells (excluding established 
cell lines)?  
  
B6 
Will the research involve human subjects in any 
manner? (e.g. as experimental subjects, or as 
interviewees, or as the source of biological materials)  
  
B7 
Will the research involve the use of computers or the 




Where none of B1-B7 above have been marked “yes”, please turn straight 






                                            
4 Standard IT functions include the use of applications such as Word, Excel, SurveyMonkey, 




Where any of B1-B7 above have been marked “yes”, the 
following action is required as applicable:  
action 
taken 
B1 Supply a copy of the Risk Assessment 5  
B2 




Append a copy of the Home Office licence (or, in the case 




Append a copy of GMOC approval, (or, in the case of a 
pending decision, append a copy of the GMOC application) 6 
 
B5 
Explain in Section C (page 4) how the human material will 
be employed and handled in accordance with the relevant 
legislation  
 
B6 Complete Section D (page 5)   
B7 
In Section C (page 4), explain how you will ensure 
compliance with relevant legislation on computer misuse 
and data protection.  
 
 
Section C      Further information as indicated in Section B (if  applicable) 
(max. 400 words)  
                                            
5 It is highly unlikely that approval will be given for any project entailing a significant risk of 
physical or psychological harm following Risk Assessment. 
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Section D Research involving human subjects (if applicable) 
D1 Number of human research subjects (approx):  
        
D2 Who are the research subjects? (Please state inclusion/exclusion 
criteria): 
      
D3 How will you recruit them for your study? 
      
D4 Research Approach & Procedures  
Tick as many as apply Yes 
Qualitative   




Questionnaires supplied with this form (in a separate file)      
Interviews   
Observation – overt  
Observation - covert (specify in box below)  
Other research procedures being used (specify in box below)  
 
      
D5 Could any of these procedures cause discomfort, anxiety, stress or 
 embarrassment?       
 Yes       No  
 (D5, continued) If the answer to D5 is yes, explain how you will seek 
to  minimise the impact:  
      




      
D7 Precautions and safeguards 
Answer ALL questions Yes No 
D7.1 Will the subject be provided with a written/oral 
explanation of the project?  
  
D7.2 Will it be explained to the research subjects that they 
may not benefit from your study?   
  
D7.3 Will the research subjects be offered the opportunity 
to decline to take part?  
  
D7.4 Will the research subjects be offered the opportunity 
to withdraw at any stage?  
  
D7.5 Will a guarantee of confidentiality be expressed to the 
subjects? 
  
D7.6 Will an offer of anonymity be given to the subjects?   
D7.7 Will the provisions of the Data Protection Act be 
adhered to?  
  
D7.8 Will the subjects be briefed on health and safety 
issues and any risks involved? 
  
D7.19 Will the subjects be provided with written contact 
details of a member of the research team? 
  
D7.10 Will the research subjects be asked to fill in a 





 If any of the questions in D7 cannot be answered in the affirmative 6, 
provide  an explanation:  
      
 
Section E     Confirmation 
E1 I have read the School Research Ethics Committee’s Principles & 
Procedures document, the School Health & Safety Policy and the 
University of Abertay Dundee Health & Safety Policy  (available on the 
Portal) and will adhere to these policies  
 Yes  
E2 I understand that it is my responsibility to ensure compliance with any 
relevant regulatory or legal requirements (such as data protection 
legislation, stored tissue regulations, animal experimentation licensing, 
etc)    
 Yes      
E3 This form has been prepared by the Proposer (as named in section A1)  
 Yes      
E4 This form has been read and approved by the Supervisor (as named in 
section A5) 
  Yes  Not applicable  
Section F     Steps to finalise & send this form 
                                            
6 Where the research is based entirely upon surveys or interviews, consent may be presumed (it 
is not necessary to obtain written consent). 
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1. Student Proposers (where applicable) - send this to your Supervisor 
2. Staff Proposers / Supervisors - please choose the most appropriate Rep for 
the research activity concerned: 
 Prof W Otten - Bioscience PhD and staff projects  
Then please email this form to: set@abertay.ac.uk 
The outcome of the application will be indicated on pages 8 onwards when the 
final E1 is emailed back to the Proposer / Supervisor. 
 
Important: research must not commence until ethical approval 




Section G  For completion by the Ethics Rep 
 
G1 Completed proposal form received by Ethics Representative 
 Prof W Otten - Bioscience PhD and staff projects  
  Date received (dd/mm/yy)        
G2 The following recommendation(s) have been made. NB for research 
involving Human Subjects the FINAL recommendation is shown in 
Section H. 
 
G2.1 The project is satisfactory and should proceed  
 
G2.2 The project should proceed on condition that all questionnaires, 
surveys and communications with external persons or bodies are 
discussed and approved in advance with the Project Supervisor. 
 
 
G2.3  The project should proceed on condition that the requirements set 
in the box below are complied with 
 
 
      
 
Except in the case of human subject research, recommendations 
G2.1, G2.2 or G2.3 (above) mean that the research project may 
commence. (Homologation will be made subsequently by the SREC.)7 
                                            




G3 The proposal requires to be re-submitted (to the ethics Rep) with 
additional information regarding:  
 
G3.1 Organisms and / or subjects (delete as appropriate)  
G3.2 Methods of data collection/procedures  
G3.3 Informed Consent  
G3.4 Confidentiality  
G3.5 Other (as per the box below)  
 
 (G3.5, continued)  
      
 
 
G4 The Project described in the Proposal has been considered 
not suitable for research, on the grounds of:  
 
G4.1 Unacceptable harm to organisms and / or subjects  
G4.2 Potential harm to the researcher  
G4.3 Risk of bringing the University into disrepute.    
G4.4 Other (as per the box below)  




      
 
G5 The Proposal will be considered by the SREC Chair for possible 
submission to a full meeting of the School Research Ethics 
Committee; the outcome will be relayed to you in due course. 
 
 
G6 The Proposal will be considered by the SREC Chair for possible 
scrutiny by an independent ethics Rep in another School; the 
outcome will be relayed to you in due course. 
 
 
Where the recommendation is G3, G4, G5 or G6 (above), 
research must not commence until ethical approval has been 
given. 
 
For attention of undergraduate & MSc students: the recommendations recorded 
in this from should be discussed with your Project Supervisor, not with the 
ethics Rep. 
 
Ethics Rep actions 






Section H - Human Subject research only 
 
For completion by the 2nd Rep 
 
H1 Completed proposal form received by 2nd Ethics Representative 
 CHOOSE...  
  Date received (dd/mm/yy)        
H2 Outcome: 
 
H2.1 The decision of the 1st Rep (as per Section G above) has been 
agreed by the 2nd Rep 
 
 
Outcome H2.1 means that the research project may commence. 
(Homologation will be made subsequently by the SREC.)8 
 
H2.2 The decision of the 1st Rep (as per Section G above) has NOT 
been agreed by the 2nd Rep (following discussion between the two 
Reps) 
 
Where H2.2 applies, the form will be passed (by the SET office) to the 
SREC Chair for arbitration. If agreement between the two reps and the 
Chair cannot subsequently be reached, the form will be referred to a 
full meeting of the SREC. In all such cases, the final decision will be 
conveyed to the proposer in writing by the SREC chair. 
 
Where the recommendation is H2.2, research must not 
commence until ethical approval has been given. 
                                            




 For attention of undergraduate & MSc students: the recommendations 
recorded in this from should be discussed with your Project Supervisor, 
not with the ethics Rep.  
 
2nd Ethics Rep actions 
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